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MICRORNA-186 AND METASTATIC PROSTATE CANCER 
Dominique Zilpha Jones 
May 30, 2016 
MicroRNA (miR) dysregulation alters cancer-associated gene expression, which 
contributes to cancer pathogenesis. For example, miR-186 over expression lead 
to enhanced proliferation and migration in pancreatic cancer cell models.  
However, the role of miR-186 in prostate cancer (PCa) remains controversial.  
Previously, miR-186-5p was up-regulated in PCa patient serum (stage III/IV) 
compared to controls. Furthermore, miR-186-5p was up-regulated in metastatic 
PCa (PC-3, MDA PCa 2b, LNCaP) relative to normal prostate epithelial cells 
(RWPE1). We hypothesized miR-186 inhibition will reduce aggressive PCa using 
metastatic cell models. To test this, we evaluated whether miR-186-5p inhibition 
would reduce aggressive PCa behavior and overexpression induce malignant 
transformation in normal cells.   
Cell proliferation (BrdU incorporation), invasion (reduced growth factor matrigel), 
colony formation (soft agar) and cell death (trypan blue exclusion) were 
examined in miR-186-5p inhibited PCa cells (PC-3, MDA PCa 2b) and 




PC-3 and RWPE1 cells to identify miR-186 candidate targets via microarray and 
qRT-PCR analyses using published reports, miR databases and statistical 
filtering (FDR p-value ≤  0.05 and ±1.2 fold change). 
MiR-186-5p inhibition reduced proliferation (27-46%) in PCa (PC-3, MDA 
PCa 2b), cellular invasion (66%) in PC-3 cells and anchorage independent 
growth (28-64%) in PC-3 cells and post-DHT (10 nM) treatment in MDA PCa 2b 
cells. Over 2,343 genes were differentially expressed in stably miR-186 inhibited 
PC-3 and overexpressed RWPE1 cells relative to controls. Out of 23 selected 
candidates, AKAP12 gene and protein was up-regulated in miR-186-5p inhibited 
PC-3 cells. MiR-186-5p overexpression decreased AKAP12 protein in HEK 293T 
cells. Additional in vitro as well as in vivo studies are needed to further elucidate 
the role of additional targets in PCa. Ultimately, the identification of novel 
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Prostate Cancer as a public health problem 
Prostate cancer (PCa) is the leading cancer and the 2nd leading cause of 
cancer related deaths among men in the U.S. [1]. Ninety-one percent of PCa 
cases are treatable among men diagnosed with localized or regional disease as 
evidenced by 100% 5-year survival rates [1].  This 5-year survival rates drop 
drastically to 28% for metastatic PCa [2].  Once PCa spreads to the bone and 
other organs, it is not responsive to conventional treatment strategies.  To 
compound the problem further, 25% of all cases diagnosed with stage I-III 
disease will experience disease recurrence within five years post treatment. 
 
PCa Risk Factors 
 There are a number of well-established and probable risk factors that 
contribute to the development of PCa. These established risk factors include 
older age (age ≥ 50 years), family history among 1st or 2nd degree relatives, low 
socioeconomic status, sedentary lifestyle, poor diet, genetic predispositions, 
hormone imbalances (androgen, testosterone, androgen 
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sensitivity), chronic inflammation, and African heritage. Data shows elevated 
risks of PCa development are generally associated with the aforementioned risk 
factors and especially men of African descent.  Based on 30 years of record 
keeping, there is significant a racial disparity associated with PCa. 
 
PCa Health Disparities 
African American men are 2.5 times more likely to die from PCa relative to 
American men of European descent [1, 3]. A number of studies have attempted 
to determine biological explanations for this disparity through the evaluation of 
clinical prognostic/diagnostic factors [e.g., prostate specific antigen (PSA), PSA 
density, tumor stage], hormone levels, and the expression of apoptotic and 
metastatic-related genes [4-11]. Unfortunately, no definitive molecular 
mechanisms have been identified contributing to this strong disparity between 
African and European American men. Thus, further investigation into the 
molecular mechanisms associated with racial disparity is warranted to increase 
our understanding of this disease and develop customized targeted therapies for 
diverse populations.  Although, this dissertation does not focus on race/ethnic 
specific biomarkers, we sought to understand the biology of a specific genomic 
biomarker within PCa cell lines common to both African-American and European-
American men diagnosed with metastatic and/or non-metastatic disease. 
 
PCa Staging and Risk Stratification 
PCa is a heterogeneous abnormal growth or neoplasm with distinct 
categories of pathologic stages.  These varying pathological stages help inform 
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medical and scientific personnel of the extent to which the cancer progressed 
and guides treatment strategies.  There are four tumor stages, three lymph nodal 
stages (N stages) and three metastatic stages (M stages). The first tumor stage 
(T1) of disease involves the tumor found in a surgical procedure called 
transurethral resection of the prostate (TURP) and less than 5% is cancer (T1a) 
or more than 5% is cancer (T1b) or tumor discovered during biopsy (T1c). In the 
second stage (T2), the tumor is located in half (or less) of one side of the 
prostate (T2a), one half (or more) on one side (T2b) or both sides (T2c) and has 
not extended beyond the prostate. For the third stage (T3) of PCa, tumor growth 
has extended outside of the prostate, but not to seminal vesicles (T3a) or has 
invaded seminal vesicles but not the lymph nodes (T3b). In stage four (T4), 
tumor growth is outside of the prostate and tumor cells have migrated to distant 
organs (i.e., lymph nodes, liver, bone), which is commonly referred to as 
metastasis.   For lymph nodal staging, Nx means no testing has been performed 
to detect cancer in the lymph node. N0 indicates the cancer has not reached any 
lymph node. N1 means the cancer has spread to the lymph nodes. For the 
degree of metastasis, the first level, Mx, indicates no testing has been performed 
to detect cancer in distant lymph nodes. Mb indicates cancer has metastasized to 
the bone. The last level, Mc, means the cancer has spread to other areas (e.g., 
lungs, brain, liver). The most common biological patterns of PCa metastasis are 
metastasis of tumor cells to the bone (90%), liver (65%), lymph nodes (59%) and 




There are common classification and risk stratification systems utilized for 
PCa. These classification and risk stratification systems were used to determine 
biospeciemens collected from patients in this study with aggressive and less 
aggressive disease. The first is the Gleason grade system, which aids in the 
evaluation of prostate biopsies and determine disease prognosis for men with 
PCa [13]. Gleason grades range from 1 (normal tissue) through 5 (abnormal 
tissue). Different areas of a tumor often have different grades and two grades 
that characterize majority of tumor. The sum of the two grades is called a 
Gleason score or sum. A Gleason score of ≤ 7 describes well to moderate 
differentiated tissue or low aggressive disease. A Gleason score range of 8 ≤ for 
poorly differentiated tissue or aggressive disease.  
 
Two common PCa risk stratification systems are the D’Amico risk criteria 
and National Comprehensive Cancer Network (NCCN) guidelines. Both the 
D’Amico and NCCN use PSA levels and Gleason scores to classify disease 
aggressiveness. The D’Amico risk criteria was established in 1998 and later 
adopted by the American Urological Association and European Association of 
Urology. This system is used to determine low, intermediate and high risk 
individuals diagnosed with non-metastatic disease [14]. Patients diagnosed 
according to following criteria; low risk [tumor stage T1/T2a, and PSA ≤10 ng/ ml, 
and Gleason Score ≤ 6], intermediate risk [tumor stage T2b, and/or PSA 10–20 
ng/mL and/or Gleason Score 7] and high-risk [tumor stage ≥T2c, PSA >20 ng/mL 
or Gleason Score 8–10].  
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In the NCCN guidelines, there is a further breakdown of low and high-risk 
individuals and includes metastatic patients [14]. Low risk is divided into not very 
low risk [T1-T2a and Gleason Score 2–6 and PSA ≤10] and very low risk [T1c 
and Gleason Score ≤ 6 and PSA <10 and 3 > biopsy cores positive and ≤ 50% 
cancer in each core]. Intermediate risk is classified as patients diagnosed with 
T2b or T2c and/or Gleason Score = 7 and/or PSA >10–20. Lastly, high risk is 
divided into not very high risk [T3a or PSA >20 or Gleason Score 8–10] and very 
high risk [T3b-4].  
 
Pathogenesis of PCa 
The prostate gland is oval in shape anatomically located interior to the 
bladder. The urethra tube runs directly through the middle of the gland. The 
gland is divided into three different zones, transition, central and peripheral. The 
peripheral zone is the largest of the three zones with contains 66% of the fluid 
producing glands. The gland is composed of three types of cells consisting of 
glandular, muscle, and fibrous cells. Gland cells produce the fluid component of 
semen. Muscle cells control urine flow and ejaculation. Fibrous cells provide 
structural support of the gland.  
In the normal prostate epithelium, there are several major processes that 
lead to prostate carcinogenesis such as chronic inflammation, oxidative 
stress/DNA damage and genomic alterations [15, 16]. Oxidative stress and DNA 
damage contributes to the pathogenesis of PCa [16]. Oxidative stress results 
from an imbalance in reactive oxygen species (ROS) and detoxifying enzyme 
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levels via the accumulation of ROS. Furthermore, oxidative stress can induce 
damages in lipids, proteins and most importantly DNA via suppression of the 
expression of anti-oxidant enzymes and induction of DNA adducts in PCa. Also, 
genomic changes such as loss of tumor suppressors, NKX3.1 and PTEN, 
TMPRSS2-ERG translocations and up-regulation of oncogene, c-Myc, EZH2 and 
Akt/mTOR and MAPK signaling are commonly detected in PCa Lastly, chronic 
inflammation mainly attributed to bacterial or viral agents, dietary factors (i.e., 
heterocyclic amines), genetic variations, amyloids, physical trauma, hormonal 
changes, and urine reflux has been previously implicated in PCa [17-21]. Chronic 
inflammation can transition into proliferative inflammatory atrophy (PIA) 
characterized by focal atrophic lesions and influx of inflammatory cells and 
stromal fibrosis [18, 21-23]. PIA lesions frequently developed into prostatic 
intraepithelial neoplasia (PIN) evident by histopathological studies [21, 22]. High 
grade PIN is widely accepted as the precursor of prostate carcinoma evident by 
numerous reports that show high grade PIN is strongly associated with prostate 
carcinoma in prostatic tumor tissue [22, 24-27].  
However recently, cancer research has implicated non-coding RNA 
species called miRNAs as massive regulators of gene expression in 
tumorigenesis. Dysregulation of these gene regulators could lead to the induction 
of oxidative stress, genomic changes and DNA damage in cancers such as 
prostate. Thus, this dissertation evaluates the biological and genetic contributions 
of a differentially expressed miRNA to the prostate tumor phenotype via changes 
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in tumor cellular behavior (i.e., growth, proliferation, invasion, anchorage 
independent growth) and gene expression profiles.        
 
Metastatic Disease 
Beyond tumorigenesis, metastasis is a complex process with that 
dramatically increases the risk of death for cancer patients and proposes a major 
issue in clinical management of PCa and all cancers. The metastatic process 
shown in Figure 1 initially involves the enhanced proliferation of primary tumor 
cells, invasion of tumor cells into adjacent surrounding tissues and basement 
membrane and then detachment from the primary tumor [28]. These cells are 
considered to have undergone epithelial mesenchymal transition (EMT). Next, 
tumor cell invasion of and survival in the circulation system and lymphatic 
channels also known as intravasation, arrest within a distant organ, extravasate 
into surrounding tissue and colonization at a secondary site [28]. Mesenchymal 
epithelial transition (MET) is required for tumor cells to establish a secondary 
tumor site.   
There are several models of metastasis, which include progression, 
transient compartment, fusion, gene transfer, early oncogenesis, and genetic 
predisposition [28]. The progression model proposed by Peter Nowell (1976) has 
been the most widely accepted model and has been supported by a number of 
studies. This model suggests that a series of mutational events occurs in 
subpopulations of the primary tumor or disseminated cells and results in a small 
fraction of cells acquiring full metastatic potential [29]. The rationale behind the 
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progression model is that primary tumor cells have a low probability to acquire all 
of the multiple alterations required for successful metastasis [29]. So only a few 
cells will successful metastasis. Although the progression model is supported by 
some studies, none of the proposed models fully explain all of the different 
clinical cases observed in metastasis. Some research suggest that metastatic 
pattern  may be due to secretion of chemokines from different tissues to attract 
tumor cells and the expression different chemokine receptors on specific organs 
also known as the “homing theory” [30]. Driving migration from the primary tumor 
site, tumor cells quickly exhaust local nutrient supply and are forced to relocate to 
another nutrient-rich environment. Chemokines may act as local 
chemoattractants to direct tumor cells to specific organs rich with their respective 
ligands during metastasis [12, 31, 32].  
 
PCa Treatment Options 
Treatment options are recommended based on patient age and disease 
aggressiveness. Initial and primary treatment for 52% of men 64 years old or 
younger with localized and regional disease is a surgical procedure called radical 
prostatectomy, which involves the removal of the prostate and surrounding tissue 
[2]. This same patient population also receives a treatment combination of radical 
prostatectomy and radiation therapy.  
 
For men 65-74 years old, radiation therapy is commonly used to treat PCa 
due the detection of aggressive disease. In patients older, surgery and/or 
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radiation are not common treatment options. Active surveillance is most likely 
recommended for older men with less aggressive disease. However, hormone 
therapy is the first line treatment option for any patient with metastatic disease. 
Newer hormone therapies (abiraterone acetate, enzalutamide) have shown to be 
effective against metastatic disease [2]. Abiraterone acetate (brand name: 
Zytiga) is a steroidal androgen synthesis inhibitor. Abiraterone, the active form of 
Abiraterone acetate, decreases circulating levels of androgens through the 
inhibition of CYP17A1 activity.  However, Enzalutamide (brand name: Xtandi) is a 
non-steroidal pure antiandrogen that reduces PSA levels by preventing the 
androgen receptor from binding to DNA and co-activator proteins. As previously 
mentioned, hormone-resistant and/or hormone refractory PCa is not responsive 
to androgen deprivation therapy.  Available treatment options for early stages of 
disease include withdrawal of anti-androgen, estrogen compounds, adrenal 
suppressants, chemotherapy (i.e., docetaxel) , immunotherapy (i.e., sipuleucel-T) 
and radiotherapy (i.e., Radium-223) as well as combination treatments [33]. 
These treatment strategies are fairly effective for local/regional disease; however, 
once PCa spreads to the bone and other organs, it is not as responsive to these 
conventional treatment methods.  Therefore, it is imperative to develop improved 
targeted treatment strategies against advanced PCa.  Chapters 2-4 of this 
dissertation focus on the identification, validation and characterization of a 
biomarker related to the beginning stages of aggressive disease (i.e., invasion, 















Figure 1. The Pathogenesis of Cancer Metastasis. This diagram was adapted from  
Fidler et al. 2003 Nature Reviews Cancer 3, 453-458 (June 2003) doi:10.1038/nrc1098. 
(http://www.nature.com.echo.louisville.edu/nrc/journal/v3/n6/fig_tab/nrc1098_F2.html)  
Metastasis is a lethal disease in all malignancies and one canonical pathway of 
metastasis pathogenesis is displayed above.  Tumor cells establish a primary tumor site 
and are provided nutrients to support growth and proliferation through angiogenesis via 
the integration of vascular network of blood vessels. Tumor growth leads the detachment 
and invasion of tumor cells into surrounding tissue and lymphatic system. Tumor cells 
escape the primary site into the blood circulation system where they interact with 
platelets, lymphocytes, other blood components and travel to distant organs. Tumor cells 
adhere to the vessel wall of distant organs and undergo extravasation to establish a 
microenvironment. Tumor cells proliferate via angiogenesis to establish a secondary 
tumor site.   
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PCa screening tools  
The prostate specific antigen (PSA) test and digital rectal exam (DRE) are 
the primary screening tools used to detect PCa in the U.S. The PSA test 
measures the serum level (nanogram per milliliter) of the prostate specific 
antigen, a protein exclusively produced by cells in the prostate gland. PSA is a 
serine protease produced at high levels by normal prostate and malignant PCa 
cells. Historically, men with elevated PSA serum levels (PSA ≥ 4 ng/ml) were 
linked to a high risk of PCa development [6, 34]. The PSA test has a specificity 
range of 38.9-93.8% and sensitivity range of 20.5-83.4% dependent upon PSA 
cutoff values and type of assay standardization [35-37]. Furthermore, different 
variations of the PSA test such as PSA density, PSA velocity and percentage of 
free PSA were developed to aid in clinical decisions about PCa detection[36-38]. 
However, the appropriate thresholds for some of these tests remain to be 
determined for the detection of PCa. The wide spread use of PSA testing has led 
to a dramatic increase in PCa detection among U.S. men. Unfortunately, the 
frequent utilization of PSA testing has led to the over-diagnosis and 
overtreatment of localized disease, which is consistently observed in PCa 
screening studies [39-45].  
 
 Two major PCa screening trials, the European Randomized Study of 
Screening for PCa (ERSPC) and Prostate, Lung Colorectal and Ovarian (PLCO) 
Cancer Screening Trial, have influence the field’s perspective on the 
effectiveness of PSA testing to detect cancer and reduce mortality [40, 44, 46]. In 
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the PLCO study, no significant difference was observed in the mortality rates of 
U.S. men receiving PSA/digital rectal exam (DRE) screenings relative to men 
with usual care after a 13 year-follow-up [44, 46]. In contrast, the ERSPC study 
observed that PSA-based screening was associated with a 20% reduction in PCa 
mortality after a 9-year follow-up among European men [40].  
 
 However, the use of the PSA test was strongly associated with a 50% rate 
of over-diagnosis of PCa in the screening group [40]. Additionally, PSA testing 
was associated with 12-13% false-positive results based upon data from the 
ERSPC and PLCO studies [40, 44, 46].  Unfortunately, it is well known now that 
the PSA test has a number of biological stimulants (e.g., bacterial infection, BPH, 
age) other than cancer that elevate PSA levels (PSA ≥ 4ng/ml) in men. Most PCa 
biopsies performed due to elevated PSA levels reveal BPH and inflammatory 
prostatitis. Although BPH does not cause PCa, its similar symptoms to PCa can 
sometimes lead to PCa misdiagnoses [47, 48]. The PLCO and ERSPC studies 
along with other reports failed to determine an overwhelming benefit for PSA 
testing in patients. It remains unclear whether PSA testing significantly lowers 
PCa mortality. This evidence has led the United States Preventive Services Task 
Force and American Urological Association to recommend against the use of the 






Future PCa biomarkers  
Consequently, the PSA test is now considered an unreliable tool for PCa 
detection. Thus, novel biomarkers that are stably expressed in prostate tissue 
and biological fluids (e.g., serum, plasma) are desperately needed to clinical 
decisions about PCa detection and determining an individual’s risk of developing 
non-metastatic versus metastatic disease. Additionally, these biomarkers will aid 
in the field of precision medicine to make inform clinical decisions about which 
patients will receive a biopsy and/or aggressive treatment. Single nucleotide 
polymorphisms (SNPs), known as genetic variations inherited in cancer-
associated genes, were once viewed as potential tools to aid in clinical decisions. 
However, there is very limited evidence of the use of SNPs in a clinical setting 
and how they have improved clinical decisions.  Recently, cancer researchers 
have turned their attention to more clinically relevant biomarkers (i.e., 
microRNAs, lncRNAs). 
 
MicroRNAs regulate normal cellular growth and development processes 
as well as disease regulated processes (i.e., autoimmune disease, diabetes, 
Parkinson’s disease, cancer). Relative to current PCa screening tools, 
microRNAs are ideal candidates to predict the presence of cancer and aid in the 
diagnosis of disease states and disease recurrence in patients due to their 
unique expression profiles that correspond to different tumor stages, Gleason 
scores, and metastatic status in cancer in tissue and biological fluids [49-52]. 
Numerous published reports show miRNAs are stably expressed in tumor 
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derived cells, plasma, serum and tissue, and consistently distinguish between 
different disease stages compared with non-cancerous biospecimens [53].  The 
non-invasive detection of highly sensitive non-coding RNA expression in 
biological fluids would greatly improve disease detection and prognosis of 
metastatic disease. MicroRNA expression profiles can provide more informative 
knowledge about the intrinsic signaling pathways that favor or suppress 
tumorigenesis [53, 54]. Ultimately, the utilization of miRNA expression profiles 
will aid in the pursuit of precision medicine and efforts to improve cancer care in 
patients [55, 56].  Thus, the focus of this dissertation is centered on discovering 
micro-RNA profiles of PCa and determining their functional role in the process of 
oncogenic transformation. 
 
Biogenesis of microRNAs and their function 
 MicroRNAs are short endogenous RNA species stably expressed in 
plant/mammalian cells, biological fluids (e.g., serum, plasma, urine) and tissue. 
These RNA species are primarily transcribed from miRNA genes by RNA 
polymerase II as primary transcripts (pri-miRNAs) and subsequently cleaved by 
RNase III class enzyme, Drosha-DGCR8 (Pasha), in the cellular nucleus to 
produce ~70 nucleotide long hairpin structure also known as precursor miRNA 
(pre-miRNA) [57]. The Exportin-5-Ran-GTP complex transports the pre-miRNA to 
the cytoplasm and further cleaved by the Dicer-TRBP complex into a mature 
miRNA duplex. The functional strand of the mature miRNA duplex is incorporated 
into the RNA-induced silencing complex (RISC) with the Argonaute (AGO2) 
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protein. The mature miRNA transcript is 17-25 nucleotides in length. Normally, 
the passenger strand is marked for degradation of the miRNA transcript. Mature 
miRNA transcripts usually bind to the 3’UTR of their mRNA target with the 
assistance of AGO2 to negatively regulate mRNA translation. MiRNAs have 
thousands of mRNA targets, which contribute to their regulation of 60% of gene 
expression via translational repression of mRNA to protein, mRNA 
cleavage/degradation and de-adenylation [57]. 
 Since their discovery in the early 1990s by the laboratories of Drs. Ruvkun 
and Ambros through the present, these naturally occurring, short, non-coding 
RNA species have been demonstrated to be influential mediators of gene 
expression in multicellular organisms. Lin-4 was the first and origin miRNA 
discovered in 1993 through genetic testing in nematodes or microscopic worms. 
Further studies revealed a regulatory function for this small RNA. MiRNAs 
regulate cellular development, behavior and differentiation in the normal cells of 
multicellular organisms [58, 59]. However, these non-coding RNAs are mostly 
absent in unicellular organisms such as mouse embryonic stem cells. Majority of 
mammalian miRNA genes are located within the introns of host genes and co-
expressed their host genes as well. Their primary function is the promotion of 
cellular differentiation in normal cells, which is essential for multicellular 
organisms. For instance, during early zebrafish development most miRNAs are 
not expressed, but in later development miRNAs have tissue-specific expression. 
MiRNAs are widely conserved in plant and mammalian cells with a high 
abundance per cell [59]. Furthermore, miRNAs have been implicated in diverse 
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biological functions such as programmed cell death, early and late vertebrate 
development. For instance, some miRNAs regulate the Notching signaling 
pathway, which is essential for proper patterning and development. Majority of 
mammalian miRNA genes are located within the introns of host genes and co-
expressed their host genes as well. Yet within the last decade, numerous studies 
have shown the dysregulation of various microRNAs (miRNAs/miRs) within 
diseases such as PCa [53, 54, 60-65]. The differential expression of miRNAs in a 
variety of solid tumors demonstrate an opportunity for miRNAs to serve as 
promising biomarkers and/or therapeutic targets due to their detectability in 
human tissue and biological fluids and strongly influence of cancer hallmarks. 
MiRNAs may serve as promising non-invasive tools to aid in the improvement of 
cancer diagnosis, prognosis, clinical management, and prevention strategies.  
 
MicroRNAs in PCa  
 A number of miRNAs are differentially expressed in PCa [53, 54, 60-65]. 
Non-coding RNAs such as miRNAs exert their effects through the modulation of 
gene expression to either promote or repress tumorigenesis and disease 
progression in various cancers, including prostate  [66, 67]. To date, there are 
approximately 120 clinical trials evaluating miRNA expression profiles in relation 
to cancer [68]. However, less than five percent (~4.2%) of these clinical trials are 





      Dysregulation of miRNA expression contributes to the pathogenesis of PCa 
through their regulation of target genes involved in cellular behaviors (e.g., 
proliferation, motility, invasion, metastasis, angiogenesis). Fifty percent or more 
of human miRNA genes are located in fragile sites, breakpoint regions and 
regions of loss of heterozygosity and/or amplification, which can lead to the 
dysregulation of miRNAs.  Oncogenic miRNAs are commonly up-regulated in 
PCa in support of tumorigenesis. In contrast, tumor suppressor miRNAs are 
down-regulated to allow the tumor phenotype to persist and prosper. However, 
miRNAs do not always function the same way in every cancer type. Sometimes 
oncogenic miRNAs also play a dual role as a tumor-suppressor within the same 
cancer or other tumor types. Tumor suppression-related miRNAs can promote 
tumorigenesis in other cancer types. Recently, studies demonstrate some 
miRNAs function in a dual capacity as both oncogene and tumor-suppressor 

























Figure 2. Intracellular Biogenesis of microRNA. This image was adapted from Winter et. 
al Nat Cell Biol. 2009 Mar;11(3):228-34. doi: 10.1038/ncb0309-228. The microRNA gene 
is transcribed by RNA polymerase II and/or III into the primary microRNA transcript (pri-
miRNA) in the nucleus. Pri-miRNA transcript is cleaved by the microprocessor complex 
Drosha-DGCR8, into a precursor hairpin (~70nts) and exported into the cytoplasm by 
Exportn-5 Ran-GTP. RNase, Dicer, and TAR RNA binding protein (TRBP) complex with 
cleaves the precursor hairpin into a double stranded into a microRNA duplex.  The 
leading miRNA strand is incorporated into the RISC complex and co-associated with 
Argonate 2 (Ago2) protein. Mature microRNA transcript commonly binds to the 3’UTR of 
target mRNA transcript and promote mRNA degradation, translational repression and/or 




Oncogenic miRNAs  
Some oncogenic miRNAs that promote tumorigenesis in PCa include 
miRs-18a, -21, -32, -96, -106b-25 cluster, -125b, -221 and -222 [53, 71]. For 
instance, overexpression of miR-221/222 was observed in androgen insensitive 
metastatic PC-3 cells [72]. Inhibition of these miRNAs resulted in the reduction of 
colony formation by 4.5-fold in metastatic PC-3 cells [72] . In contrast, 
overexpression of miRs-221and -222 enhanced cellular proliferation by 2-fold 
and colony formation by 3-fold in metastatic androgen sensitive LNCaP cells via 
down-regulation of p27Kip1(CDKN1B), a major cyclin dependent kinase inhibitor. 
Mutation or loss expression of p27 can lead to uncontrolled cellular proliferation.  
 
MiR-125b is another oncogenic miRNA in PCa. MiR-125b expression was 
up-regulated in androgen independent PCa LNCaP sublines, cds1 and cds2, and 
prostatic tumor tissue compared to PCa LNCaP cells and benign tissue, 
respectively [73]. Overexpression of miR-125b in cds1 cells significantly 
increased cellular proliferation via down-regulation of BAK1, a pro-apoptotic 
gene.   
 
MiR-21 is a well-known oncogenic miRNA not only in PCa, but in other 
solid tumors as well. Inhibition of miR-21 expression in metastatic androgen-
independent DU145 and PC-3 cells significantly reduced cell motility 72 and 48 
hrs post-transfection, respectively [74]. MARCKS was identified as a direct target 
of miR-21 evident by the up-regulation of MARCKS protein expression in a dose-
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dependent treatment with anti-sense miR-21 in both DU145 and PC-3 cells. 
Additionally, inhibition of miR-21 via the anti-sense miR-21 significantly reduced 
the cellular invasion of DU145 cells relative to cells transfected with the anti-
sense control (p-value = 0.00079). This report suggests that cell motility 
reduction in DU145 and PC-3 cells is due to the up-regulation of MARCKS, a 
gene involved in the regulation of the actin cytoskeleton.  
 
The miR-106b-25 cluster is a group of miRNAs including miRs-106b, -93 
and -25. Several reports implicate that the miR-106b-25 cluster plays an 
oncogenic role in PCa. The miR-106b-25 cluster is up-regulated in metastatic 
PCa cell lines and malignant tissue relative to normal cells and tissue [75, 76]. 
For instance, Poliseno and associates (2010) observed that transient 
overexpression of the miR-106b-25 cluster down-regulated the protein 
expression of PTEN, a major tumor suppressor, by 40% in metastatic DU145 
cells [76]. In the same report, inhibition of the mir-106b-25 cluster and other 
miRNAs (miRs-19a, -22) reduced cellular growth in DU145 cells after 6 and 7 
days relative to controls. Also, stably miR-106b-25 cluster overexpressing DU145 
cells increased tumor growth in nude mice relative to PIG retroviral vector as the 
empty vector control. Furthermore, MCM7, the host gene of the miR-106b-25 
cluster, exhibited an oncogenic function via the increase of colony formation 
relative to empty vector and known oncogenes, c-MYC and RAS. 
Overexpression of MCM7 and miR-106-25 cluster members enhanced the 
transformation of wild type mouse embryonic fibroblasts (MEFs) relative to miR-
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106-25 cluster alone. In another study, overexpression of the miR-106b-25 
cluster in 22Rv1 cells significantly increased ECM binding and colony formation 
in soft agar [75]. Additionally, miR-106b, one of the miR-106b-25 cluster 
members, modestly reduced CASP7 protein levels in PCa xenograft 22Rv1, 
normal prostate epithelial RWPE1 and LNCaP cells. However, only the inhibition 
of miR-106b reduced ECM binding and colony formation in soft agar relative to 
the control and double inhibition of miR-106b and CASP7 in DU145 cells. This 
observation indicates that there are other miR-106b targets involved in altering 
ECM binding and anchorage independence in PCa. Further, in the same study, 
PCa patients who exhibited a high expression of miR-106b in their tumor tissue 
showed early biochemical recurrence compared to patients with a low expression 
(p-value = 0.014). Liang and co-workers (2014) observed that 24 hrs of hypoxia 
induced the expression of the miR-106b-25 cluster and reduced the gene and 
protein expression of REST (RE-1 silencing transcription factor), a tumor 
suppressor, in LNCaP cells [77]. Moreover, ectopic expression of miR-106b-25 
cluster down-regulated REST protein expression in metastatic androgen-
independent PC-3 cells as well.  
 
In PCa, miR-96 also promotes the tumor phenotype via its effects on 
cellular proliferation and colony formation. In a report by Yu and colleagues 
(2014), transient overexpression of miR-96 significantly enhanced cellular 
proliferation and colony formation in LNCaP cells relative to negative control [78]. 
Inhibition of miR-96 in metastatic PC-3 cells reduced cell proliferation and colony 
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formation in the LNCaP cells. In both cell lines, FOXO1, a tumor suppressor 
gene was identified a target of miR-96. This report suggests that the suppression 
of cell proliferation and colony formation in PC-3 cells and the increased in these 
cellular behaviors in LNCaP cells were primarily due to the up-regulation and 
down-regulation of FOXO1 protein level, respectively. In a recent study, Siu and 
co-workers (2015) identified AKT1S1 as a target of miR-96 in established clonal 
PTEN/TP53 double knockout AC1and AC3 cell lines, which exhibited a high 
expression of miR-96. Additionally, the expression of miR-96 and AKT1S1 is 
mediated by TGFβ signaling. TGFβ treatment (10ng/ml) increased miR-96 
expression and reduced AKT1S1 expression in PC-3 and relative to vehicle 
controls.    
 
MiRs-32 and -148a promote prostate tumorigenesis through their 
regulation of cell cycle and cell growth.  In a study by Jalava and colleagues 
(2012), overexpression of miR-32 and/or miR-148a significantly increased the 
growth of LNCaP cells [79]. Further analysis revealed that a significant 
population of LNCaP cells transfected with miR-148a were in the DNA synthesis 
(S) phase of the cell cycle. Moreover, overexpression of miR-32 was shown to 
down-regulate mRNA and protein expression of BTG2 in LNCaP cells. Whereas, 
PIK3IP1 was identified as a direct target of miR148a via its transcript and protein 
down-regulation in miR-148a overexpressing LNCaP cells. In the same study, 
BTG2 staining was lower in castration-resistant PCa (CRPC) (n = 94) tissue 
specimens relative to PCa specimens (n =170) and associated with advanced 
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disease (pT3 vs pT2) among cancer patients. In fact, the absence of BTG2 was 
strongly associated with a shorter progression-free survival of PCa relative to 
patients with BTG2 expression.  
MiR-18a is another miRNA that plays an oncogenic role in PCa. It is up-
regulated in metastatic PCa cell lines and tumor tissues relative to normal 
prostate epithelial cells and adjacent tissue [80]. Hsu and co-workers (2014) 
identified STK4, a tumor suppressor gene, as a putative target of miR-18a 
evident by the down-regulation of STK4 mRNA and protein expression in ectopic 
miR-18a expressing PC-3 and DU145 cells. Inhibition of miR-18a significantly 
reduced colony formation and cell proliferation in 22Rv1 cells. Tumor growth of 
anti-miR-18a 22Rv1 cells implanted in nude mice was reduced relative to the 
growth of anti-miR control cells.   
 
Tumor suppressor miRNAs 
In contrast, tumor suppressive miRNAs (e.g., miRs -29b, -34,  -101, -126-
3p, -145, 146a, -200 family, -675) play an important role in the repression of the 
tumor phenotype associated with PCa [53, 71]. For instance, Ru and associates 
(2012) observed miR-29b was down-regulated in androgen insensitive- and 
sensitive-PCa cell lines, PC-3 and LNCaP, and tumor tissue relative to 
immortalized normal prostate epithelial cells and non-tumor tissue [81]. 
Overexpression of miR-29b impairs wound healing and decreases cellular 
invasion in PC-3M cells, a highly metastatic PCa cell line derived from PC-3 
cells. Ectopic miR-29b expression significantly reduces the number of 
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metastases in vivo. In the same report, Snail, a major EMT marker, was identified 
as a direct target of miR-29b due to a decrease in Snail protein expression in 
miR-29b overexpressing PC-3M cells. Furthermore, miR-29b inhibition resulted 
in an up-regulation of Snail protein expression in LNCaP cells.  
 
MiR-34a is a mediator of p53 that acts as a tumor suppressor in PCa. It is 
significantly under-expressed in laser captured micro-dissected (LCM) malignant 
tissue (n = 10) and metastatic PC-3 cells compared with adjacent normal tissue 
and normal epithelial prostate cells, respectively [82]. Cellular invasion and 
colony formation in soft agar was suppressed in stably miR-34a transfected PC-3 
cells. Moreover, the tumor growth of stably miR-34a transfected PC-3 cells was 
reduced in nude mice. PC-3 cells overexpressing miR-34a exhibited a higher 
apoptotic population relative to the negative control. Overexpression of miR-34a 
down-regulated the protein expressions of c-Myc oncogene and metastasis 
mediator RhoA. The report suggests that miR-34a-induced reduction of cellular 
invasion, colony formation and tumor growth via the induction of apoptosis and 
down-regulation of c-Myc.  
 
In a recent report (2014), miR-146a was shown to function as a tumor 
suppressor in PCa [83]. Stable miR-146a overexpression significantly inhibits 
anchorage independent growth in the prostate epithelial non-metastatic P69 and 
highly metastatic M12 (a subline of P69) cell lines relative to vector control. In 
contrast, miR-146a inhibition in both cell lines increased colony formation in soft 
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agar. In M12 cells, miR-146a overexpression enhanced both cellular proliferation 
and invasion compared with the vector control. The inhibition of miR-146a 
produced the reverse effects on these cellular processes. Similar effects were 
observed in relation to cell proliferation in PC-3 and P69 cells relative to vector 
control. Additionally, Rac1 was identified as a direct target of miR-146a evident 
by the down-regulation of Rac1 protein level in both P69 and M12 cells. 
Moreover, the expression of miR-146a was down-regulated and Rac1 was up-
regulated in tumor tissue (n = 28) relative normal tissue (n = 28), which exhibits 
an inverse relationship between their expression profiles. In an earlier report, 
miR-146a was significantly under-expressed in hormone-refractory PCa cell lines 
(LNCaP, C4-2B, PC-3) and tumor tissue relative to androgen-dependent cell 
lines (LNCaP, PC-3-AR9) and non-cancerous tissue [84]. Forced overexpression 
of miR-146a down-regulated ROCK1, an oncogene, protein expression in PC-3 
cells.  
 
MiR-145 is a severely under-expressed miRNA in PCa cells and functions 
as a tumor suppressor.  For instance, one report observed that miR-145 
expression was significantly down-regulated in metastatic PCa cells (i.e., DU145, 
LNCaP, PC-3) relative to normal epithelial PWR-1E [85]. Also, low expression of 
miR-145 was detected in prostate tumor tissue compared with normal adjacent 
tissue. Moreover, miR-145 overexpression reduced cell viability in PC-3 cells in a 




The miR-200 family is a well-known tumor suppressor family in PCa. 
Forced expression of miR-200b in PC-3 cells significantly decreased the 
tumorigenic potential in an orthotropic PCa model relative to parental PC-3 and 
negative control cells [86]. Tumor tissue obtained from this model exhibited a 
reduction in cellular proliferation via staining for Ki-67, a proliferation marker, 
relative to controls. Furthermore, overexpression of miR-200b significantly 
decreased angiogenesis evident by a reduction in microvascular density and cell 
invasion of within miR-200b positive PC-3 tumors to negative control [86].  Also, 
overexpression of miR-200b negatively influences the EMT via down-regulation 
of mRNA and protein expression of ZEB1, a potent EMT mediator, in PC-3 cells. 
MiR-200c is low in LNCaP and DU145 cells [87]. A loss of miR-200c expression 
was observed in PC-3B1, derived from SCID mice bone marrow injected with 
PC-3 cells, and PC-3 due to DNA hyper methylation of miR-200c of CpG islands.  
 
MiR-101 is another miRNA that functions exclusively as a tumor 
suppressor in PCa. In a report by Varambally and associates (2009), ectopic 
expression of miR-101 decreased cellular invasion and tumor growth of 
metastatic DU145 cells relative to control miR and empty vector, respectively 
[88]. Additionally, DU145 tumor growth reduction was accompanied by a 
decrease in EZH2 protein expression. EZH2, a histone methyltransferase, is 
commonly elevated in aggressive and localized PCa. In contrast, miR-101 is 
normally under-expressed in metastatic PCa (n = 32) relative to benign controls 
(n =26). This inverse relationship between miR-101 and EZH2 suggests that 
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EZH2 may be a potential target of miR-101. The report further suggests that the 
loss of miR-101 expression allows for the unrestricted up-regulation of EZH2 to 
maintain the tumor phenotype of DU145 cells. 
  
MiR-675 also plays a tumor suppressor role in PCa. Derived from long 
non-coding RNA (lncRNA) H19, miR-675 is significantly under-expressed in 
highly metastatic M12 cells relative to non-metastatic prostate epithelial P69 cell 
line [89].  Inhibition of miR-675 expression in P69 cells resulted in a significant 
increase of cellular migration. In contrast, miR-675 overexpression dramatically 
reduced cellular migration of metastatic PC-3 cells, but not M12 cells. In P69 
cells, miR-675 overexpression led to a decrease in the protein expression of 
TGFBI, an extracellular matrix protein. TGFBI also known as transforming growth 
factor β induced protein is highly expressed in metastatic PCa and has been 
previously implicated in the promotion of cell adhesion, motility, invasion and 
metastasis in other cancers [89]. 
 
Dual role miRNAs in PCa 
Interestingly, there are only two miRNAs (miRs-133, -375) that have been 
identified to exhibit both an oncogenic and tumor suppressor role in PCa [51, 69, 
70]. MiR-133b was significantly under-expressed in PCa tumor specimen (n = 69) 
compared normal adjacent tissue (n = 69) [69].  A low tumor to normal tissue 
miR-133b ratio was indicative of a shorter disease recurrence-free survival in 
patients compared with patients with a higher ratio. Moreover, a univariate 
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analysis revealed a marginal association between miR-133b and a decrease in 
risk of biochemical recurrence (HR = 0.16; 95% CI = 0.02-1.06; p-value = 0.06). 
Overexpression of miR-133b in androgen-independent PC-3 cells significantly 
reduced cellular proliferation 96 and 144 hrs post-transfection relative to miR-
control.  MiR-133b overexpressing PC-3 cells treated with recombinant human 
TRAIL (20ng/ml) showed a significant induction of apoptosis, which suggests 
miR-133b promotes cellular death. However in another study by Li and 
associates (2014), overexpression of miR-133b in androgen-dependent PCa cell 
lines (LNCaP, 22Rv1) significantly enhanced cell proliferation. Indeed, ectopic 
miR-133b expression decreased the apoptotic cell population in LNCaP cells 
relative to negative control. In contrast, forced miR-133b overexpression 
increased the apoptotic cell population in PC-3 cells. MiR-133b expression was 
the lowest in less aggressive LNCaP cells and highest in aggressive PC-3 cells. 
Additionally, DHT treatment (100nM) within 48 hrs induced an increase in miR-
133b expression in LNCaP cells relative to vehicle control.  Androgen-sensitivity 
mediates miR-133b expression levels and its effect on tumor phenotypes.  
 
MiR-375 also has a dual function in PCa dependent on androgen 
sensitivity status. Costa and colleagues (2015) observed that miR-375 is 
significantly up-regulated in prostatic tumor tissue (n =114) relative to normal 
tissue (n =15) [70]. Moreover, higher levels of miR-375 were expressed in cases 
with higher Gleason scores (Gleason score ≥ 7) and advanced disease (pT3b) 
relative to patients with lower Gleason scores (Gleason score < 7) and tumor 
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stages (pT2 n = 58, pT3a n = 24). Ectopic miR-375 expression induced apoptosis 
and reduced cellular proliferation and invasion in metastatic PC-3 cells. In normal 
prostate epithelial RWPE1 cells, miR-375 overexpression decreased cell 
proliferation. However, this observation did not reach a level of significance.  
Mechanistically, overexpression of miR-375 down-regulated the CCND2 
transcript, a regulator of the cell cycle, which is also normally under-expressed in 
PCa. This suggests that miR-375 expression promotes cell cycle arrest in both 
metastatic PCa cells and normal epithelial cells. The aforementioned studies on 
miR-133b and miR-375 support the concept that miRNAs can have a dual 
function within one disease type. These studies aid in the understanding of how 
to appropriately target miRNAs that play both an oncogenic and tumor 
suppressive roles to identify robust markers in PCa. 
 
Clinical Applications of microRNAs 
Clinical trials are critically evaluating the role of miRNA expression in 
relation to PCa and their therapeutic use against disease progression. 
Unfortunately, a small percentage (4.2%) of clinical trials is evaluating miRNA 
expression profiles in PCa. Currently, there are six clinical trials investigating 
miRNA expression in relation to high-risk PCa, androgen deprivation therapy, 
therapies (i.e., abiraterone acetate, enzalutamide, radiotherapy) against 
metastatic hormone-resistant disease and high-risk PCa [NCT01220427, 
NCT02366494, NCT01503229, NCT02471469, NCT01444820, NCT02391051]. 
Three of the six clinical trials are currently recruiting study participants and two 
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trials are ongoing. Currently, no data have been published in relation to any of 
the clinical trials. In a phase 2 clinical trial, the efficacy of abiraterone acetate 
treatment against metastatic and hormone-resistant PCa is being evaluated by 
the University of Washington [NCT01503229]. This study is utilizing miRNA 
expression profiles to monitor molecular changes in tumor metastases.  In a 
phase 3 clinical trial, investigators are evaluating acute and delayed genito-
urinary and gastrointestinal toxicity in high-risk prostate adenocarcinoma patients 
treated with hypofractionated and conventional radiation therapy 
[NCT01444820]. As secondary outcome of this study, the expression of X- 
chromosome-linked micro-RNAs will be evaluated in response to radiation.  
 
Chemopreventive agents that alter miRNA expression offer other clinical 
applications for miRNAs as well [85, 90-98]. For instance, Geinstein (50 µM), a 
dietary isoflavone, up-regulates the gene and protein levels of ARHI, a tumor 
suppressor gene, via down-regulation of oncogenic miRs-221 and -222 in 
metastatic PC-3 cells [94]. Another chemopreventive agent, Resveratrol is a 
natural phytoalexin that down-regulates oncogenic miRNAs (miRs-7, -17, -18b -
20a, -20b -106a, -106b, -129, -185, -764*) and up-regulates tumor suppressor 
miRNAs (miRs-149, -150, -575, -671-5p, -939, -1290) in metastatic LNCaP cells 
[93]. Epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, up-
regulates tumor suppressor miR-330 expression in hormone-refractory PCa 
xenograft model relative to vehicle controls [95]. Chemopreventive agents that 
enhance the expression of tumor suppressor miRNAs and repress the 
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expression of oncomiRs may serve as excellent therapeutic agents against 
cancer to reduce disease burden in patients. Ultimately, miRNA profiles could be 
utilized to monitor physiological changes in response to disease progression 
and/or conventional treatments to evaluate the effectiveness of therapeutic 
agents and patient response to therapies [99-112]. 
This research project seeks to provide insight on the role of an 
understudied miRNA, miR-186, in prostate tumorigenesis. In this study, elevated 
expression levels of miR-186-5p were detected in PCa patients diagnosed with 
tumor stage I, III and IV relative to disease-free individuals. Furthermore, its 
expression was up-regulated in androgen sensitive and insensitive metastatic 
PCa cell lines relative normal epithelial cells. However, only two reports have 
evaluated miR-186 expression in PCa [63, 113]. The studies present conflicting 
data on the expression of miR-186-5p in prostate tumor tissue. Furthermore, the 
aforementioned studies do not provide a definitive function of miR-186-5p in 
PCa.  
To address this gap research and define the true role of miR-186-5p in 
PCa, we characterized the expression of miR-186-5p in vitro and determine the 
impact of miR-186-5p expression on the prostate tumor phenotype and epithelial 
PCa cells.  Moreover, we identified a potential mRNA target regulated by miR-
186 in PCa. Characterization of miR-186 in vitro will serve as the foundation of 
future studies evaluating the role of miR-186 prostate tumorigenesis.  
Our study findings suggest that miR-186-5p inhibition reduces, 
proliferation, anchorage independent growth and invasion in metastatic PCa (i.e., 
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PC-3, MDA PCa 2b) and also miR-186 overexpression in normal epithelial cells 
(i.e., RWPE1) proliferation and increased cell death. These tumor specific effects 
reveal miR-186-5p inhibition reduces prostate tumor phenotype aggressiveness 
and miR-186-5p is potentially oncogenic and supports prostate tumorigenesis via 
its endogenous up-regulation. Furthermore, we showed miR-186-5p inhibition led 
to the up-regulation of tumor suppressor gene, AKAP12. Ultimately, the detection 
of elevated miR-186-5p serum levels in combination with current PCa screening 
tools may improve the detection of aggressive disease and identification of high-
risk patients. Additionally, miR-186-5p and its regulated genes may serve as 
potential therapeutic targets for current therapeutic agents to modulate and 




DIFFERENTIAL EXPRESSION OF MIRNAS IN THE SERUM OF PROSTATE 
CANCER PATIENTS 
Introduction: 
The prostate specific antigen (PSA) test and digital rectal exam are gold 
standards for PCa detection. However, these tools demonstrate a marginal or no 
impact on prostate mortality rates among men in the U.S. and Europe. In 2009, 
two major epidemiological studies, the Prostate Lung Colorectal and Ovarian 
(PLCO) Screening Trial and European Randomized Study of Screening for PCa 
(ERSPC), evaluated the effectiveness of PSA testing and DRE against PCa 
mortality [40, 44, 46].  Based upon the data collected from these and other 
studies, the use of PSA testing by physicians or urologists has been discouraged 
for patients due to the recommendations made by the American Urological 
Association and the U.S. Preventive Services Task Force.  Therefore, additional 
biomarkers are needed to aid in the improvement of PCa detection.   
  As described in Chapter 1, miRNA dysregulation has been shown to play 
a pivotal role in the development and/or disease progression of PCa [71, 114, 
115, 116 ]. These non-coding RNAs bind to the 3’UTR region of their mRNA 
targets and invoke post-transcriptional changes such as degradation, 
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repression of translation to protein, and deadenylation of mRNA targets. 
MicroRNAs target a vast number of mRNA transcripts. Consequently, 
microRNAs influence about 30-60% gene expression in tumor-associated 
processes (e.g., proliferation, motility, invasion, metastasis, angiogenesis) [53, 
54, 60-65]. For instance, aberrant miRNA expression in PCa can distinguish 
between clinical features such as poorly and moderate differentiated tumor 
tissue, primary, metastatic disease, non-recurrent disease and biochemical 
recurrent patients in PCa [52, 117].  MiRNAs may serve as potential prognostic 
and diagnostic markers to aid in the detection and clinical management of PCa 
[62, 113]. Additionally, these short, non-coding RNAs can also be utilized as 
complementary tools for current screening procedures in PCa detection due to 
their ability to reflect the physiological changes in cancer, high stability and 
detectability in mammalian cells, tissue and different biological fluids [52, 65, 
118].    
  
MiRNAs generally participate in the regulation of cellular homeostasis, as 
previously discussed in Chapter 1. However in cancer, they can function as 
either oncogenes, tumor suppressors or both-depending on tumor type and 
hormonal sensitivity in some cancers such as PCa. MiRNAs are found in cells, 
tissues and biological fluids (saliva, urine, plasma, and serum). Changes in 
miRNA expression profiles have been linked to disease progression and different 
tumor stages of disease in PCa. These non-coding RNAs are highly stable and 
detectable in tissue, cell lines and biological fluids for hrs and/or days after 
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synthesis. The stability of miRNAs are attributed to the complex they form with a 
protein called Argonaute (AGO2), which prevents degradation of miRNAs [119]. 
During miRNA biosynthesis, miRNAs form a complex with AGO2 and this 
complex facilitates the degradation of target mRNA transcript and/or repression 
of translation to protein. 
 
A population of miRNAs are secreted from various cell types (i.e., tumor 
cells) and released into the extracellular space [120]. Commonly referred to as 
circulating miRNAs, miRNAs in biological fluids are released via exosomes (50-
100 nm), microvesicles (100-1000 nm), or are complexed to AGO2 and/or in high 
density lipoprotein particles shed from various cell types. Circulating miRNAs 
travel through the extracellular space and where they can be released into 
plasma, serum, saliva and/or urine [118].  These extracellular vesicles are 
mediate cell-to-cell communication and transport genetic information (i.e., 
miRNAs, mRNA) between different cells [118]. Reports suggest circulating 
miRNA expression profiles correspond to distinct stages in PCa [52, 117, 121]. 
Due to their high stability, detectability in biological fluids strong correlation to 
physiological changes, miRNAs are ideal candidates for disease detection and 
prognosis in PCa. However, there are major issues associated with the extraction 
of circulating miRNAs and the normalization methods required for their 





Challenges of miRNA detection 
   MiRNA expression profiles have the potential to serve as prognostic and 
diagnostic markers in PCa. However, the low abundance of miRNA in serum and 
use of different normalization techniques for miRNA expression across different 
solid tumor types plague miRNA detection. MiRNA extraction from serum yield 
low abundance of circulating miRNA and sometimes there are difficulties 
quantifying nucleic acid concentrations via spectrophotometry. Highly robust and 
sensitivity quantitation methods are needed to measure the concentration miRNA 
in serum.  Currently, there are no endogenous controls for miRNA expression 
normalization in serum. In the literature, various normalization techniques for 
miRNA expression are used in different tumor types [118]. However, there is 
overlap between some cancer types. In breast, lymphoma, colon and oral 
cancer, miR-16 and 18s are used as controls to normalize miRNA expression in 
serum. In contrast, RNU6B is used as a control for miRNA expression in the 
serum of gastric and colon cancer patients.  In PCa, reports by Brase et al. 
(2010) and Mitchell et al. (2008) spike denatured serum samples with cel-miRs-
39, -54 or 238 to normalize miRNA profiles [52, 122]. No control has been 
determined as the best overall control for miRNA expression among cel-miRs-39, 
-54 or 238 in PCa. In other PCa studies, RNU6B, median Ct value and absolute 
quantification are normalization techniques for serum and/or plasma samples 
[60].   Ultimately, the utilization of various normalization procedures could lead to 
great inconsistencies among serum-based miRNA expression profiles in prostate 
and other cancers.   
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Circulating miRNAs as prognostic and diagnostic tools 
 Circulating miRNAs non-invasively discriminate between PCa and healthy 
individuals as well as localized versus metastatic disease.  Several reports have 
demonstrated miRNA expression profiles correspond to specific disease stages 
and advanced disease [52, 65, 117, 123, 124]. MiRs-141 and -375 were 
significantly up-regulated in prostatic tumor tissue (n=36) relative to benign 
prostate tissue (n=36)  (p-value < 0.001) [52]. These miRNAs were also elevated 
in the serum of PCa patients with lymph node metastasis score N1 (n = 43) 
compared to those without lymph node spread (n =23) (p-value < 0.05). In this 
study, miRNA expression was normalized using miRs-cel-39, cel-54, and cel-238 
in serum to control for RNA extraction efficiency and cDNA synthesis. However, 
only miR-141 was significantly higher in patients with aggressive disease 
(Gleason Score > 8) relative to intermediate differentiated tumor tissue (Gleason 
Score = 7) (p-value < 0.05).  Additionally, miR-375 expression was significantly 
higher in metastatic PCa serum samples compared with localized disease serum 
(FDR p-value = 0.036). In a recent report (2013), elevated serum levels of miR-
141 corresponded to a greater number of bone metastases (metastases > 5) in 
hormone-naive PCa (p-value = 0.028), hormone-sensitive (p-value = 0.014) and 
hormone-refractory (p-value = 0.028) PCa patients relative to patients with lower 
metastases (3 > metastases) [123]. Serum-based miRNA expression profiles in 
the previous study were normalized to Sp6 and miR-cel-39. Circulating 
oncogenic miRs-195, -26a, and let7i were significantly up-regulated in the serum 
of PCa patients (n = 37) compared to BPH patients (n = 18) (p-value = 0.015-
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0.048) [65]. The expression of all miRNA expression profiles in the serum was 
normalized to miR-cel-39. Furthermore, this study suggests that these miRNAs 
may serve as monitoring tools in disease management since the removal of the 
prostate dramatically reduced the expression these circulating miRNAs. 
Furthermore, miRNAs can distinguish between patients with advance disease 
and low-grade disease. In a report by Mihelich and associates (2015), 14 
miRNAs (miRs-let-7a, -103, -107, -130b, -106a, -26b, -451, -223, -93, -24, 30c, -
874, -100, -146a) predicted the absence of high-grade PCa (Gleason grade 4 
and/or 5) in the plasma of BPH (n = 50) and low-grade PCa (Gleason grade =3) 
patients (n = 50) with a negative predictive value of 0.938 and positive predictive 
score of 0.366 (p-value < 0.05) [117]. MiRNA expression profiles analyzed in 
serum were normalized to Sp6 and miR-cel-39 expression. A negative predictive 
value is the probability that patients with a negative screening test truly have a 
negative disease diagnosis. However, a positive predictive score is the 
probability that patients truly have a positive diagnosis. In the same study, 8 
miRNAs accurately predicted a subset of PCa patients at low risk of biochemical 
recurrence with a negative predictive value of 0.941. The data suggest that these 
8 miRNAs may serve a pre-surgical predictor of disease recurrence.  In 
metastatic castration resistant PCa patients (n = 25), the up-regulation of miR-
423-3p in plasma was significantly associated with high Gleason score (Gleason 
Score ≥ 8), lymph nodal N1 status, and biochemical recurrence (PSA ≥ 0.2 
ng/mL on two occasions after prostatectomy) relative to patients with localized 
disease (n = 25) (p-value < 0.004) [124]. Similarly to previous studies, circulating 
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miRNA expression profiles were normalized to miR-cel-39, Sp6, and Sp3, 
respectively. 
  In this study, we evaluated the expression of 377 mature microRNAs in 
the serum of European-American PCa patients diagnosed with tumor stage I, III 
and IV disease. The goal of this evaluation was to identify differentially expressed 
circulating miRNAs in the serum that influence PCa development and/or 
aggressive disease. Fortunately, we identified two up-regulated circulating 
miRNAs (miRs-106b-5p and -186-5p) in the serum of PCa patients relative to 
non-cancerous controls. Moreover, we evaluated the expression of a serum-
based miRNA, miR-186-5p, in different prostate tumor cell lines. Circulating 
miRNAs reflect physiological changes associated with the disease states within 
PCa. The study findings identified an up-regulated circulating miRNA, miR-186-
5p, in PCa patient serum, which was also up-regulated in three metastatic PCa 
cell lines (i.e., PC-3, LNCaP, MDA PCa 2b). This miRNA may play a role in 
aggressive tumor phenotype associated prostate tumorigenesis and serve as a 











 Human Serum Biospecimens 
Serum (0.5-1 ml) from 15 men with PCa and 5 non-cancerous individuals 
was collected from patients prior to any therapy and obtained by BioServe 
Biotechnologies Biorepository (Beltsville, MD). Samples were divided into non-
cancerous controls (n=5), patients diagnosed with PCa stage I (n=5), stage III 
(n=5), and stage IV (n=5).  De-identified clinical characteristic data was provided 
for each patient by BioServe Biotechnologies (Beltsville, MD). Descriptive 
statistics were performed to determine patient median age, age range, median 
weight, weight range, body mass index (BMI) median, and BMI range. A high 
percentage of PCa patients had a smoking history (66.7%) and tumor 
classification of adenocarcinoma (60%). Statistical analyses for age, PSA levels 
and BMI were performed using the Wilcoxon Rank-Sum test and cut-off 
significance level of p-value ≤ 0.05.   
 
microRNA Isolation from Serum 
 Total isolation of microRNA was performed using the miRVana microRNA 
Isolation kit (Catalog # AM 1561, Thermo Fisher Scientific, Waltham, MA). Serum 
(250 µl) samples from 20 patients were transferred to phase tubes. Trizol LS 
Reagent (1 ml) was added to each sample in 1.5 ml tubes in a chemical hood 
and pipetted up and down 30 times at room temperature. Each sample was 
spiked with 2ul of cel-miR-39 (1nM, internal control miRNA) and incubated at 
room temperature for 5 minutes (mins). Pure ACS grade 98% chloroform (200 µl) 
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was added to each sample and shaken up and down for 15 seconds (secs). 
Samples were immediately transferred to phase lock tubes and incubated for 5 
mins at room temperature. Samples were centrifuged at 12,000xg at 4oC for 15 
mins. Aqueous phase (400 µl) of each sample was transferred to new 1.5ml 
tubes and 100% isopropanol (500 µl, 1.25x times aqueous phase volume) was 
added to each sample. Samples were pipetted up and down several times, each 
mixture (700 µl) was applied to a filter cartridge and centrifuged at 10,000 xg for 
30 secs. This step was continued until each sample was completely filtered 
through at room temperature. Flow-through was discarded after each 
centrifugation. Sample filters were washed with wash solution 1 (700 µl) one time 
and wash solution 2/3 (500 µl) two times using centrifugation at 10,000xg for 30 
secs at room temperature. Filters were centrifuged an additional time at 10,000xg 
for 1 minute to remove residual fluid and transferred to new 1.5ml tubes. 
Nuclease-free H2O preheated at 95
oC was applied to each filter and incubated 
for 5 mins. Total RNA was eluted using centrifugation at 12,000 xg for 1 minute 
to room temperature. Serum samples were stored at -80oC until further use. 
Statistical analysis for miRNA validation was performed using Unpaired Student 
T-test and cut-off significance level of p-value ≤ 0.05  
 
miRNA Expression 
Reverse transcription of total RNA (10 ng) was performed using TaqMan 
microRNA Reverse Transcription kit, miRNA specific RT primers and Peltier 
Thermal Cycler (PTC 200). Cycling cDNA was synthesized using the following 
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cycling conditions 16oC for 30 mins, 42oC for 30 mins, 85oC for 5 mins and hold 
indefinitely at 4oC. qRT-PCR was performed using  miRNA specific PCR TaqMan 
Assays (Life Technologies) and the following cycling conditions: hold for 2 mins 
at 50oC, 10 mins at 95oC for 1 cycle, 15 secs at 95oC and 1 minute at 60oC  for 
40 cycles. Amplification of cDNA was performed using the Applied Biosystems 
Step One PCR system (Applied Biosystems, Carlsbad, CA).  The relative 
expression of microRNA compared with U44 snRNA was calculated using 2-∆∆Ct 
method. 
 
Taqman Array Human MicroRNA 
Expression profiling for miRNA was performed using the Taqman Array 
Human MicroRNA Pool A Cards v.2 (Thermo Fisher Scientific, Waltham, MA, 
Carlsbad, CA) according to the manufacturer’s recommendations. The array card 
consisted of 377 miRNA assays, three endogenous controls (RNU6, RNU44 and 
RNU48) and one negative control unrelated to human (ath-miR-159a).  Each 
total RNA sample was diluted to 2 ng/µl using nuclease-free water.  Diluted RNA 
samples were reverse transcribed to produce cDNA in a 7.5 µl reaction using the 
TaqMan miRNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, 
MA, Carlsbad, CA) in addition to Megaplex RT Primers Human Pool A 10X 
(Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA). Samples were pre-
amplified using TaqMan PreAmp Master Master Mix 2X and Megaplex PreAmp 
Primers Human Pool A (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA) 
in a 25 µl reaction. The pre-amplification conditions were initiated in PCR tubes 
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at were 95°C for 10 min, 55°C for 2 mins and 72°C for 2 mins followed by 12 
cycles of 95°C for 15 secs and 60°C for 4 mins and followed by 99.9°C for 10 
mins and held at 4°C. Pre-amplified products were diluted with 75 µl of TE (0.1X, 
pH 8.0) and stored at -15°C. Then samples were thawed and added into a PCR 
reaction mix and 100 µl of mix was dispensed into each port of the TaqMan 
MicroRNA array. Then array was centrifuged for 2 times at 1200 rpm for 1 
minute, sealed and placed into the ABI 7900 Real Time PCR system. 
 
 Taqman Array Human MicroRNA Statistical Analysis 
MicroRNA expression profiles of 377 targets (Pool A TLDA card) in total 
RNA derived from PCa serum (n = 15) and non-cancerous controls (n = 5) were 
evaluated using R-programming software. MicroRNA profiles were normalized to 
the global median Ct value for each array (global Ct median value - target Ct 
value). After global normalization, missing Ct values associated targets were 
imputed using k nearest neighbor (kNN) imputation. miRNA expression profiles 
with too many missing values were screened off and not included in final 
analysis. Differentially up-regulated and down-regulated miRNAs for each each 
PCa stage vs. controls were determined using moderated t-tests and ANOVA in 
the R package limma [125-127]. Statistical analyses on miRNA expression 
profiles were adjusted for multiple hypothesis testing using the False Discovery 
Rate (FDR) method. MicroRNA profiles that reached statistical significance (FDR 






Table 1. Characteristics of Human Cell lines. Cell lines utilized in the current 
study are described in the table above. Tumor grade was not available for 







 Immortalized European American metastatic (PC-3, DU145) and normal 
prostatic epithelial cell lines (RWPE1, RWPE2) were obtained from American 
Type Culture Collection (ATCC) (Manassas, VA). E006AA and MDA-PCa-2b 
cells were obtained from Drs. Shahriar Koochekpour and Deepak Kumar. All cell 
lines were grown and maintained in a humidified incubator at 37oC with 5% CO2. 
 E006AA is an immortalized androgen-dependent human primary PCa 
epithelial cell line derived from a 50 year old African American male diagnosed 
with stage 2 (T2aN0M0) localized PCa. This cell line was obtained from Dr. 
Shahriar Koochekpour at Roswell Park Cancer Institute (Buffalo, NY). The 
E006AA cell line was sub-cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) medium supplemented with 10% of fetal bovine serum (FBS), 1% of 200 
nM L-glutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific, Waltham, 
MA) and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of 
Streptomycin, 25 µg/ml Amphoterricin B] (Catalog # 30-004-Cl, Mediatech Inc., 
Manassas, VA). 
 
 MDA-PCa-2b is an androgen dependent human immortalized epithelial 
cell line derived from a 63-year old African American male diagnosed with lung 
and bone metastasis. The cell line was obtained from Dr. Deepak Kumar at the 
University of the District of Columbia (Washington, D.C.). MDA-PCa-2b cells 
were sub-cultured in Kaighn’s modified Ham’s F-12K medium (Catalog #21127-
022, Thermo Fisher Scientific, Waltham, MA) supplemented with hydrocortisone 
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(100 pg/ml) (Catalog# H0396-100MG, Sigma) and human recombinant epidermal 
growth factor (EGF) (10 ng/ml), FBS (20%) and antibiotic [10,000 I.U./ml of 
penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml Amphoterricin B ] (Catalog # 
30-004-Cl, Mediatech Inc., Manassas, VA). 
 
 PC-3 is an androgen-independent immortalized human epithelial cell line 
derived from a 62-year old European American male with prostatic 
adenocarcinoma grade IV and bone metastasis. PC-3 cells were sub-cultured in 
Kaighn’s modified Ham’s F-12K medium (Catalog #21127-022, Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10% of FBS, 1% of 200nM L-
glutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific, Waltham, MA) 
and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of Streptomycin, 25 
µg/ml Amphoterricin B] (Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA). 
 
 LNCaP clone is an androgen dependent human immortalized epithelial 
cell line derived from a 50-year old European American male diagnosed with left 
supraclavicular lymph node metastasis. LNCaP cells were sub-cultured in RPMI 
1640 (Catalog # 11875-093, Thermo Fisher Scientific, Waltham, MA) 
supplemented with 10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog# 
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000 
I.U./ml of penicillin, 10,000 µg/ml of Streptomycin, 25 µg/ml Amphoterricin B] 




22Rv1 is an immortalized human prostate carcinoma epithelial cell line 
derived from a CWR22 xenograft. After castration –induced regression and 
relapse of parental androgen-dependent CWR22 xenograft, cells were serially 
propagated in mice.  The cell line was obtained from Dr. Deepak Kumar at the 
University of the District of Columbia (Washington, D.C.). 22Rv1 cells were sub-
cultured in RPMI 1640 (Catalog # 11875-093, Thermo Fisher Scientific, Waltham, 
MA) supplemented with 10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog# 
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000 
I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml Amphoterricin B] 
(Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA). 
 
C4-2B is a bone metastatic subline derived from C4-2 cells orthotopically 
injected into castrated male mice. C4-2B cells were extracted from large ossesus 
tumors in mice. C4-2B cells were sub-cultured in T-medium supplemented with 
10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog# 25030-081, Thermo 
Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000 I.U./ml of penicillin, 
10,000 µg/ml of Streptomycin, 25ug/ml Amphoterricin B] (Catalog # 30-004-Cl, 
Mediatech Inc., Manassas, VA). T-medium is composed of the following: 
Kaighn’s modified Ham’s F-12K medium, Dulbecco’s Modified Eagle’s medium, 
200 µg/ml of Biotin (Catalog# 84639, Sigma Aldrich, St. Louis, MO), 200 ng/ml 
3,3,5-triloda-l-thyronine sodium salt (Catalog# 16397, Sigma Aldrich, St. Louis, 
MO), 5mg/ml of transferrin (Catalog# T8158, Sigma Aldrich, St. Louis, MO), 10 
mg/ml of adenine hydrochloride (Catalog# A9795, Sigma Aldrich, St. Louis, MO) 
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and 2.5ml of ITS Liquid Media Supplement (100X) (Catalog# 13146, Sigma 
Aldrich, St. Louis, MO). 
 
DU145 is an androgen-independent immortalized human epithelial cell line 
derived from a 69 year old European American male with prostate carcinoma and 
brain metastasis.  DU145 cells were sub-cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) medium supplemented with 10% of fetal bovine serum (FBS), 
1% of 200 nM L-glutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific, 
Waltham, MA) and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of 
Streptomycin, 25 µg/ml Amphoterricin B ] (Catalog # 30-004-Cl, Mediatech Inc., 
Manassas, VA). 
 
 RWPE-1 is an immortalized normal human prostate epithelial cell line 
obtained from a European American donor and immortalized with human 
papillomavirus 18. RWPE-2 is an immortalized normal prostate epithelial cell line 
derived from RWPE1 cells and transformed by v-ki-Ras. Both RWPE1 and 
RWPE2 were sub- cultured in Keratinocyte-SFM (Catalog # 17005-042, Thermo 
Fisher Scientific, Waltham, MA) supplemented with bovine pituitary extract (BPE) 
(50 µg/ml), human recombinant epidermal growth factor (EGF) (5 ng/ml), and 1% 
of antibiotic [10,000 I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml 





microRNA Isolation from cell lines 
 Total isolation of mRNA and microRNA was performed using the miRVana 
microRNA Isolation kit (Catalog# AM 1561, Thermo Fisher Scientific, Waltham, 
MA). Cells were seeded at an optimal cell density into 60 mm plates in growth 
medium. Cells were washed once with 1X PBS (2 ml), lysed in dishes with 
mirVana lysis buffer (600 µl), harvested with cell scraper and pipetted into 1.5ml 
tubes. Cells were vortexed for 30 secs to completely lyse cells. Homogenate 
additive (1/10 of cell lysate volume) was added to cell lysates and vortexed for 30 
secs. Samples were incubated on ice for 10 mins and equal volume of 
acid/phenol chloroform mixture was added to each tube. Samples were vortexed 
for 60 secs and separate into aqueous and organic phases through centrifugation 
at 10,000xg for 5 mins at 4oC using Eppendorf Centrifuge 5810R. Aqueous 
phase (≥ 400 µl) was pipetted into new 1.5ml tubes and 100% EtOH (1.5 x 
aqueous layer volume) was added to each tube. Samples were added to filters in 
new collection tubes, centrifuged at 10,000 xg for 30 secs. Samples were 
processed at room temperature and flow-through was discarded after 
centrifugation. Filters were washed once with 700 µl of wash 1 solution and 
centrifuged at 10,000 xg for 30 secs. Filters were washed twice with 500µl of 
wash 2/3 solution and centrifuged at 10,000 xg for 30 secs. Filters were 
centrifuged at 10,000 xg for 1 minute to remove residual fluid and transferred to 
new collection tubes. Elution buffer (60 µl) was added to the center of each filter 
and incubated for 5 mins. miRNA was eluted through centrifugation at 10,000 xg 
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for 1 minute at room temperature. Samples were placed on ice and RNA 


























Serum was collected from PCa patients diagnosed with tumor stage I, III, 
IV and disease free patients that self-identified as men with European ancestry 
as reported in Table 2. Controls were received a diagnosis of a normal prostate 
at the time of serum collection. PCa cases (n = 15) had an age range of 47-72 
and a median age of 69. Non-cancerous controls had an age range of 56-71 and 
a median age of 69. No significance difference was observed between the 
median age of cases and controls (p-value = 0.726). The prostate serum antigen 
(PSA) median among cases was significantly higher relative to non-cancerous 
controls (p-value = 0.048). Sixty percent (n = 9) of the cases were identified as 
adenocarcinoma and 40% (n = 6) of the cases were not reported or classified. 
Sixty-seven percent of the PCa patients (n =10) had a history of smoking; 
however the smoking status among the controls was not available for this study 
population. Relative to the controls, no difference was detected between PCa 
patient BMI median relative to controls. Majority of the cancer patients received 
at least 2 types of therapy (73.3%) against PCa, which include chemotherapy (n 
= 2, 13.3%), radiation (n = 8, 53.3%), surgery (n = 7, 46.7%), and hormonal 
























Table 2. Population Description of PCa Patients. Clinical data for patients from Bioserve 
is displayed in the above table. Patients (n=20) self-identified as European American 
males. Majority of PCa cases were diagnosed with adenocarcinoma (60%), had a 
smoking history (66.7%) and received 2 or more therapies. Relative to controls, cases 
had higher median serum PSA level, weight and BMI value relative to controls. 
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Differentially expressed serum-based miRNAs in PCa 
MicroRNA profiling was performed using total RNA from collected from 
serum of PCa patients diagnosed with stages I (n = 5), III (n = 5) and IV (n = 5) 
relative to non-cancerous controls (n = 5), as described in Chapter 2 methods 
section. MicroRNA array profiling measured the expression of 377 miRNAs in the 
serum of PCa patient diagnosed with localized disease (stage I), pre-metastatic 
and bone metastatic disease (Stage IV) relative to non-cancerous controls (n = 
5), as summarized in Figure 3. After global normalization of miRNA profiles, array 
analysis revealed 26 miRNAs were differentially expressed in PCa patients.  
Relative to non-cancerous controls, 17 miRNAs (miRs-18a, -122, -133a, -145, -
150, -186, -191, -197, -296, -342-3p, -374, -454, -484, -518d, -744, -885-5p, -let-
7b) were down-regulated in serum from PCa patients, shown in Table 3. In 
contrast, nine miRNAs (miRs-21, -92a, -99b -106b, -142-3p, -185, -302b, -320, -
520e) were up-regulated in PCa serum relative to controls (Table 2). However, 
only 6 miRNAs (miRs-106b-5p, -186-5p, -302b-3p, -342-3p, -520e, -885-5p) were 
adherent to the following selection criteria; FDR p-value ≤ 0.05 and fold change 
(0.5 > FC, FC ≥ 2). These miRNAs were selected for further validation via qRT-






















Figure 3. Heatmap of Differentially expressed  miRNAs in PCa serum. Color scheme for 
heatmap: orange (no change), red (high expression) and yellow (low expression). The 
expression of 377 miRNAs in the serum of patients with diagnosed with tumor stage I, III 











Table 3. Differentially expressed miRNAs in PCa serum.  After global normalization, 26 
miRNAs were differentially expressed in PCa serum relative to non-cancerous controls. 
Relative to non-cancerous controls, only 9 miRNAs were up-regulated in PCa stage I, III 
and IV disease. The remaining 17 miRNAs were down-regulated in PCa serum. After 
adjusting for multiple hypothesis testing (false discovery rate [FDR] p-value ≤ 0.05), only 
6 miRNAs were determined to be differentially expressed in prostate serum. Significant 
FDR p-values are bolded in the above table. 
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Validation of miRNAs 
The expression of miRs-106b-5p, -186-5p, -302b-3p, -342-3p, -520e, and 
-885-5p was measured in two independent total RNA isolations from serum 
(Table 2). All miRNA expression was normalized to a spiked-in external control, 
miR-cel-39 and analyzed using specific miRNA Taqman qRT-PCR assays. No 
differences were detected in the expression of cel-miR-39 in serum between non-
cancerous and PCa cases (Figure 5). Among the selected miRNAs, the 
expression of miRs-520e and 302b were below the detectable level (Ct value < 
37 or undetermined) in PCa patient and non-cancerous control serum. The 
expression of miR-885-5p was inconsistent between total RNA isolations for 
patients and controls (Figure 8). Therefore, this miRNA was not further validated 
in vitro. MiR-342-5p was up-regulated in PCa serum relative to non-cancerous 
controls. Unfortunately, this up-regulation was not statistically significant. 
However, miRs106b-5p and -186-5p were significantly up-regulated in PCa 
serum relative to non-cancerous controls in both independent isolations (Figures 
6-7). MiR-186-5p was selected for further validation and characterization in vitro 
to determine its role in PCa due to the limited evidence available on this miRNA 












Figure 4. Flowchart of miRNA profiling for serum-based miRNAs. The expression of 377 
mature miRNA profiles was evaluated in the serum of PCa patients (n = 15) and non-
cancerous controls (n= 5). MiRNA profiles were normalized to global median Ct value 
among all the miRNA profiles. Next, miRNA profiles associated with missing values (≥ 
50) were imputed using K nearest neighbor imputation program. After global 
normalization, the array determined that 26 miRNAs were differentially expressed in PCa 
serum relative to non-cancerous controls. After adjusting for multiple hypothesis testing 
using the false discovery rate (FDR) (FDR p-value ≤ 0.05), 6 miRNAs were determined 
to be differentially expressed serum-based miRNAs. Selected miRNAs were individually 
validated in the serum of PCa and controls. After validation, the expression of only two 













Figure 5. Ct values of MiR-Cel-39 (cel-39) in PCa serum and non-cancerous controls. 
MiR-Cel-39 is a non-human synthetic miRNA was used as an external control for miRNA 
isolation from serum. Cel-39 was spiked into denatured serum to control for the 
normalization of miRNA expression in non-cancerous controls and PCa patients. No 
significance differences were determined in the Ct values between controls and cases 
(p-value = 0.116). Statistical analysis was performed using a non-parametric one way 
















Figure 6.  MiR-106b-5p expression in PCa serum. Expression of miR-106b-5p and -186 
was validated in two independent isolations of miRNA from serum. MiRNA expression 
was measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous 
controls (n = 5). A) MiR-106b-5p was up-regulated by 3.1-11.8-fold in patients diagnosed 
with tumor stage I, II, and III disease relative to non-cancerous controls in the 1st 
isolation (p-value > 0.02). B) MiR-106b-5p was up-regulated in only tumor stage I and III 
disease relative to controls.  Statistical analysis was performed using Unpaired t-test and 












Figure 7.  MiR-186-5p expression in PCa serum. Expression of miRs-186-5p was 
validated in two independent isolations of miRNA from serum. MiRNA expression was 
measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous 
controls (n = 5). A) MiR-186-5p was significantly up-regulated by 2.6-8.1-fold in tumor 
stage I and II serum from both isolations relative to non-cancerous controls (p-value < 
0.03). B) However, miR-186 expression was only significantly elevated by 7.9-fold in 
stage IV disease in the second isolation relative to non-cancerous controls (p-value = 
0.02).  Statistical analysis was performed using Unpaired t-test and significance level of 













Figure 8. MiR-885-5p expression in PCa serum. Expression of miR-885-5p was 
validated in two independent isolations of miRNA from serum. MiRNA expression was 
measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous 
controls (n = 5). A) MiR-885-5p was significantly down-regulated by 46-57% in patients 
diagnosed with stage I and II disease relative to non-cancerous controls (p-value = 0.02-
0.0034). B) However, in the second isolation miR-885-5p expression was up-regulated 
by 2.5-7.4 fold in stage III disease relative to non-cancerous patients (p-value = 0.005). 
Statistical analysis was performed using Unpaired t-test and significance level of 0.05 




















Figure 9. Mature miR-186-5p expression in androgen dependent and independent PCa 
cell lines. The relative expression of miR-186-5p was measured in normal prostate 
epithelial cells (RWPE1, RWPE2), non-metastatic (E006AA), prostate carcinoma 
xenograft (22Rv1), bone (PC-3), lymph node (LNCaP), brain (DU145) metastatic PCa 
cells using specific Taqman primers and qRT-PCR. MiR-186 expression was not 
significantly higher in RWPE2, E006AA, 22Rv1, and DU145 cell lines relative RWPE1 
cells. However, miR-186-5pwas up-regulated by 3.2-16.2-fold in three metastatic PCa 
cell lines (LNCaP, MDA PCa-2b, PC-3) relative to normal prostate epithelial RWPE1 
cells. Metastatic PC-3 cells exhibited a 16-fold increase, the highest expression, in the 
expression of miR-186-5p relative to normal prostate epithelial cells (p-value = 0.0002). 
MiRNA expression was normalized to endogenous control miR, RNU44, and measured 
in three independent experiments. Statistical analysis of experiments was performed 


















Figure 10. Ct values of RNU6 and RNU44 in normal prostate epithelial and PCa 
cell lines. A) Higher Ct values were detected for RNUB6 in normal epithelial and 
PCa cell lines (p-value = 0.571). B) However, lower Ct values (higher expression) 
were detected for RNU44 in normal epithelial and PCa cell lines relative to 
RNU6. The Ct value of RNU44 in PC-3 cells was significantly higher relative to 
C4-2B (p-value = 0.0061). Statistical analysis was performed using a non-
parametric one way non-parametric ANOVA test and Dunn’s multiple hypothesis 




Expression profile of miR-186-5p in metastatic and non-metastatic PCa cell lines 
The expression of miR-186-5p was measured in androgen sensitive 
metastatic (i.e., LNCaP, C4-2B, 22Rv1, MDA-PCa-2b), androgen sensitive non-
metastatic (i.e., E006AA) and insensitive metastatic (DU145, PC-3) PCa cell 
lines relative to normal epithelial prostate cells (RWPE1) and k-Ras transformed 
normal epithelial cells (RWPE2) using qRT-PCR. These cell lines are also 
described in Table 1. MiRNA expression was normalized to the expression of 
endogenous control miR RNU44 in PCa cell lines.  RNU44 was selected as an 
endogenous control miR as supposed to RNU6 due to lower Ct values, which are 
indicative of higher expression in normal epithelial and PCa cell lines used in this 
study (Figure 10). Expression of miR-186-5p was not significantly up-regulated in 
transformed normal epithelial (RWPE2), prostate carcinoma xenograft (22RV1), 
metastatic PCa (DU145) and non-metastatic PCa (E006AA) cells relative to 
RWPE1 cells. However, miR-186-5p was significantly up-regulated by 3.2-16.2-
fold in metastatic PCa cells (LNCaP, MDA-PCa-2b and PC-3) relative to the 
control cell line (RWPE1), as shown in Figure 9 (p-value < 0.01). In LNCaP cells, 
miR-186-5p expression was up-regulated by 3.4-fold relative to normal epithelial 
cells (p-value = 0.009).  Additionally, the miR-186-5p was up-regulated by 3.2-
fold in MDA PCa 2b cells relative to RWPE1 cells (p-value = 0.005). Interestingly, 
miR-186-5p expression was most pronounced in androgen insensitive metastatic 
PC-3 cells with a 16.2-fold increase relative to RWPE1 cells (p-value = 0.0002). 
However, miR-186-5p expression in PCa cell lines did not exhibit a dependence 




  Circulating non-coding RNAs (e.g., mRNAs) in serum play a pivotal role in 
many cancers, including PCa.  MiRNAs are essential regulators of genes 
involved in various hallmarks of cancer. At the beginning of this study, there were 
limited reports on the expression of circulating miRNAs in PCa. To address this 
research gap, we initiated a pilot study to evaluate whether circulating miRNAs 
were differentially expressed in the serum collected from PCa patients diagnosed 
with non-metastatic and metastatic disease relative to disease-free men. In the 
current study, six circulating miRNAs (-106b-5p, -186-5p, -302b-3p, -342-3p, -
520e, -885-5p) were differentially expressed in the serum of PCa patients using a 
intermediate high-throughput Taqman array cards. Two circulating miRNAs (-
106b-5p, 186-5p) were up-regulated in the serum of PCa patients when 
compared to controls, following qRT-PCR.  Since miR-106b-5p was 
characterized as an oncogenic miRNA with several direct gene targets using 
PCa cell models, further analysis was focused on miR-186 [75, 76, 96, 128, 129]. 
In addition to the up-regulation of miR-186 in the serum of PCa patients, we also 
demonstrated miR-186 was up-related in a few metastatic PCa cell models (PC-
3, MDA-PCA-2b, LNCaP).   
 Some discrepancies were detected in the expression of circulating 
miRNAs between the microarray and individual qRT-PCR analyses. For instance, 
miR-186-5p was down-regulated in the serum of PCa patients using the 
microarray data but up-regulated following qRT-PCR. Discrepancies between the 
micro-array and qRT-PCR were presumably attributed to the difference in 
normalization techniques (i.e., global normalization and miR-cel-39 external 
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control) used for these two genomic approaches.  In particular, analysis of 
miRNA using Taqman array requires global normalization; whereas, qRT-PCR 
required the use of an external control (i.e. miR-39) that was spiked in the serum 
samples. However, qRT-PCR findings that used an external control were 
considered more reliable than Taqman Array data.  Global normalization of 
Taqman array data was heavily reliant upon median Ct values of all miRNAs 
analyzed, which may lead to false positive results or mis-interpretation of the 
directionality of the expression of circulating miRNAs.  Normalization of qRT-PCR 
data of circulating miRNAs using miR-cel-39 as an external control helped to 
control for sample losses during the total RNA isolation, cDNA generation, 
miRNA isolation steps.  Since there is no appropriate endogenous control for 
circulating miRNAs, previously published reports suggest the use of synthetic 
miRNA Caenorhabditis elegans 39 to normalize circulating miRNA profiles 
among PCa patients [52, 117, 123, 124].  Consequently, miR-cel-39 was used in 
the current study to normalize miRNA expression in serum due to its common 
use in literature in relation to PCa. 
 
 Although there are no published reports on the expression of miR-186 in 
the serum from PCa patients and appropriate controls, miR-186-5p expression 
has been evaluated in two independent prostate tumor tissue-based studies with 
mixed results [63, 113]. In one study, miR-186-5p was significantly down-
regulated in fresh frozen tumor tissue (n = 50) relative to benign hyperplasia (n = 
30) and matched non-malignant tissue (n = 50) among German men [113].  This 
 67 
 
study failed to remove surrounding normal tissue from cancerous tissue using 
micro-dissection, which may have skewed miR-186-5p expression within a non-
pure population of tumor tissue.   
 Commensurate with our serum based findings, Ambs and colleagues 
(2008) observed an up-regulation of miR-186-5p expression in laser 
microdissected tumor tissue of prostate patients diagnosed with extraprostatic 
disease (i.e., extension of the tumor outside or independent of the prostate) 
relative to patients with no extraprostatic disease among European (n = 30) and 
African American (n = 30) men [63]. Unlike the previous report among German 
PCa patients, this 2008 study evaluated miR-186-5p expression using micro-
dissected tissue, which provides a pure population of tumor cells in which the 
miRNA profiles are not contaminated, skewed or diluted by normal surrounding 
tissue (personal communication with Dr. Lacey McNally, University of Louisville). 
Therefore, miR-186-5p expression in the Ambs study rather than the German 
study was given more consideration in relation to our study findings. 
 
 Previously, miR-186-5p expression has been reported as up-regulated in 
several different malignancies [99-104, 130]. Furthermore, miR-186 has 
demonstrated an oncogenic function via its down-regulation of anti-tumor 
associated genes in cancer. For instance, miR-186 overexpression led to the 
down-regulation of tumor suppressors, FOXO1 and NR5A2, in vitro in 
endometrial and pancreatic cancer, respectively [100, 103]. Additionally in 
cervical cancer cells, miR-186 overexpression down-regulated the gene 
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expression of pro-apoptotic gene, P2X7 [101]. However, the role of miR-186 in 
cancer may be tumor specific because it appears to have a tumor suppressor 
role in other cancers [106-112]. In the next chapter of this dissertation, we 
demonstrate inhibition of miR-186 corresponds with a suppression of cellular 
proliferation, anchorage independent growth and cellular invasion suggest miR-
186 exhibits an oncogenic role in PCa within our metastatic PCa cell models. 
 
 We have considered study limitations, strengths and future directions.  
The analysis of circulating miRNA expression was restricted by a small sample 
size of PCa patient serum. To our knowledge, our lab is the first to demonstrate 
the up-regulation of miRNA-186-5p in the serum of PCa patients as well as 
metastatic cell models.  Given the discrepancy in the directionality of the Taqman 
array and qRT-PCR of serum-based miRNAs, we speculate global normalization 
may not be the best normalization technique for circulating miRNAs in PCa.  We 
propose normalization of circulating miRNA profiles using an external control like 
miR-cel-39 may be more appropriate than a global normalization used for the 
Taqman array analysis.  To prevent future issues in miRNA profiling during high-
throughput analysis, we will include miR-cel-39 and other synthetic 
Caenorhabditis elegans miRNAs within customized microarrays to normalize the 
expression of serum-based miRNAs.  In future studies, we will confirm the up-
regulation of miR-186-5p and other oncomiRs in serum and matched micro-
dissected PCa tumor samples relative to age-matched controls using 
ethnically/racially diverse sub-groups. Additionally, we will evaluate miR-186-3p, 
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the passenger strand of miR-186, expression to determine whether only miR-
186-5p is uniquely up-regulated in PCa serum and cell lines. The up-regulation of 
miR-186 based on disease-state or disease aggressiveness within independent 
studies may support it’s utility as a prognostic tool. 
 
 Circulating non-coding RNAs (i.e., miRNAs) have the great potential to 
serve as clinical biomarkers capable of distinguishing between lethal and non-
lethal disease.  In addition, miRNA’s have the capacity to monitor physiological 
changes and evaluate the effectiveness of different therapies against PCa in 
patients. For instance, after prostate patients underwent a radical prostatectomy 
the serum-based expression of oncogenic miRs-195, -26a and -let-7i 
dramatically reduced in patients. Moreover, several studies demonstrate that 
miRNA expression profiles relate to early stage, advanced, and recurrent disease 
[52, 65, 117, 121, 123, 124]. MiRNA expression profiles that correspond to 
specific disease stages provide an opportunity to improve current prognostication 
and clinical management strategies. Furthermore, miRNA expression may help 
enhance the capacity of current PCa tools, namely PSA test and digital rectal 
examination to identify individuals with a high-risk of developing aggressive or 
recurrent disease as well as those who may benefit from more aggressive 
treatment or follow-up care.  Ultimately, miRNAs may serve as non-invasive 
biomarkers with the capacity to improve PCa prognostication, treatment and 









 MiRNAs are differentially expressed in tumor cells and greatly influence 
several cellular hallmarks of cancer (i.e., proliferation, migration, anchorage 
independent growth and invasion) via their regulation of target mRNAs [73, 75, 
79, 81, 89]. Specifically, miR-186 expression alters tumor cellular behavior in 
vitro in several malignancies including bladder, pancreatic, ovarian and lung 
[103, 106, 107, 112, 130, 131]. MiR-186 is an intronic miRNA located on 
chromosome 1 at 1p31.1 within the ZRANB2 gene locus. This miRNA is 
differentially expressed in various tumor types including PCa [63, 99-104, 106-
113]. In some cancers, miR-186 plays an oncogenic role due its overexpression, 
but in other neoplasms miR-186 functions as a tumor suppressor. Previously, we 
demonstrated an up-regulation of miR-186-5p expression levels in the serum of 
PCa patients diagnosed with stage I, III and IV disease relative to non-cancerous 
controls. Additionally, we also observed a significant up-regulation of miR-186-5p 
in metastatic PCa cell lines (LNCaP, MDA PCa-2b, PC-3), but highest in PC-3 
relative to normal prostate epithelial RWPE1 cells. However, miR-186-5p has 
never been characterized as an oncogenic miRNA in PCa. 
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 Several reports demonstrate miR-186 expression is down-regulated in 
cancer-associated fibroblasts, oral squamous, non-small cell lung, colorectal, 
bladder and ovarian cancer [106-112, 130, 131]. In two reports, miR-186 was 
under-expressed in non-small lung cancer (NSCLC) tumor tissue and cell lines 
(A549, NCI-H358, H157, H1299) relative to adjacent normal tissue and normal 
bronchial epithelial cells (16HBE) [106, 107]. In the same studies, overexpression 
of miR-186-5p inhibited cellular migration and invasion in NSCLC cell lines [106, 
107]. Overexpression of miR-186 in bladder cancer cell lines (i.e., HT-1346, RT4) 
lead to a decrease in cellular proliferation, and invasion [130]. Furthermore in a 
recent report (2015), miR-186 expression was significantly low in cisplatin-
resistant epithelial ovarian cancer (EOC) cell lines (i.e., ACRP, C13*, 
OVCAR3/DDP) relative to cisplatin-sensitive ovarian cancer cell lines (i.e., 
A2780, OV2008, OVCAR3) [112]. Ectopic expression of miR-186 reduced cell 
motility via reduction of vimentin and increase of E-cadherin protein expressions 
in cisplatin-resistant EOC cell line, ACRP. Additionally, higher miR-186 
expression was exhibited in platinum sensitive ovarian tumor tissue from patients 
with progression-free survival greater than 6 months. In another study, miR-186 
overexpression reduced proliferation and invasion of bladder cancer cells [131]. 
Collectively, these aforementioned reports suggest that miR-186 plays a tumor 
suppressive role in NSCLC, and ovarian cancer. 
In contrast, miR-186 expression is up-regulated in endometrial, 
pancreatic, esophageal, cervical, head/neck, and non-melanoma skin cancer [99-
104, 130, 132]. For instance, Zhou and co-workers (2008) observed that miR-186 
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expression was up-regulated in HeLa cells, a cervical adenocarcinoma cell line, 
relative to human ecto-cervical-vaginal epithelial cells (hEVEC) [101]. MiR-186 
expression was also shown to be up-regulated in endometrial tumor tissue and 
an endometrial cell line, Ishikawa, relative to controls [100]. In pancreatic cancer, 
miR-186 is up-regulated in tumor tissue (surgical specimens T2, T13, T29, T33, 
T34, T36-38, T40) and cell lines (BxPC-3, Panc-1, MIA, Hs766T, HPAFII, ASPC-
1) relative to normal pancreatic tissue and human pancreatic ductal epithelial 
(HPDE) cells [102]. In another report, overexpression of miR-186 in pancreatic 
cell lines (Panc-1, BxPC-3, and MiaPaca-2) induced cellular proliferation and 
migration relative to negative controls [103]. These effects were reversed after 
inhibition of miR-186 in pancreatic cell lines. Moreover in the same report, miR-
186 was significantly up-regulated in the tumor tissue of pancreatic cancer 
patients with poor survival (median survival of 13.8 months) relative to patients 
with low miR-186 expression with a longer survival time [103]. Additionally, 
overexpression of miR-186-5p led to enhanced cell proliferation, anchorage 
independent growth and colony formation of J82 bladder cancer cells [130]. 
Together these reports suggest an oncogenic function for miR-186 demonstrated 
via its overexpression in various cancers. However, whether miR-186 plays an 
oncogenic or tumor suppressor role in PCa is unknown.  
To date, only two reports have evaluated the expression profile of miR-
186 in PCa tumor tissue [63, 113]. However, these reports conflict with one 
another and do not reveal a definitive role of miR-186 in PCa. In a report by 
Erdmann and associates (2014), miR-186 expression was significantly down-
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regulated by 2.7-3.4-fold in tumor tissue (n = 50) relative to tumor-free (n = 46) 
and benign hyperplasia (n = 30) tissue [113].  Furthermore, AMACR and PSMA 
were identified as putative targets of miR-186 in PCa through qRT-PCR and 
exemplary scatter plots; however, the study did not confirm the impact of miR-
186 expression on these targets via western blot or luciferase reporter assays 
[113]. In another report, miR-186 expression was up-regulated by 1.3-fold in 
tumor tissue with extraprostatic disease (n = 17) relative to tumor tissue without 
extraprostatic disease (n = 35) [63]. Due to these conflicting reports, a definitive 
role for miR-186 remains to be identified in PCa.  
Therefore, we addressed this research gap through the characterization of 
the effects miR-186 overexpression in normal cells and inhibition in PCa cell 
lines. The different hallmarks of cancer such as enhanced cellular proliferation, 
invasion and anchorage independence were evaluated in relation to miR-186-5p 
expression in metastatic PCa and normal prostate epithelial cells. We 
hypothesized the miR-186-5p inhibition will impede  proliferation and invasion to 
reduce the aggressiveness of tumor phenotype associated with metastatic PCa. 
Furthermore, we hypothesized miR-186-5p overexpression in normal prostate 










 Cell Culture  
 Cell lines (i.e. PC-3, MDA PC 2b, E006AA, RWPE1) previously described 
in Chapter 2 were used to perform characterization experiments.  
 
DNA Isolation 
 Cells were plated in a T75 flask and grown to 80% confluency. Cells were 
washed once in 1X PBS (2 ml), trypsinized with 0.05% Trypsin for 5 mins and 
trypsin was neutralized with growth medium containing FBS. Cells were 
transferred to 15ml tubes and pelleted through centrifugation at 1200 rpm for 5 
mins. Cell pellets were washed in 1X PBS (1 ml) and centrifuged at 1200 rpm for 
5 mins. Genomic DNA was isolated from cell pellets using the DNeasy Blood and 
Tissue kit (Catalog# 69504, Qiagen, Valencia, CA). In brief, ATL buffer (180 µl) 
and proteinase K (20 µl) were added to each cell pellet and mixed thoroughly. 
Samples were transferred into 1.5ml tubes. Samples were incubated at 56oC and 
constantly tapped until cells lysed completely. AL buffer (200 µl) was added to 
each sample and vortexed briefly. Samples were incubated at 56oC for 10 mins 
and 100% EtOH (200 µl) was added to each tube and vortexed for 10 secs. 
Samples were applied to DNeasy mini-spin columns in collection tubes and 
centrifuged at 6,000xg for 1 minute at room temperature. Mini-spin columns were 
transferred to new collection tubes, washed with AW1 buffer (500ul) and 
centrifuged at 6,000xg for 1 minute. Samples were transferred to new collections, 
washed with AW2 buffer (500 µl) and centrifuged at 16,100xg for 4 mins. Mini-
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spin columns were transferred to new collection tubes and heated AE elution 
buffer (100 µl) was added to each column. Samples incubated at room 
temperature for 1 mins and DNA was eluted through centrifugation at 6,000 xg 




Cells were plated at an optimal cell density in 60mm dishes and incubated 
at 37oC for a given time frame. Cells were trypsinized with Trypsin 0.05% for 5 
mins, neutralized with growth medium containing FBS and transferred to 15ml 
tubes. Cells were centrifuged at 1200rpm for 5 mins. Cell pellet was washed in 
1X PBS (1 ml) once and centrifuged at 1200rpm for 5 mins. PBS was removed 
and 1 ml of Trizol Reagent (Invitrogen) was added to cell pellets, thoroughly 
mixed into solution and transferred to 1.5 ml tubes. Mixture incubated at room 
temperature for 5 mins. Chloroform (200 µl/1ml of Trizol) was added to mixture 
and shaken for 15 secs and incubated at room temperature for 3 mins. Samples 
were centrifuged at 12,000 xg for 15 mins at 4oC. Aqueous phase (≥ 400ul) was 
transferred to new 1.5ml tubes and 100% isopropanol (500ul/ 1ml of Trizol) was 
added to each tube. Samples were vortexed for 10 secs and incubated at room 
temperature for 10 mins. Samples were centrifuged at 12,000xg for 10 mins at 
4oC. Supernatant was discarded and RNA pellets were washed in 80% EtOH 
(1ml per 1ml of Trizol). Samples were vortexed briefly (10 secs) and centrifuged 
at 7500 xg for 5 mins at 4oC. RNA pellets air dried for 5-30 mins and 
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resuspended in molecular grade H2O. Samples were incubated at 60
oC for 15 
mins and RNA concentrations using a Nano drop Spectrophotometer.    
 
microRNA Isolation from cell lines 
Total isolation of mRNA and microRNA was performed using the miRVana 
microRNA Isolation kit (Catalog# AM 1561, Thermo Fisher Scientific, Waltham, 
MA). Cells were seeded at an optimal cell density into 60 mm plates in growth 
medium. Cells were washed once with 1X PBS (2 ml), lysed in dishes with 
mirVana lysis buffer (600 µl), harvested with cell scraper and pipetted into 1.5ml 
tubes. Cells were vortexed for 30 secs to completely lyse cells. Homogenate 
additive (1/10 of cell lysate volume) was added to cell lysates and vortexed for 30 
secs. Samples were incubated on ice for 10 mins and equal volume of 
acid/phenol chloroform mixture was added to each tube. Samples were vortexed 
for 60 secs and separate into aqueous and organic phases through centrifugation 
at 10,000 xg for 5 mins at 4oC using Eppendorf Centrifuge 5810R. Aqueous 
phase ( ≥ 400 µl) was pipetted into new 1.5ml tubes and 100% EtOH (1.5 x 
aqueous layer volume) was added to each tube. Samples were added to filters in 
new collection tubes, centrifuged at 10,000 xg for 30 secs. Samples were 
processed at room temperature and flow-through was discarded after 
centrifugation. Filters were washed once with 700 µl of wash 1 solution and 
centrifuged at 10,000 xg for 30 secs. Filters were washed twice with 500 µl of 
wash 2/3 solution and centrifuged at 10,000 xg for 30 secs. Filters were 
centrifuged at 10,000 xg for 1 minute to remove residual fluid and transferred to 
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new collection tubes. Elution buffer (60 µl) was added to the center of each filter 
and incubated for 5 mins. miRNA was eluted through centrifugation at 10,000 xg 
for 1 min at room temperature. Samples were placed on ice and RNA 
concentrations were determined using a Nanodrop Spectrophotometer.                
 
Transient Transfection 
RWPE-1 and RWPE-2 cells were seeded at a cell density of 8x105 into 60 
mm dishes and incubated 37oC overnight. Cells were washed twice in PBS 
before transfection. Cells were transfected using mirVana miR-186 mimic (19 
nM) (Assay# MC11753, Catalog# 4464066, Thermo Fisher Scientific, Waltham, 
MA, Carlsbad, CA), mirVana mimic scramble control (19 nM) (Catalog# 4464059, 
Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA) and Superfect 
transfection reagent (Catalog# 301305 Qiagen, Valencia, CA) according to 
manufacturer’s instructions. The miR-186 mimic is a small, chemically modified 
double-stranded RNA molecule that mimic the endogenous miRNA and enable 
miRNA functional analysis by up-regulation of miRNA activity. The mimic is the 
same length as the mature miRNA transcript. In brief, a 10 µM stock solution was 
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR-
186 mimic (10 pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles 
of mirVana mimic scramble control and mirVana miR-186 mimic in Superfect 
reagent (10 µl), growth medium (600 µl) and 1ml of Opti-MEM Reduced Serum 
Media (Catalog# 11058921, Thermo Fisher Scientific, Waltham, MA). After a 2hr 
incubation at 37oC, 1ml of growth medium was added each dish. After 24hrs, 
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cells were used cellular behavior assays (e.g., cellular proliferation, migration, 
invasion, and colonogenic assay).   
PC-3 cells were seeded at a cell density of 6x105 and MDA-PCa-2b cells 
were seeded at a cell density of 8x105 into 60mm dishes and incubated at 37oC 
overnight.  Cells were transfected using miR-186-5p mirVana inhibitor (33 nM) 
(Assay# MH11753, Catalog# 4464084, Thermo Fisher Scientific, Waltham, MA, 
Carlsbad, CA), mirVana inhibitor scramble control (33 nM) (Catalog# 4464078, 
Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA), JetPrime reagent and 
buffer (Catalog# 114-01, Polyplus Transfection, New York, NY) according to 
manufacturer’s instructions. MiR-186-5p is a small, chemically modified single-
stranded RNA molecule designed to specifically bind to and inhibit endogenous 
miRNA molecules and enable miRNA functional analysis by down-regulation of 
miRNA activity. The miRNA inhibitor is the reverse complement and same length 
as the mature miRNA transcript.  In brief, a 10 µM stock solution was made for 
the mirVana inhibitor scramble control (10 pmoles/µl) and mirVana miR-186 
inhibitor (10 pmoles/µl). Cells were transfected in 60 mm dishes with 72.6pmoles 
of mirVana inhibitor scramble control and mirVana miR-186 inhibitor in JetPrime 
reagent (2 µl), JetPrime buffer (200 µl) and 1ml of Opti-MEM Reduced Serum 
Media (Catalog# 11058921, Thermo Fisher Scientific, Waltham, MA). After a 2-hr 
incubation at 37oC, 1ml of growth medium was added each dish. After 24hrs, 
cells were used cellular behavior assays (e.g., cellular proliferation, migration, 
invasion, and colonogenic assay).  Post-transfection 24hrs, microRNA was 
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isolated from cell lines to confirm overexpression and inhibition of miR-186 via 
qRT-PCR.   
HEK-293T cells were at a cell density of 8x105 into 60 mm dishes and 
incubated 37oC overnight. Cells were washed twice in PBS before transfection. 
Cells were transfected using mirVana miR-186 mimic (19 nM), mirVana mimic 
scramble control (19 nM) (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA) 
according to manufacturer’s instructions. In brief, a 10 µM stock solution was 
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR-
186 mimic (10pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles 
of mirVana mimic scramble control and mirVana miR-186 mimic in 1ml of Opti-
MEM Reduced Serum Media (Catalog# 11058921, Thermo Fisher Scientific, 
Waltham, MA), JetPrime reagent and buffer (Catalog# 114-01, Polyplus 
Transfection, New York, NY) according to manufacturer’s instructions. After a 2hr 
incubation at 37oC, 1 ml of growth medium was added each dish. After 24 hrs, 
cells were used western blot analyses.   
 
Mir-186 precursor and anti-miR constructs 
Genomic DNA from RWPE1 cells was used to clone a 579 bp BamHI/NotI 
fragment consisting of the miR-186 precursor using forward primer 
(GCGGATCCGAGCCATGCTTATGCTACTG), and reverse forward (GCGCGG 
CCGCCCAGGTATATGGCACAG) via PCR with the following cycling conditions: 
95oC for 5 mins for 1 cycle, 95oC for 15 secs, 57.5oC for 30 secs, 72oC for 30 
secs followed by 35 cycles and held 4oC.  Size of PCR product was confirmed via 
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gel electrophoresis and eluted from gel using Gen Elute Agarose Spin Column kit 
(Catalog# 56500, Sigma Aldrich, St. Louis, MO).  PCR product was cloned into 
the pENTR/D-Topo vector (Thermo Fisher Scientific, Waltham, MA) using 
Gateway system and spread on kanamycin (50 mg/ml) agar plates. Plasmid DNA 
was isolated from bacterial colonies using the QIAprep Spin Miniprep Kit 
(Catalog # 27104, Qiagen, Valencia, CA) and sequenced by Eurofins Genomics 
(Louisville, KY) to verify correct cloning.  
 
Designed forward and reverse anti-miR-186 oligos from sequence 
provided from Thermo Fisher Scientific, Waltham, MA and ordered from Eurofins 
Genomics (Louisville, KY). Anti-miR-186 forward (5’CACCgcGGATCC 
TGCTTGTAACTTTCCAAAGAATTCTCTCCTTTTGGGCTTTCTGGTTTTATTTTA
AGCCCAAAGGTGAATTTTTTGGGAAGTTTGAGCT 3’) (1mM) and anti-miR-186 
reverse (5’GCGGCCgcAGCTCAAACTTCCCAAAAAATTCACCTTTGGGCTTAA 
AATAAAACCAGAAAGCCCAAAAGGAGAGAATTCTTTGGAAAGTTACAAGCA 
3’) (1mM) oligos were annealed together with 10X Annealing Buffer (100mM Tris-
HCl pH 7.5, 1M NaCl, 10mM EDTA pH 7.5) according to cycling conditions: 87oC 
(10o degrees above Tm) for 10 mins, 87-25oC at a rate of 0.1oC/sec, 25oC for 30 
mins and hold at 4oC. The annealed anti-miR-186 oligo was run on 0.1% TAE 
agarose gel Mir-186 precursor (579bp) and anti-miR-186 (100bp) was shuttled 
into pcDNA-DEST47 expression vector and sequenced by Eurofins Genomics 
(Louisville, KY) to verify correct cloning. The pcDNA-DEST47-miR-186 mimic 
construct was used to stably overexpress miR-186 in RWPE1 and RWPE2 cells 
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and the pcDNA-DEST47-Anti-miR-186 construct was used to stably inhibit miR-
186 in PC-3 cells. 
 
Stable Transfection 
RWPE-1 cells were seeded at a cell density of 8x105 into 60 mm dishes 
and incubated 37oC overnight. Cells were washed twice in PBS before 
transfection. Cells were transfected using pcDNA-DEST47-miR-186 
overexpression construct (1 µg), pcDNA-DEST47 as the negative control (1 µg) 
(Thermo Fisher Scientific, Waltham, MA) and 10 µl of Superfect reagent (Qiagen, 
Valencia, CA) according to manufacturer’s instructions. PC-3 cells were seeded 
at a cell density of 6x105 into 60mm dishes and incubated 37oC overnight. Cells 
were transfected using pcDNA-DEST47-anti-miR-186 construct (1 µg), pcDNA-
DEST47 as the negative control (1 µg) (Thermo Fisher Scientific, Waltham, MA) 
and JetPrime reagent (Polyplus Transfection, New York, NY) according to 
manufacturer’s instructions. Forty-eight hours post-transfection, growth medium 
(3 ml) was replaced and cells were treated with G418 Sulfate (800 µg/ml) 
(Catalog# 30-234-CR, MEDIATECH INC) for 10-14 days and then cultured in 
G418 Sulfate (400 µg/ml) for expansion. 
 
miRNA Expression 
Reverse transcription of total RNA (10ng) was performed using TaqMan 
microRNA Reverse Transcription kit, miRNA specific RT primers and Peltier 
Thermal Cycler (PTC 200). cDNA was synthesized using the following cycling 
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conditions 16oC for 30 mins, 42oC for 30 mins, 85oC for 5 mins and hold 
indefinitely at 4oC. qRT-PCR was performed using  miRNA specific PCR TaqMan 
Assays (Life Technologies) and the following cycling conditions: hold for 2 mins 
at 50oC, 10 mins at 95oC for 1 cycle, 15 secs at 95oC   and 1 minute at 60oC  for 
40 cycles . Amplification of cDNA was performed using the Applied Biosystems 
Step One PCR system (Applied Biosystems, Carlsbad, CA). The relative 
expression of microRNA compared with U44 snRNA was calculated using 2-∆∆Ct 
method. 
 
Cell Proliferation Assays  
Trypan Blue Exclusion Assay 
Transiently and stably miR-186 transfected cells were seeded at a cell 
density of 10x103 or 50x103 into 6-well plates and incubated at 37oC over the 
time course of 5-6 days. Cells was washed in PBS (1X) twice, cleaved with 
TrypLE Select  (Catalog # 12563-029, Thermo Fisher Scientific, Waltham, MA) 
and placed in the incubator for 5 mins. Trypsin was neutralized with growth 
medium containing FBS and cells were transferred to 15 ml tubes. Cells were 
mixed thoroughly and used to make a 1:2 dilution of cells with 0.4 w/v Trypan 
Blue solution in PBS (Catalog# 25-900-C1, Mediatech, Manassas, VA). Cell 







5-bromo-2’-deoxyuridine (BrdU) Incorporation 
Transiently transfected PC-3 (2x103), MDA PCa 2b (2x103) and RWPE1 
(5x103) cells (100 µl/well) were seeded into 96-well black plates and incubated 
for 24 hrs at 37oC overnight. Cellular proliferation was measured using the Cell 
Proliferation ELISA BrdU colorimetric kit (Catalog # 11647229001, Sigma Aldrich, 
St. Louis, MO). The 5-bromo-2’-deoxyuridine (BrdU) labeling solution (1:100, 10 
µl/well) in growth medium was added to cells to monitor the incorporation of BrdU 
into newly synthesized DNA. Cells were incubated at 37oC in BrdU labelling 
solution for 24hrs. For each experiment, experimental controls consisted of 
blanks (medium/BrdU/ BrdU anti-body) and background controls (cells/anti-
body). After each time intervals, BrdU label was removed from adherent cells. 
Cells were incubated in FixDenat solution (200 µl/well) at room temperature for 
30 mins and removed thoroughly. Anti-BrdU-POD working solution (1:100) was 
added to cells for 90 mins at room temperature and then removed. Cells were 
washed three times in PBS 1X solution. Substrate solution was added to each 
well and incubated at room temperature for 15 mins. Cellular proliferation was 
quantified using the difference in the absorption of BrdU incorporated in the DNA 
of newly proliferating cells at the testing wavelength, 370 nm, and the reference 
wavelength, 492 nm, using a Biotek Synergy HT plate reader.    
  
ATP Lite Assay  
 Transiently miR-186 transfected PC-3 cells were seeded at a cell density 
of 2x103 (100 µl/well) into 96-well black plates and incubated for 24 hrs at 37oC. 
One vial of lyophilized substrate solution was reconstituted in 5 ml of substrate 
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buffer solution and gently agitated until solution was homogenous. Mammalian 
cell lysis buffer (50 µl) was added to each well of 96-well plates. Plates were 
shaken for 5 mins at 700 rpm to lyse cells and stabilize ATP. Immediately before 
measurement, substrate solution (50 µl) was added to each well. Cellular viability 
and proliferation was measured via luminescence intensity after 72, 96 and 120 
hrs using ATPlite Luminescence Assay System Kit (Catalog# 6016941, Perkin 
Elmer, Waltham, MA) and Advanced Medical Imaging (AMI) instrument. ATPlite 
is an Adenosine TriPhosphate (ATP) monitoring system based on firefly 
(Photinus pyralis) luciferase and uses ATP as a marker of cell viability. 
Luminescence is emitted from the chemical of ATP with luciferase and D-
luciferin.  This luminescence assay is the alternative to colorimetric, fluorometric 
and radioisotopic assays for the quantitative evaluation of proliferation and 
cytotoxicity of cultured mammalian cells.  
 
 Anchorage Independent Growth Assay 
Sterile 3.5% agar solution in 1X PBS was used to make a 0.7% agar 
solution with growth medium. The 0.7% agar-medium solution was used to make 
a 0.35% agar-medium solution. The 0.35% agar-medium solution (3 ml) was 
added to 6-well plates to form base layer and plates were incubated at 4oC for 60 
mins to set agar base. Transiently transfected and/or stable cells (10x103 cell 
density) in a final volume of 3 ml were gently mixed with 0.7% agar-medium 
solution (3 ml) to make a 0.35% agar-medium solution. The cells in the 0.35% 
agar-medium solution were added onto the agar base layer in the 6-well plates. 
Cells were allowed to incubate at 37oC and form colonies in soft agar for 2-3 
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weeks. Colonies were counted at 4X magnification in bright field setting using 
bright field microscopy. 
  
5-α-DHT Treatment  
 5 -alpha Dihydrotestosterone (DHT) (Catalog# D-073-1ML, Lot# 
FE02101503, Sigma Aldrich, St. Louis, MO) in methanol was purchased at 1 
mg/ml (1mM). DHT (100ul) was diluted 1:10 in PBS 1X (900ul) to make a 
solution of 100 µM. Next, DHT solution (100 µM) was diluted 1:100 in 5ml of PBS 
1X to make s solution of 1uM. DHT solution (1 µM) was diluted 1:10 in 5ml of 
PBS 1X. Androgen sensitive MDA PCa 2b cells were transfected with miR-186-
5p inhibitor (33 nM) and scramble control (33 nM), serum starved for in reduced 
Opti-MEM I Reduced serum media (Catalog# 31985070, ThermoFisher 
Scientific, Waltham, MA) for 24 hrs and treated with DHT (10 nM) for 24 hrs in 
growth medium with FBS. Treated cells were plated in 0.35% soft agar with DHT 
(10 nM). 
 
Cellular Invasion Assay 
Polyethylene Terephthalate hanging inserts (1.1cm2) with pore size of 
8.0µm and placed in a 12-well plate. Reduced growth matrigel was thawed and 
100 µl was added on top of inserts in a 12-well plate. Matrigel was incubated at 
37oC for 1hr to form a thin gel layer and cells (25x103) in serum-free medium 
were seeded on top of matrigel. A solution of growth medium (0.6 ml) containing 
FBS and FBS (0.6 ml) was pipetted into the lower chambers of a 12-well plate. 
Growth medium and FBS in the lower chamber was used to make contact with 
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insert membrane and create a chemoattractant gradient for cells. After 48hrs, 
inserts were washed in 1X PBS with sterile q-tip and cells that migrated through 
the insert into the lower chamber were washed with 1X PBS. Migrate cells in the 
lower chamber were stained with 0.4% crystal violet in ethanol and quantified 






















Mir-186 inhibition induces cellular death in both metastatic PCa and normal 
prostate epithelial cells  
  To determine whether alteration of miR-186 expression modified cellular 
death in PCa, we inhibited the expression of miR-186-5p in metastatic PCa cells 
(Figure 12A). We also evaluated the effect of cellular behavior in relation to miR-
186-5p overexpressed in normal prostate epithelial cells (Figure 15A). We 
selected RNU44 as a endogenous control miR to normalize miRNA expression 
due to its expression being more stable and higher amplification in prostate cells 
than RNU6, a commonly used endogenous control miR in other cancers (Figure 
10). First, we evaluated the duration of a transient transfection in PC-3 and 
RWPE1 cells. We determined that transient transfections last up to 144 hrs post 
transfection, which is beyond the time frame for the in vitro studies in this study 
(Figures 11, 14).  A small chemically modified single-stranded RNA molecule 
inhibitor was used to inhibit miR-186-5p expression. The inhibitor is designed to 
specifically bind to and inhibit endogenous miRNA molecules and enable miRNA 
functional analysis by the down-regulation of miRNA activity. The miRNA inhibitor 
is the reverse complement and same length as the mature miRNA transcript. A 
small, chemically modified double-stranded RNA molecule was used to 
overexpress miR-186-5p. The mimic is designed to mimic the endogenous 
miRNA and enable miRNA functional analysis by the up-regulation of miRNA 
activity. The mimic is the same length as the mature miRNA transcript. MiR-186-
5p expression was transiently inhibited in androgen insensitive PC-3 cells and 
androgen sensitive MDA PCa 2b cells as shown in Figure 12A. The death rate of 
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transfected PC-3 and MDA PCa 2b cells were evaluated for up to 120 hrs using 
trypan blue exclusion or cellular death assays as described in Chapter 2 
methods. After 5 days, the cellular death of PC-3 and MDA PCa 2b cells treated 
with the miR-186-5p inhibitor (33nM) was increased by 20-31% relative to 
scramble control (33nM). Cellular death was increased by 28-31% in PC-3 
treated with the miR-186 inhibitor relative to scramble control as shown in Figure 
12B (p-value ≤ 0.055). In Figure 12B, miR-186 inhibition in MDA-PCa-2b cells 
induced cellular death by 20-31% relative to scramble control (p-value = 0.334). 
However, cellular death was not significantly reduced in PC-3 and MDA PCa 2b 
cells. Next, PC-3 cells were stably transfected with pcDNA-DEST47-anti-miR186 
and pcDNA-DEST47 constructs. Stable anti-miR-186 PC-3 cells exhibited a 30% 
reduction in miR-186-5p expression relative to empty vector shown in Figure 13A 
(p-value = 0.0022). Stable miR-186-5p inhibition in metastatic PC-3 cells resulted 
in a 32-51% increased of cell death after 5 days relative to empty vector control 















Figure 11. Stability of transient miR-186 inhibition in PCa cells. PC-3 cells were 
transiently transfected with scramble negative control and miR-186 inhibitor for 24hrs. 
Expression of miR-186-5p was measured A) 24 and B) 144 hrs post-transfection via 
qRT-PCR. Post-transfection, miR-186-5p expression was decreased by 73% (p-value = 
0.003) and 50% (p-value = 0.0001), after 24 and 144 hrs, respectively (p-value < 0.004). 
We set scramble control to 1 fold change. Data was quantitated from at least three 
independent experiments and error bars are the standard deviation between 
experiments. Statistical analysis was performed using Unpaired t-test and significance 










Figure 12. The effect of transient miR-186-5p inhibition on cell death in PCa. A) PC-3 
and MDA PCa-2b cells were transiently transfected with miR-186-5p inhibitor (33nM) 
and significantly reduced miR-186-5p expression by 66-73% relative to scramble control 
as examined by qRT-PCR (p-value = 0.0061, 0.0002). B) Post-transfection, cellular 
death of PC-3 and MDA PCa-2b cells was monitored every 24 hrs up using trypan blue 
exclusion assay. MiR-186 inhibition induced cellular death by 31% (Day5) in PC-3 and 
by 20-31% (Day5, 6) in MDA PCa-2b cells relative to scramble control (p-value = 0.055, 
0.334). Data was quantitated from at least two separate independent experiments and 
error bars are the standard deviation between experiments. Statistical analysis was 









Figure 13. The effect of stable miR-186 inhibition on cellular death in PC-3 cells. A) PC-
3 cells were stably transfected with pcDNA-DEST47-anti-miR-186-5p and pcDNA-
DEST47 constructs using G418 treatment. MiR-186-5p expression was stably reduced 
by 30% in PC-3 cells relative to empty vector as revealed by qRT-PCR (p-value = 
0.0022). B) Cellular death of stable anti-miR-186 PC-3 cells were monitored every 24hrs. 
Cell death was induced by 33-51% in stable anti-miR-186 PC-3 cells relative to empty 
vector as examined by trypan blue exclusion assay (p-value ≤ 0.02). Data was 
quantitated from one experiment and error bars correspond to between three separate 
cell counts standard deviation. Statistical analysis was performed using Unpaired t-test 












Overexpression of miR-186-5p suppresses cellular death in normal prostate 
epithelial cells 
 
To determine the impact of miR-186-5p expression on cellular death in 
normal prostate cells, miR-186-5p was transiently overexpressed in normal 
epithelial RWPE1 cells to evaluate the transformation capacity of potential 
oncogenic miR-186-5p alone. The stability of transient miR-186-5p 
overexpression was evaluated in normal prostate epithelial cells. Ectopic 
expression was observed to last 144 hrs post-transfection, shown in Figure 14.  
MiR-186-5p was transiently overexpressed by 761-fold increase in RWPE1 cells 
24 hrs post-transfection with miR-186-5p mimic (19nM) relative to scramble 
control (19nM) as shown in Figure 15A. The death rate of transfected RWPE1 
cells was monitored up to 120 hrs using trypan blue exclusion assays as 
described in Chapter 3 methods.  Overexpression of miR-186 in normal epithelial 
RWPE1 cells significantly induced cellular death by 27% after 5 days relative to 
scramble control shown in Figure 15B (p-value = 0.0008). Next, in a more 
physiological model miR-186-5p was stably overexpressed in RWPE1 cells by 
2.6 fold increase relative to empty vector (Figure 16A). Interestingly, stable 
overexpression of miR-186-5p resulted in a more pronounced increase of 50-
76% in cellular death relative to empty vector control, shown in Figure 16B. After 
day 5, the RWPE1 cells expressing the miR-186 mimic construct displayed the 








Figure 14. Stability of transient miR-186 overexpression in normal epithelial cells. 
RWPE1 cells were transiently transfected with scramble negative control and miR-186 
mimic for 24hrs. Expression of miR-186-5p was measured A) 24 and B) 144 hrs post-
transfection via qRT-PCR. Post-transfection, miR-186 was up-regulated by 761–fold (p-
value = 0.0426) and 83-fold (p-value = 0.0213) relative to scramble control after 24hrs 
and 144hrs, respectively. Data was quantitated from at least three independent 
experiments and error bars correspond to standard deviation. Statistical analysis was 











Figure 15. The effect of transient miR-186-5p overexpression on cellular death in normal 
epithelial cells. A) RWPE1 cells were transiently transfected with miR-186-5p mimic and 
scramble negative control for 24 hrs. MiR-186-5p expression was up-regulated in 
RWPE1 cells relative to negative control as examined by qRT-PCR. B) Post transfection, 
cellular death of RWPE1 cells were monitored every 24hrs up to 120hrs using trypan 
blue exclusion assay. Overexpression of miR-186 induced cellular death by 27% in 
RWPE1 cells relative to negative control (p-value = 0.0008). Data was quantitated from 
at least three separate independent experiments and error bars calculated with standard 
deviation.  Statistical analysis was performed using Unpaired t-test and significance level 

















Figure 16. The effect of stable miR-186-5p overexpression on cell death in normal 
prostate epithelial cells. A) RWPE1 cells were stably transfected with pcDNA-DEST47-
miR-186-5p mimic and pcDNA-DEST47 constructs using G418 treatment. MiR-186 was 
stably overexpressed by 2.6-fold in RWPE1 cells relative to empty vector as examined 
by qRT-PCR (p-value = 0.0019). B) Cellular death of stable miR-186 mimic RWPE1 cells 
every 24hrs up to 120hrs examined by trypan blue exclusion assay. Cellular death was 
increased by 50% on Day 5 (p-value < 0.0001) and 76% on Day 6 (p-value =0.009) in 
stable miR-186 mimic RWPE1 cells relative to empty vector. Data was quantitated from 
one experiment and error bars correspond to the standard deviation between three 
separate cell counts. Statistical analysis was performed using Unpaired t-test and 







MiR-186 alters the capacity of metastatic PCa cells to proliferate in vitro 
 Self-sustained cellular proliferation is an essential hallmark of cancer. 
Malignant cells produce their own growth signals [i.e., tumor growth factor-β 
(TGF-β), platelet-derived growth factor (PDGF), epidermal growth factor (EGF)] 
to stimulate uncontrolled proliferation in tumorigenesis [133].  To determine the 
effect of miR-186-5p expression on proliferation, we evaluated the cellular 
proliferation of transiently miR-186-5p inhibited metastatic PCa cells, PC-3 and 
MDA PCa 2b, and miR-186-5p overexpressing RWPE1 cells using BrdU assays 
as described in Chapter 2 methods. Cellular proliferation in both metastatic PC-3 
and MDA PCa 2b cells was reduced significantly shown in Figure 17. Newly 
proliferating cells was decreased by 46% in PC-3 cells and 27% in MDA-PCa-2b 
cells relative to scramble controls shown in Figures 17A and 17B, respectively. 
Additionally, the effect of miR-186-5p on cell viability and proliferation was also 
detected in metastatic PC-3 cells using the ATP Lite Luminescence detection kit 
as described in the Chapter 2 methods.  In Figure 18, a 48-58% reduction in cell 
viability and proliferation was detected in metastatic PC-3 cells after 72-120 hrs 
relative to scramble control.  In contrast, transient miR-186 overexpression 
slightly reduced cellular proliferation by 10% in RWPE1 cells relative to scramble 
control (Figure 19A).  Post-transfection, cellular proliferation was decreased by 
24% in E006AA cells treated with miR-186-5p mimic relative to negative control 






Figure 17. The effect of miR-186 inhibition on cellular proliferation in metastatic PCa. 
PC-3 and MDA PCa-2b cells were transiently transfected for 24 hrs with miR-186-5p 
inhibitor and scramble negative control. Cellular proliferation of PC-3 and MDA PCa-2b 
cells was examined after 24hrs by BrdU colorimetric assays. A) Post-transfection, 
cellular proliferation was decreased by 46% in PC-3 cells treated with miR-186-5p 
inhibitor relative to scramble control (p-value = 0.032). B) Post-transfection, cellular 
proliferation was decreased by 27% in MDA PCa-2b cells treated with miR-186-5p 
inhibitor relative to scramble control (p-value = 0.0039). Statistical analysis was 
performed using an Unpaired Student’s T test and significance cut-off p-value ≤ 0.05. 
Data was quantitated from at least three separate independent experiments and error 
bars calculated with standard deviation. Statistical analysis was performed using 




















Figure 18. Proliferation of miR-186-5p inhibited PC-3 cells. PC-3 cells were transiently 
transfected with miR-186-5p inhibitor and scramble control for 24 hrs. Cellular 
proliferation of PC-3 cells 72, 96 and 120hrs post transfection evaluated by ATP Lite 
assay. MiR-186-5p inhibition reduced proliferation by 22-58% in PC-3 cells relative to 
scramble controls (p-value < 0.0001).  Cell proliferation was decreased by 58% after 
72hrs, 48% after 96hrs and 22% after 120hrs.  Data was quantitated from one 
experiment and error bars were calculated from the standard deviation of 6 replicates 
using the ATPLite assay Statistical analysis was performed using Unpaired t-test and 






Figure 19. The effect of miR-186-5p overexpression on proliferation in normal prostate 
epithelial and non-metastatic PCa cells. RWPE1 and E006AA cells were transiently 
transfected for 24hrs with miR-186-5p mimic and scramble negative control. Cellular 
proliferation of RWPE1 and E006AA cells was examined after 24 hrs by BrdU 
colorimetric assays. A) Post-transfection, cellular proliferation was decreased by 10% in 
RWPE1 cells treated with miR-186-5p mimic relative to negative control  (p-value = 
0.013). B) Post-transfection, cellular proliferation was decreased by 24% in E006AA 
cells treated with miR-186-5p mimic relative to negative control (p-value = 0.0055). Data 
was quantitated from three independent experiments and error bars calculated with 
standard deviation. Statistical analysis was performed using Unpaired t-test and 




MiR-186-5p inhibition alters anchorage independence in metastatic PCa  
 
 To evaluate the effect of miR-186 expression on anchorage independent 
growth, we seeded transfected normal epithelial (RWPE1), non-metastatic 
(E006AA) and metastatic (PC-3, MDA PCa-2b) cells into 0.35% soft agar and 
their growth was monitored at 37oC for 2-3 weeks. RWPE1 and E006AA cells 
exhibited low miR-186 expression. MiR-186 was transiently overexpressed in 
both cell lines and plated into 0.35% soft agar. Over the course of 2-3 weeks, 
both RWPE1 and E006AA treated with scramble control and miR-186-5p mimic 
exhibited no colony formation (Data not shown).  
       MiR-186 was up-regulated in metastatic PCa cell lines, PC-3 and MDA PCa-
2b, relative to normal prostate epithelial RWPE1 cells. We transiently inhibited 
the expression of miR-186 in PC-3 and MDA PCa 2b cells and seeded cells into 
0.35% soft agar. In Figure 20A, a reduction of 64% in colony formation of 
metastatic PC-3 cells treated with the miR-186 inhibitor relative to scramble 
control (p-value = 0.0022). MiR-186-5p inhibition did not significantly impede 
colony formation in androgen sensitive metastatic MDA PCa 2b cells shown in 
Figure 20 B (p-value = 0.335). However, after stimulation of the androgen 
receptor with 5-alpha-DHT treatment  (10 nM) a modest 28% decrease in colony 
formation was observed in MDA PCa 2b cells treated with the miR-186-6p 


















Figure 20. The effect of miR-186-5p inhibition on anchorage independence in metastatic 
PCa. Metastatic PC-3 and MDA PCa 2b cells were transiently transfected with scramble 
negative control and miR-186 inhibitor for 24hrs. Post-transfection, cells were grown in 
0.35% soft agar for 2-3 weeks at 37oC. Colony formation of PC-3 cells treated with miR-
186 inhibitor was significantly decreased by 64% relative to scramble control (p-value = 
0.0022).  In MDA PCa 2b cells, colony formation was slightly reduced by reduced by 
12% relative to scramble control (p-value = 0.335). However, stimulation of the androgen 
receptor with α-DHT treatment (10nM) after miR-186-5p inhibition did significantly 
decrease colony formation in by 28% in MDA PCa 2b cells (p-value= 0.034). Data was 
quantitated from at least three independent experiments and error bars calculated with 
standard deviation. Statistical analysis was performed using Unpaired t-test and 




Suppression of cellular invasion in metastatic PCa 
To determine whether inhibition of miR-186-5p impacted cellular invasion 
of metastatic PCa cells, metastatic PC-3 and MDA PCa 2b cells were transiently 
transfected with the miR-186-5p inhibitor and scramble for 24hrs. Post-
transfection, PC-3 and MDA PCa 2b cells were seeded on top of reduced growth 
factor matrigel in 12-well plates. A 1:1 solution of growth medium and FBS was 
pipetted into the lower chamber of each well to serve as a chemoattractant for 
PCa cells.  Reduced growth factor matrigel was used to reduce the influence 
growth factors on the cellular invasion of PCa cells. After 48 hrs, the cells were 
fixed in 100% methanol and stained in 0.4% crystal violet overnight. In Figure 
21A, a significant reduction in cell invasion (66%) was observed in metastatic 
PC-3 cells transfected with the miR-186-5p inhibitor relative to scramble control 
(p-value = 0.0024). In metastatic MDA PCa 2b cells, miR-186 inhibition reduced 
cellular invasion by 38% relative scramble control as shown in Figure 21B (p-
value = 0.0892). Unfortunately, this reduction was not statistically significant 
















Figure 21. Cellular invasion of miR-186-5p inhibited metastatic PCa cells. PC-3 and 
MDA PCa 2b cells were transiently transfected with scramble control and miR-186-5p 
inhibitor for 24 hrs. Post-transfection, cells were seeded on top of reduced growth factor 
matrigel. After 48 hrs, cells were fixed in methanol and stained with 0.4% crystal violet. 
A) Cell invasion was reduced by 66% in metastatic PC-3 cells treated with the miR-186-
5p inhibitor relative to the scramble control (p-value = 0.0024). B) However, miR-186-5p 
inhibition did not significantly reduced cell invasion in MDA PCa 2b cells (p-value = 
0.0892). Data was quantitated from at least three independent experiments and using an 
average of 3 different fields of view at 10X magnification. Statistical analysis was 
performed using an Unpaired Student’s T test and significance level of p-value ≤ 0.05 






Aberrant expression of intronic miR-186 has been implicated in various 
solid tumor malignancies [99-104, 106-112, 130, 131].  The influence of miR-186-
5p expression on tumor cellular behavior has undergone characterization in a 
limited number of cancers [103, 106, 107, 112, 130, 131].  For instance, miR-
186-5p overexpression enhanced the cellular proliferation, migration, colony 
formation and anchorage independent growth of pancreatic and bladder cancer 
cells [103, 130]. However, there are no published reports on the role of miR-186-
5p in relation to different cancer hallmarks using PCa cell models (i.e., 
proliferation, invasion, anchorage independent growth). We hypothesized miR-
186-5p inhibition would impede the tumor phenotype in metastatic cells and miR-
186-5p overexpression would increase the aggressiveness of non-metastatic 
cells and induce malignant transformation of normal epithelial cells. In the current 
study, inhibition of miR-186-5p led to a reduction in cell proliferation, invasion, 
and anchorage independent growth in metastatic PCa cells but not non-
metastatic cell models. Moreover, miR-186 overexpression increased cellular 
death and proliferation in normal prostate epithelial cells.  These findings 
implicate an oncogenic role for miR-186-5p in both metastatic PCa and normal 
epithelial cells. 
  In vitro characterization of miR-186-5p revealed pertinent information 
related to its effects on PCa and normal cell behavior. For instance, cell death 
was not significantly affected by transient miR-186-5p inhibition in metastatic PC-
3 and MDA PCa 2b PCa cell lines. However, stable miR-186 inhibition 
significantly increased cell death in PC-3 cells. This data suggests permanent 
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rather than transient knockdown of miR-186 in the cellular genome in PCa cells 
may lead to a significant increase in cell death metastatic PC-3 PCa cells.  
Additional studies are needed to assess whether permanent miR-186 inhibition 
will influence cellular death in other metastatic cell lines (e.g., MDA PCa 2b). 
Moreover, transient inhibition of miR-186-5p significantly reduced the proliferative 
capacity of metastatic PC-3 and MDA PCa 2b PCa cells. In agreement with our 
in vitro data, miR-186-5p inhibition was also associated with a decrease in 
cellular proliferation of pancreatic and bladder cancer cell lines [103, 130].  
 
Initially, miR-186-5p overexpression was expected to increase the cellular 
death and proliferation of normal prostate epithelial RWPE1 cells.  However, in 
the current study, transient overexpression of miR-186-5p led to a decrease in 
proliferation and increase in cell death in RWPE1 cells. Similar to our findings, 
overexpression of another oncogenic miRNA, miR-375 in RWPE1 cells resulted 
in a reduction of cell proliferation, presumably due to an increase in cellular death 
[70].  However in the current study, cellular death has not been identified as the 
biological explanation for reduced proliferation yet.  We speculate reduction in 
cellular proliferation in miR-186 overexpressed RWPE1 cells may be attributed to 
increased cellular death; however, subsequent studies are needed to test this 
hypothesis.  In addition, we cannot rule out the possibility that miR-186-5p 
overexpression in the normal epithelial cell lines may lead to necrosis or 
autophagy. Ultimately, miR-186-5p overexpression alone was not sufficient for 
malignant transformation in the normal epithelial cells. In order for malignant 
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transformation to take place in the normal epithelium, multiple genomic changes 
and insults induced by oxidative stress, and mutations in major tumor 
suppressors (i.e., PTEN, p53, NKX3.1) and oncogenes (i.e. c-Myc) must occur 
based upon Knudson hypothesis or multiple hits hypothesis. Knudson hypothesis 
is a theory that a single cell must undergo a series of mutational events to 
achieve malignancy. The accumulation of genetic changes and insults will lead to 
DNA damage and ultimately genetic instability that will make normal cells more 
susceptible to malignant transformation. Thus, multiple genetic insults may 
increase RWPE1 cells susceptibility to malignant transformation via miR-186 
overexpression. 
Unexpectedly, miR-186-5p overexpression reduced the cellular 
proliferation of non-metastatic E006AA cells. We speculated that miR-186-5p 
overexpression would increase the aggressiveness of these non-metastatic cells. 
E006AA cells are androgen sensitive and possess a wild type p53 protein, but 
null for PTEN protein [134]. Although miR-186-5p was severely overexpressed in 
E006AA cells, it is possible that androgen receptor stimulation may be required 
to increase sensitivity or susceptibility to miR-186-5p overexpression to enhance 
proliferation. Furthermore, p53 may combat tumor aggressive effects exerted by 
miR-186-5p overexpression. Future studies should address whether miR-186-5p 
oncogenic function may be restricted to metastatic or advanced disease or 
require androgen receptor stimulation to exert its effects in PCa.   
 Interestingly, the suppression of three different cancer hallmarks (i.e., 
proliferation, invasion and anchorage independent growth) was primarily 
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observed in transiently miR-186-5p inhibited metastatic PC-3 cells. The PC-3 
cells exhibited the highest expression of miR-186-5p compared to the other PCa 
cells. It is possible that this cell line was more sensitive to miR-186-5p inhibition 
due to a dependence on miR-186-5p expression to maintain its malignant 
transformation.  Therefore, any reduction of miR-186-5p expression in PC-3 cells 
suppresses the tumor phenotype of these cells.   
 Anchorage independent growth and cell invasion are characteristics of 
advanced disease as well as assessments of the neoplastic nature of tumor 
cells. To our knowledge, there are no published reports on the influence of miR-
186-5p on anchorage independent growth using cancer cell models.  Transient 
inhibition of miR-186-5p alone was sufficient to decrease anchorage independent 
growth in androgen insensitive metastatic PC-3 cells, but not MDA PCa 2b cells. 
However, miR-186-5p inhibition of MDA PCa 2b cells after androgen receptor 
stimulation via 5-alpha DHT treatment (10 nM) lead to a reduction in anchorage 
independent growth. Normally androgen receptor stimulation induces cellular 
proliferation and/or growth. It may be possible that DHT treatment sensitizes 
MDA PCa 2b cells to the effects of miR-186-5p inhibition. This observation 
implicates an involvement of androgen receptor signaling in androgen sensitive 
cells for miR-186 to exert its effects on anchorage independent growth. Although, 
miR-186-5p expression does not appear to be dependent on androgen receptor 
sensitivity status based upon its expression in our PCa cell lines.  But this 
observation implies miR-186-5p may be influenced by androgen sensitivity. 
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Moreover, overexpression of miR-186-5p in RWPE1 and non-metastatic E006AA 
cells did not promote anchorage independent growth in soft agar.    
 The current study revealed transient inhibition of miR-186-5p reduced cell 
invasion in androgen insensitive PC-3 cells. However, we did not observe a 
reduction in cell invasion of androgen sensitive MDA PCa 2b cells.  However, we 
cannot rule out the possibility that androgen stimulation of miR-186 inhibited 
MDA PCa 2b cells will lead to a reduction in cellular invasion.  Similar to the 
impact of DHT on anchorage independent growth of miR-186 inhibited MDA PCa 
2b cells, it is plausible androgen receptor signaling is essential for miR-186-5p 
effects on tumor cellular behavior using androgen sensitive PCa cell models.  
MiR-186-5p expression has been previously shown to alter cell invasion in two 
studies. Contrary to our findings, these reports suggest a tumor suppressor role 
for miR-186-5p demonstrated by a decrease in cell invasion via miR-186 
overexpression in bladder and NSCLC cancer. However, our study suggests an 
oncogenic role for miR-186-5p in PCa.  
    Collectively, in vitro studies in bladder and pancreatic cancer and our 
study findings support an oncogenic role for miR-186-5p. Overexpression of miR-
186-5p in pancreatic and bladder cancer cells led to the enhancement of the 
tumor phenotype (i.e., increased proliferation, colony formation, invasion). 
Inhibition of miR-186-5p in pancreatic and PCa cells in the current study led to a 
reduction in the tumor phenotype. Although there is conflicting data on miR-186-
5p expression in bladder cancer, more consideration was given to the report that 
suggested an up-regulation of miR-186 based their analysis of miR-186-5p in 
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tumor tissue carefully selected by NIH’s The Cancer Genome Atlas and the 
procurement bladder cell lines from a reliable repository, ATCC [130, 131]. 
However, several studies propose a tumor suppressor role for miR-186-5p. Only 
two studies have evaluated miR-186-5p expression in NSCLC tissue and cell 
lines [106, 107]. Both reports failed to analyze miR-186-5p expression in laser 
captured micro-dissected tumor tissue. Moreover, one report does not explain 
the collection process for their matched tumor and normal tissue biospecimens 
as well. Additionally, both studies only evaluated miR-186-5p in 4 out of the 12 
common NSCLC cell lines in the literature [106, 107, 135]. Additionally, each 
study evaluated miR-186-5p expression in different normal bronchial epithelial 
cell lines (16HBE, BEAS-2B) as controls to compare with miR-186-5p expression 
in NSCLC cell lines [106, 107, 135]. In another report, miR-186-5p was only 
evaluated in ovarian tumor tissue (stage IIIC, IV), but not normal adjacent tissue 
[112]. Furthermore, this study failed to analyze miR-186 in micro-dissected tumor 
tissue as well. Collectively based upon the aforementioned failures, these reports 
may have slightly skewed results in relation to miR-186. 
  We have considered the limitations, strengths and future directions of the 
current study. The characterization of miR-186-5p using PCa and normal 
epithelial cell models was restricted to the available cell lines in the current 
laboratory and laboratories of collaborators. In the current study, possible 
mechanisms responsible for miR-186-5p up-regulation in PCa were not 
evaluated. Therefore, future studies will elucidate potential biological 
mechanisms (e.g., dysregulation of miRNA machinery components, 
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hypomethylation) responsible for the up-regulation of mature miR-186-5p in 
serum and metastatic PCa cells. Previously, the up-regulation of miRNA 
machinery such as RNase enzymes, Dicer and/or Drosha, have been associated 
with miRNA dysregulation in cancer [136-139].  It is possible that the up-
regulation of Dicer and Drosha may contribute to elevated levels of miR-186-5p 
observed in not only PCa, but several other malignancies (i.e., pancreatic, 
bladder, cervical, and endometrial) as well.  
 Epigenetic changes (i.e., global/regional hypomethylation and 
hyperacetylation) may also attribute to the up-regulation of oncogenic miRNAs.. 
In cancer, hypomethylation of promoter regions of oncogenic-related genes may 
allow high expression of oncomiRs such as miR-186-5p. Additionally, 
hyperacetylation may be another mechanism responsible for miRNA up-
regulation. During hyperacetylation, the chromatin structure relaxes and exposes 
the DNA wrapped around histones. This may present an opportunity for 
transcription factors that positively regulate miR-186-5p to bind to DNA regulatory 
elements and induce miR-186-5p expression. Thus the investigation of miRNA 
biogenesis machinery and epigenetic changes may lead to additional biological 
explanations for miR-186-5p up-regulation in PCa. 
 In the current study, there was no change in anchorage independent 
growth of miR-186 inhibited MDA-PCA-2b cells; however, we observed a 
significant decrease in anchorage independent growth following stimulation of 
miR-185 inhibited MDA-PCA-2b cells with DHT (an androgen stimulator). 
Therefore, future studies will assess whether miR-186-5p inhibition suppresses 
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the cell growth, proliferation, invasion of androgen sensitive cells (e.g., LNCaP, 
MDA-PCa-2b) following DHT treatment. Moreover, additional in vitro and in vivo 
studies are needed to assess whether miR-186-5p overexpression and inhibition 
alters cellular proliferation, anchorage independent growth, cell invasion, tumor 
growth, and tumor metastasis using other androgen sensitive metastatic PCa cell 
lines (i.e., TSU-Pr1, MDA PCa-2a, ALVA-101) as well as xenograft cell lines (i.e., 
VCaP, DuCaP) Furthermore, our study suggests miR-186 may target genes 
involved in proliferation, anchorage independent growth and invasion in 
metastatic PCa cell models.  Consequently, additional in vitro studies are 
needed, similar to those in Chapter 4, to identify and validate miR-186 targets 
responsible for attenuating aggressive tumor behavior in metastatic PCa cell 
models with and without androgen stimulation.  Our laboratory also has interest 
in retrospective studies to assess whether miRNA-186 or other oncomiRs 
detected in serum or micro-dissected prostate tumor specimen may correspond 
with higher risk of biochemical or disease recurrence among PCa patients 
following a radical prostatectomy.  Given the assumption that the aforementioned 
pre-clinical and serum/tissue based studies demonstrate miR-186 inhibition may 
reduce tumor burden and metastatic potential, future clinical trials can test the 
therapeutic benefit of miR-186 inhibitor alone or in combination with immuno- or 
chemotherapy.  Although toxicity and efficacy of miRNA inhibitors have not been 
evaluated in clinical trial studies to treat metastatic PCa, miR mimics have 
transitioned from the bench to the bedside.  Currently, there are two phase I 
clinical trials evaluating the toxicity and efficacy of tumor suppressor miRNA 
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mimics, miRs-16 and -34, as therapeutic agents to treat advance disease in liver 
and non-small lung cancer [NCT01829971, NCT02369198]. These clinical trials 
present promise for the utilization of miRNA inhibitors as potential therapeutic 
agents to treat cancer as well. Adverse side effects are expected with miRNA 
mimics or inhibitors; however, this concern is typical for any therapeutic agent. 
To potentially mitigate these adverse effects of miRNA mimics or inhibitors, these 
therapeutic agents should be directly administered to prostate tumor cells located 
in the prostate and/or distant organs using a biomarker targeting system. This 
system would consist of the miR-186-5p inhibitor encapsulated within a bio-
degradable nanoparticle attached to a substrate and/or ligand that binds to a 
protein and/or receptor specifically and highly expressed in prostate tumor cells.   
Collectively, the aforementioned proposed studies may assist with the 
identification and validation of miRNAs as well their inhibitors/mimics as 
prognostic, therapeutic and clinical management tools necessary to reduce the 








IDENTIFICATION AND VALIDATION OF MIR-186 GENE TARGETS  
 
Introduction: 
      MicroRNAs regulate a vast number of mRNA targets to exert their 
effects on cellular processes in normal and tumor cells. Commonly, miRNAs bind 
to the 3’UTR of mRNA transcripts. However, some studies have revealed 
miRNAs also bind to the 5’UTR of as well and do not rely solely on complete 
complement binding to regulate target genes. Aberrant gene expression profiles 
in PCa are partially attributed to the dysregulated miRNAs that regulate them. 
MiR-186 has been implicated as a tumor suppressor in oral squamous, non-small 
cell lung, colorectal and ovarian cancer [106-112]. However, miR-186 has also 
been linked to an oncogenic role in several malignancies as well [63, 99-104, 
106-108, 140, 141]. Although the aforementioned reports exhibit that miR-186-5p 
expression is up- and/or-down-regulated in some cancers, miR-186-5p 
characterization in vitro studies in our lab (Chapters 2 and 3) support an 
oncogenic role for miR-186 in PCa. Elevated levels of this miRNA are associated 
several cancers, which further support an oncogenic function for miR-186-5p. 
Moreover, some aforementioned reports have identified tissue specific targets of 
miR-186. However, targets for miR-186-5p in PCa cells have not been validated 
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[63, 113]. Thus, the identification of miR-186-5p targets in PCa would provide 
mechanistic evidence to elucidate the potential role of miR-186-5p in PCa.   
 
miRNA-186 and its gene targets in cancer 
 Several miR-186 gene targets have been identified and validated in 
various solid tumors. Additionally, the biological outcomes via overexpression 
and/or inhibition of miR-186-5p were evaluated in different cancers as well.  
Forced expression of miR-186 down-regulates the gene and/or protein 
expression of pro-apoptotic gene, P2X7, tumor suppressor-related genes 
(NR5A2, FOXO1, AKAP12, PPM1B), glucose transporter GLUT1, PTTG1, and 
oncogenic genes (ROCK1, NSBP1), which are direct miR-186 targets as shown 
in Table 4 [100, 101, 103, 105-108]. Among the cancers that under-express miR-
186-5p, several targets have been validated in the literature [106-112, 131]. For 
instance, overexpression of miR-186 inhibits cellular migration, invasion and 
glucose uptake of cancer cells via down-regulation of pituitary tumor transforming 
1 (PTTG1), Rho-associated protein kinase (ROCK1) and GLUT1 expression in 
NSCLC and cancer associated fibroblasts, respectively [106-108]. In one study, 
ectopic expression of miR-186 decreased ROCK1 and PTTG1 protein 
expression in HEK 293T and NSCLC cell line, A549, respectively. Sun and co-
workers (2014) observed that miR-186 overexpression decreases GLUT1 gene 
and protein expression [108].  In another study, overexpression of miR-186 
resulted in a down-regulation of oncogenic-related gene, NSBP1, in HT-1376 
bladder cancer cells [131]. 
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 However, miR-186 also plays an oncogenic role in several cancers (i.e., 
pancreatic, cervical, bladder, and endometrial) via the down-regulation of anti-
cancer-related genes [100, 101, 103, 105, 130]. For instance, overexpression of 
miR-186 was associated with a decrease in the mRNA expression of pro-
apoptotic P2X7 gene in HEK 293T cells. Furthermore in HEK 293T cells, miR-186 
inhibition resulted in an increase of P2X7 gene expression relative to controls.  In 
another report, ectopic miR-186 expression suppressed the protein expression of 
tumor suppressor, FOXO1, in endometrial cancer HEC-1B cells [100]. Whereas, 
inhibition of miR-186 led to an increase in the protein expression of FOXO1 and 
p27, a mediator of cell cycle arrest and senescence, in endometrial cancer 
Ishikawa cells [100, 101]. Moreover, Goeppert and associates (2010) 
demonstrated that overexpression of miR-186 in HEK 293 cells reduced gene 
expression and luciferase activity of AKAP12, a tumor suppressor in liver cancer 
[105]. In two other reports, miR-186-5p overexpression in pancreatic (i.e., Panc-
1, BxPC-3, and MiaPaca-2) and bladder (i.e., J82) cancer cells led to the down-
regulation of tumor suppressor genes, NR5A2 and PPM1B, relative to controls, 
respectively [103, 130]. Unfortunately, no definitive miR-186-5p targets have 
been validated in PCa due to limited reports [99-112, 130, 131]. Therefore, we 








Table 4. Validated Gene Targets of miR-186 in Cancer. Aberrant expression of 
miR-186 detected via qRT-PCR in 14 different studies for several malignancies. 
Six studies show miR-186-5p up-regulated in pancreatic, endometrial, 
esophageal, and cervical cancer. In contrast, other studies detected miR-186-5p 
down-regulated in non-small cell lung, oral squamous, and ovarian cancer. 
However, conflicting miR-186-5p expression data exists in relation to bladder and 





 We hypothesized based our in vitro studies that overexpression of miR-
186-5p would lead to the down-regulation of tumor suppressor genes in PCa. 
AKAP12 was validated as a direct target of miR-186-5p in a metastatic PCa cell 
line, PC-3. In previous reports, AKAP12 has been identified as a tumor 
suppressor in gastric and PCa [142, 143]. Transient ectopic expression of miR-
186-5p down-regulated AKAP12 endogenous protein expression in HEK 293T 
cells. Additionally, transient miR-186-5p inhibition in PC-3 cells lead to a slight 
up-regulation of endogenous AKAP12 protein. Furthermore, this tumor 
suppressor gene may be considered as a potential target of future therapeutic 



















 Cell lines (PC-3, RWPE1) used to analyze gene expression profiles 
altered by miR-186-5p overexpression and/or inhibition were previously 
described in Chapter 3 methods. 
 
 HEK 293T is an immortalized and transformed human epithelial embryonic 
kidney cell line with a SV40 T-antigen derived from a human fetus. 293T cells 
were sub-cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) medium 
supplemented with 10% of FBS, 1% of 200nM L-glutamine [100x] (Catalog# 
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000 
I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25ug/ml Amphoterricin B] 
(Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA). 
 
microRNA Isolation from cell lines 
miRNA isolation from cells protocol was previously described in Chapter 3 
methods.  
 
Transient and Stable Transfection 
    Transient and stable transfection protocols were previously described in 
Chapter 3 methods. 
 
HEK-293T cells were at a cell density of 8x105 into 60 mm dishes and 
incubated 37oC overnight. Cells were washed twice in PBS before transfection. 
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Cells were transfected using mirVana miR-186 mimic (19 nM), mirVana mimic 
scramble control (19 nM) (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA) 
according to manufacturer’s instructions. In brief, a 10 µM stock solution was 
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR-
186 mimic (10pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles 
of mirVana mimic scramble control and mirVana miR-186 mimic in 1ml of Opti-
MEM Reduced Serum Media (Catalog# 11058921, Thermo Fisher Scientific, 
Waltham, MA), JetPrime reagent and buffer (Catalog# 114-01, Polyplus 
Transfection, New York, NY) according to manufacturer’s instructions. After a 2hr 
incubation at 37oC, 1 ml of growth medium was added each dish. After 24 hrs, 
cells were used western blot analyses.   
 
miRNA Expression 
     miRNA expression procedure was p previously described in Chapter 3 
methods. 
 
 Human Gene Expression Array  
Total RNA was isolated from a total of 24 samples described as metastatic 
PC-3 cells with transient (n = 3) and stable inhibition of miR-186 (n = 3), normal 
epithelial RWPE1 cells with transient (n = 3) and stable overexpression of miR-
186 (n = 3) and their respective controls, scramble control (transient) (PC-3 n = 
3; RWPE1 n = 3) and empty vector control (stable) (PC-3 n = 3; RWPE1 n = 3). 
Ectopic and inhibition expression of miR-186 in the cell lines were performed 
independently in triplicate. RNA sample purity and integrity was assessed using 
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the Agilent 2100 Bioanalyzer instrument. RNA quality (A260/A280) was evaluated 
using a Nanodropper spectrophotometer.    
According to the instructions of the 3’IVT Plus Reagent kit (Catalog# 902416, 
Affymetrix Inc., Santa Clara, CA), sample and stock preparations were performed 
in non-stick nuclease-free tubes. Serial dilutions for the poly-A control was 
prepared in the following order: 1st dilution was a 1:20 dilution of poly-A control 
stock (2µl) pipetted into poly-A control dilution buffer (38 µl), 2nd dilution was a 
1:50 dilution of the 1st dilution (2 µl) pipetted into poly-A control dilution buffer (98 
µl), 3rd dilution was 1:50 dilution of the 2nd dilution (2 µl) pipetted into poly-A 
control dilution buffer (98 µl), 4th dilution was a 1:4 dilution of the 3rd dilution (5 µl) 
pipetted into poly-A control dilution buffer (15 µl) and 2 µl of the 4th dilution poly-A 
RNA solution was added to each total RNA (250 ng) sample. The First-Strand 
Master mix [x26, 3’ First-Strand buffer (4 µl), 3’First-Strand Enzyme (1 µl)] was 
made, mixed thoroughly by gently vortexing tubes, centrifuged briefly to collect 
mixture at the bottom of the tubes and placed on ice. First-Strand master mix (5 
µl) was added to each sample, mixed thoroughly by gently vortexing tubes and 
centrifuged briefly to collect mixture at the bottom of the tubes. For the first-
strand synthesis reaction, samples were incubated for 2 hrs at 42oC and at least 
2 mins at 4oC. Immediately after incubation, samples were centrifuged briefly to 
collect cDNA at the bottom of tubes and placed on ice for 2 mins. The Second-
Strand master mix [x26, 3’ Second-Strand Buffer (5 µl), 3’ Second-Strand 
Enzyme (2µl), Nuclease-free H2O (13 µl)] was made, mixed thoroughly by gently 
vortexing tubes, centrifuged briefly to collect mixture at the bottom of the tubes 
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and placed on ice. Second-Strand master mix (20 µl) was added to each First-
Strand cDNA sample (10 µl), gently vortexed and centrifuged briefly. Samples 
were incubated for 1hr at 16oC, 10 mins at 65oC and held at 4oC for at least 2 
mins in a thermocycler. After incubation, samples were immediately centrifuged 
and placed on ice. In Vitro Transcription (IVT) master mix [x26, 3’ IVT Biotin 
Label (4 µl), 3’ IVT Buffer (20 µl), 3’ IVT Enzyme (6 µl)] was prepared at room 
temperature, gently vortexed and centrifuged briefly. IVT master mix (30 µl) was 
transferred to each Second-Stranded cDNA sample, gently vortexed and 
centrifuged briefly to collect reaction at the bottom of tube. Samples were 
incubated for 16hrs at 40oC and held at 4oC to synthesize complementary RNA 
(cRNA) using a thermocycler. After incubation, samples were centrifuged briefly 
and placed on ice. Purification beads and cRNA were equilibrated to room 
temperature. Purification beads (100 µl) were added to each cRNA sample (60 
µl) in 96-well plate. Each mixture was pipetted up and down 10 times and 
incubated for 10 mins at room temperature to facilitate cRNA binding to beads. 
Plate was moved to a magnetic stand to capture beads. Supernatant was 
carefully aspirated off beads and discarded after 5 mins. Purification beads were 
washed with 80% EtOH (200µl) for an incubation period of 30 secs three times. 
After the final wash, 80% EtOH was slowly aspirated off and discarded without 
disturbing the purification beads. Beads were air dried on the magnetic stand for 
5 mins until no liquid is visible. Plate was removed from magnetic stand and pre-
heated (65oC) nuclease-free H2O (27 µl) was added to each sample. After a 1 
minute incubation, samples were pipetted up and down 10 times or until beads 
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were fully resuspended into solution. Plate was moved to magnetic stand for 5 
mins to capture purification beads. Supernatant (eluted cRNA) for each sample 
was transferred to nuclease-free tubes and placed on ice. The quality and yield 
of cRNA was measured using a nanodrop spectrophotometer. Purified cRNA 
was fragmented by divalent cations and elevated temperature. Labeled cRNA 
(12 µg) was transferred to nuclease-free tubes and brought up to required 
volume (25.6 µl) with nuclease free H2O. 3’ Fragmentation buffer (6.4 µl) was 
added to each sample for a total volume of 32 µl, gently vortexed and centrifuged 
briefly. Samples were incubated for 35 mins at 94oC and held at 4oC for at least 2 
mins in a thermocycler. After incubation, samples were centrifuged briefly and 
placed on ice. Agilent Bioanalyzer was used to check fragmentation of cRNA.   
GeneChip PrimeView Human Gene Expression arrays were removed from 4oC 
storage and allowed to equilibrate to room temperature. Hybridization oven was 
pre-heated at 45oC, pre-hybridization buffer was allowed to equilibrate to room 
temperature and 20X hybridization controls (bioB, bioC, bioD, cre) were heated 
at 65oC for 5 mins in a thermocycler. For the 100 format, a hybridization master 
mix [x25, control oligo B2 (3nM, 3.3 µl), 20X hybridization controls (10µl), 2X 
hybridization mix (100µl), DMSO (20 µl), nuclease-free H2O (40 µl)] was made to 
add to fragmented and biotin-labeled cRNA (10 µg) to make hybridization cocktail 
for a total volume of 200ul. Hybridization cocktail was gently vortexed and 
centrifuged briefly. Each array was processed one at a time. Array was vented 
from the insertion of a pipette tip into the upper right septum and filled with pre-
hybridization buffer (130 µl) from the bottom left septum and placed in pre-heated 
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oven (45oC) for 10 mins. Pre-hybridization buffer was removed from array. 
Hybridization cocktail was incubated for 5 mins at 99oC and 5 mins at 45oC in a 
thermocycler. After incubation, samples were centrifuged briefly. Array was 
refilled from the lower bottom septum with hybridization cocktail (130 µl) avoiding 
insoluble matter. Both septa were covered with ½” tough spots to minimize 
evaporation and/or leaks. Array was loaded into the hybridization oven and 
incubated at a rotation of 60rpm for 16hrs at 45oC. Array was removed from the 
oven and tough-spots were removed from the array.  Hybridization cocktail was 
extracted from the array and refilled with wash buffer A. Array was allowed to 
equilibrate at room temperature before washing and staining protocol. In the 
fluidics station, stain cocktail 1 (600 µl) was placed in stain holder 1, statin 
cocktail 2 (600µl) was placed on stain holder 2 and array holding buffer (800 µl) 
was placed in buffer holder 3. Array was washed and stained according to array 
type, the type of hybridization components and fluidics protocol FS450_0002. 
Each array was analyzed by gene chip scanner (Affy.Command console Version 
3.3).   
 
 Statistical Analysis of Human Gene Expression Array 
 Statistical analysis of gene expression data from arrays was performed 
using the Partek Genomics Suite 6.6 software (St. Louis, MO). Gene expression 
profiles differentially expressed by 1.2-fold change with their corresponding p-
value were identified in metastatic PC-3 cells and normal epithelial RWPE1 cells. 
Genes overexpressed in PC-3 cells and under-expressed in RWPE1 cells were 
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identified as potential miR-186 targets. Next, gene expression profiles were 
adjusted by multiple hypothesis testing using a false discovery significance level 
of ≤ 0.05.  Principal component analyses for gene expression in the PC-3 and 
RWPE1 cell lines and experimental groups were performed to determine the 
spread between biological replicates and each experimental group. 
    
miR-186 Target Selection 
  MiR-186 potential targets were selected from differential expressed genes 
in stable anti-miR-186 PC-3 and stable ectopic miR-186 expressing RWPE1 
cells. Genes down-regulated in stable RWPE1 cells and up-regulated in stable 
PC-3 cells by ± 1.2 fold change. Expression profiles were adjusted for multiple 
hypothesis testing using the FDR cut off p-value of 0.05. Genes that survived 
multiple hypothesis testing were further filtered using in silico tools (MetaCore, 
Ingenuity, microrna.org) and validated targets in the literature to determine direct 
and indirect targets of miR-186. After filtering, 21 genes were selected to be 
potential direct targets. Also, two additional targets were selected as potential 
indirect target of miR-186. 
 
 mRNA Expression 
 Total RNA (500ng or 1µg) was reverse transcribed using qScriptTM cDNA 
SuperMix (Catalog# 95048-025, Quanta Biosciences). Quantitative real-time 
PCR (qRT-PCR) of synthesized cDNA was performed using a 2hr cycling 
protocol on Applied Biosystems Step Up Real or 7900 PCR system and 
PerfeCTa SYBR Green FastMix ROX (Catalog# 95073-012, Quanta 
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Biosciences) according to the manufacturer’s instructions. The relative 
expression of mRNA transcripts were normalized to GAPDH expression and 
calculated using 2-∆∆Ct method. Primers used in gene expression analysis are the 
following: AKAP12 (Catalog# PPH06033A, Qiagen, Germantown, MD) and 
TRIB3 (Catalog# PPH05870C, Qiagen, Germantown, MD). Gene expression was 
measured using the following cycling conditions: 10 mins at 95oC for 1 cycle, 15 
secs at 95oC and 1 minute at 60oC for 40 cycles, then melting curve 15 secs at 
95oC, 1 minute at 60oC, +0.3oC per second and 15 secs at 95oC. 
 
Western Blot Analysis  
HEK 293T and PC-3 cells were seeded in 60 mm dishes. HEK 293T cells 
were transiently transfected with negative scramble control (19 nM) and miR-186 
mimic (19 nM). PC-3 cells were transiently transfected with negative scramble 
control (33 nM) and miR-186 inhibitor (33nM). Whole cell protein lysates were 
collected 24, 48, 72, 96 hrs post-transfection in Radio-Immunoprecipitation Assay 
(RIPA) buffer (Catalog #R0278, Sigma Aldrich, St. Louis, MO) supplemented with 
1:100 dilution of 100mM sodium orthovanadate (Catalog# 567540-5GM, Sigma 
Aldrich, St. Louis, MO) and 1:100 dilution of protease inhibitor cocktail (Catalog# 
P8340, St. Louis, MO). Protein concentrations were determined by Bradford 
assay (Catalog# 5000001, Bio-Rad, Hercules, CA). Cell lysates were separated 
by MP TGX 4-20% gels (Catalog# 4561094, Bio-Rad, Hercules, CA) and 
transferred to PVDF membranes (Catalog# 1704272, Bio-Rad, Hercules, CA) 
using the Trans-Blot Turbo system (Bio-Rad, Hercules, CA). Protein expression 
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of AKAP12 and TRIB3 was measured using primary monoclonal mouse AKAP12 
antibody (Catalog# WH0009590M1-100, Sigma Aldrich, St. Louis, MO), primary 
monoclonal mouse TRIB3 antibody (Catalog# sc-390242, Santa Cruz 
Biotechnology, Dallas, TX), and secondary anti-mouse antibody (Catalog# 7076, 
Cell Signaling, Danvers, MA). Anti-B-actin (Catalog# A5316, Sigma Aldrich, St. 
Louis, MO) at a 1:5,000 dilution was used as a loading control.  Anti-AKAP12 
(1:500) and Anti-TRIB3 (1:200) were detected in cell lysate (35ug) from HEK 
293T and PC-3 cells. Densitometry analysis was performed using ImageJ 



















Differential gene expression influenced by miR-186 inhibition and overexpression  
   To identify potential miR-186 targets in PCa, gene expression profiles 
were evaluated in total RNA extracted from transiently and stably miR-186 
inhibited PC-3 cells and transiently and stably miR-186 overexpressing RWPE1 
cells. The PC-3 cells were chosen as a cell model for miR-186-5p inhibition for 
the microarray analysis due to their pronounced expression of miR-186-5p 
relative to normal epithelial cells (Figure 9). Also, RWPE1 cells were used as a 
cell model for miR-186-5p overexpression in the analysis to provide information 
on the dysregulation of gene profiles impacted by miR-186 in the normal prostate 
cellular phenotype. Gene profiles were identified as potential miR-186 target 
based on the following selection criteria: 1.2 fold change, false discovery rate 
(FDR) p-value ≤ 0.05 and unique and/or common genes in PC-3 and RWPE1 
cells (Figure 22). After filtering profiles according to the selection criteria, 222 
genes were identified as up-regulated by ≥ 1.2-fold change in transient miR-186 
inhibited PC-3 relative to scramble control (Data not shown). Before adjusting for 
multiple hypothesis testing, 344 targets were down-regulated (≥ 1.2-fold change) 
in transient miR-186-5p over-expressing RWPE1 cells relative to scramble 
control (Data not shown). However, gene profiles in the transient RWPE1 cells 
did not survived multiple hypothesis testing. In contrast, a total of 2,898 genes 
were down-regulated in stable RWPE1 cells and 4009 targets were up-regulated 
in stable PC-3 relative to the empty vector controls (Figure 23).  After filtering 
according to the selection criteria for 2,343 genes were down-regulated  in stable 
RWPE1 cells and 3,454 genes were up-regulated in stable PC-3 cells relative to 
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empty vector (Figure 23). Gene expression profiles altered in stable PC-3 and 
stable RWPE1 cells were further examined due to a larger selection of genes  
and being more physiological cell models compared to the transient cell models. 
Moreover, we identified potential miR-186 targets from microarray analyses using 
previously validated miR-186 targets and miR-186 targets predicted by in silico 
tools (e.g., miR Base, microRNA.org, Metacore and Ingenuity). A combination of 
these predicted targets were used to further filter differentially expressed genes 
from the human gene expression arrays. Twenty-three targets were selected for 
further validation via qRT-PCR, and western blot analysis (Figure 24).  
 
miR Target Selection 
The microarray analysis for the physiological cell models (i.e., stable anti-
miR-186 PC-3 and stable miR-186 RWPE1 cells) revealed a wealth of 
informative gene expression profiles. Twenty-three genes (JUN, FN1, p53, 
WNT5A, CASP9, FOXO3, VEGFA, c-Myc, EGR1, AKAP12, FOXG1, STAT4, 
CCL20, PTEN, SMAD4, WASL, PAK1, YY1, TDG, IL1RL1, TRIB3) were selected 
as predicted targets of miR-186 from the gene expression profiles that survived 
multiple hypothesis testing and further filtering on gene targets predicted by in 
silico tools (11,000 genes), validated mRNA transcript targets and biological role 
in cancer. Previous reports demonstrated that miR-186 directly target genes 
involved in tumor suppression (i.e., FOXO1, NR5A2), oncogenesis (ROCK1), 
stimulation of cell migration and/or invasion, cell cycle regulation (i.e., CDK2, 
CDK6, cyclin D1), meschymal phenotype regulation (TWIST1) and apoptosis 
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(i.e., P2X7) [100, 101, 103, 105-108]. These twenty-three genes included two 
possible indirect targets of miR-186, IL1RL1 and TRIB3, due to their significant 
up-regulation (8 and 11-fold) in stable anti-miR-186 PC-3 cells. Furthermore, the 
microrna.org database was utilized to determine the binding sites of miR-186 for 
all 23 genes (Data not shown). This database uses mirSVR and PhastCons 
scoring methods to determine potential direct gene targets of miR-186. The 
PhastCons score is a probability that each nucleotide belongs to a conserved 
element. A negative value indicates faster-than expected evolution and a positive 
value imply conservation (threshold minimum = 0.566). mirSVR is a regression 
model that assesses a weighted sum of a number of sequence and context 
features of the predict miRNA-mRNA duplex to aid in the prediction of target sites 
of 6-mer or better seed site, or a mirSVR score ≤ -0.1. (www.microrna.org). The 
gene and protein expression of selected potential targets were further validated 
























Figure 22. Gene selection criteria for miR-186 potential targets. Human GeneChip 
Primeview Human gene expression array contained 49,395 genes. Gene expression 
profiles were evaluated using the 3’UTR region of each gene via qRT-PCR.  In silico 
tools (i.e., MetaCore, Mirbase.org, Ingenuity) were used to determine about 11,000 
predicted targets for miR-186. Gene expression profiles of predicted targets that ± 1.2 
fold change and false discovery rate (FDR) p-value ≤ 0.05 were identified as potential 
miR-186 targets in PC-3 and RWPE1 cells. Common and unique targets were identified 
in each cell line as well. Additional target selection was performed using identified and 
validated miR-186 targets in from miR databases and published reports to produce a list 
of 21 targets. Genes not identified as putative targets, but highly up-regulated in PC-3 






Figure 23. Identification of potential miR-186 targets in PCa. Gene expression profiles of 
50,000 targets in stable miR-186 overexpression in RWPE1 cells and stable miR-186 
inhibition in PC-3 cells were evaluated by human gene expression Affymetrix 
microarrays. The down-regulation of 2343 differentially expressed gene targets were 
identified in RWPE1 cells relative empty vector. In stable PC-3 cells, 3454 gene targets 
were up-regulated relative to empty vector. There were 555 common genes identified as 







Figure 24. Gene list of predicted direct targets of miR-186. In the microarray analysis, a 
total of 21 targets (JUN, FN1, p53, WNT5A, CASP9, FOXO3, VEGFA, c-Myc, EGR1, 
AKAP12, FOXG1, STAT4, CCL20, PTEN, SMAD4, WASL, PAK1, YY1, TDG) were 
identified as differentially expressed genes due to alternate miR-186-5p expression 
based  on the gene selection criteria (± 1.2 fold change and false discovery rate (FDR) 
p-value ≤ 0.05). The above common and unique gene targets in PC-3 and RWPE1 cells 
were identified as direct miR-186 targets via in silico tools (Ingenuity, MetaCore, 
www.microrna.org, MirBase). In addition, we identified as a potential indirect miR-186-5p 







AKAP12 is a direct target of miR-186 in metastatic PCa  
Only a select number of miR-186 targets (p53, PTEN, CASP9, FOXO3, 
AKAP12, PTEN, TRIB3, IL1RL1) were validated from the microarray analysis 
based on time and budget constraints.  Gene expression of potential miR-186 
targets were analyzed in miR-186-5p inhibited PC-3 cells and miR-186-5p 
overexpressing RWPE1 cells.  PC-3 cells were transiently transfected with miR-
186-5p inhibitor (33 nM) and scramble control (33 nM). RWPE1 cells were 
transiently transfected with miR-186-5p mimic (19 nM) and scramble control (19 
nM). Cell lysates were collected 24, 48, 72, and 96 hrs post transfection. Total 
RNA was isolated from cells at the indicated time points using the mirVana 
microRNA isolation kit. Total RNA was reverse transcribed into cDNA and 
expression of miR-186-5p and selected genes were validated by qRT-PCR. Next, 
whole cell protein lysates from transient miR-186-5p inhibited PC-3 cells and 
miR-186-5p overexpressing HEK 293T cells were collected 24, 48, 72, 96hrs 
post transfection to measure the endogenous protein expression of gene targets. 
No significant difference was detected in the transcript expression of p53, 
CASP9, FOXO3, PTEN, and IL1RL1. The gene expression of pro-apoptotic 
gene, TRIB3, was up-regulated after 48 hrs post-transfection in metastatic PC-3 
cells relative to scramble control (Figure 25A). However, this up-regulation was 
not significant. Tumor suppressor, AKAP12, was up-regulated by 1.78-fold 72 hrs 
post-transfection in PC-3 cells relative to scramble controls (Figure 25B). 
Additionally, miR-186 has three different binding sites on the AKAP12 transcript 
(Figure 26). In stable anti-miR-186 PC-3 cells, AKAP12 gene expression was up-
regulated by 1.6-fold relative to empty vector (Figure 27A). Furthermore, AKAP12 
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transcript expression was extremely under-expressed in metastatic MDA PCa 2b 
and LNCaP cells relative to normal epithelial RWPE1 cells (Figure 27B). 
However, AKAP12 was up-regulated by 2-fold in PC-3 cells relative to RWPE1 
cells (Figure 28B). Although AKAP12 was up-regulated in PC-3 cells, miR-186-
5p expression in PC-3 cells (16-fold) is 8 times more than the expression of 
AKAP12 expression.   
To determine the effect of miR-186-5p expression on the endogenous 
protein of AKAP12 and TRIB3, immunoblotting analyses were performed in HEK 
293T and PC-3 cells.  HEK-293T cells were transiently transfected with miR-186 
mimic (19 nM) and scramble control (19 nM) for 24-72 hrs. After 72hrs post 
transfection, AKAP12 protein expression was decreased in HEK 293T cells 
(Figure 28A). Transient miR-186-5p inhibition in PC-3 cells with miR-186 inhibitor 
(33nM) and scramble control (33 nM) resulted in the slight up-regulation of 
AKAP12 protein expression in PC-3 cells 48hrs post-transfection relative to 
scramble control. Unfortunately, TRIB3 exhibited no protein expression changes 













Figure 25. Expression of potential miR-186 targets, TRIB3 and AKAP12, in metastatic 
PC-3 cells. Transiently transfected PC-3 cells with miR-186 inhibitor and scramble 
negative control. Cell lysates were collected 24, 48, 72, 96 hrs post-transfection and total 
RNA was isolated from lysates using mirVana microRNA isolation kit. TRIB3 and 
AKAP12 gene expression in PC-3 cells was examined by qRT-PCR. A) Pro-apoptotic 
gene, TRIB3, expression was up-regulated by 1.72-fold increase after 48 hrs relative to 
negative control (p-value = 0.0769).  B) Tumor suppressor AKAP12 gene expression 
was up-regulated 1.78-fold increase after 72 hrs relative to negative control (p-value = 
0.0346). Data was quantitated from at least three independent experiments. Statistical 
analysis was performed using an Unpaired Student’s T test and significance cut-off p-
















Figure 26. Predicted binding sites for hsa-miR-186 on the AKAP12 transcript. Mir-186 
has three potential binding sites for the AKAP12 gene as predicted by in silico tool 
www.microrna.org.  mirSVR score is the result of a regression model that computes a 
weighted sum of a number of sequence and context features of the predicted 
miRNA::mRNA duplex [144]. Context features are divided into duplex, sequence and 
global.  The duplex features include base pairing at the seed region, and 3'end of the 
miRNA. The sequence features include A/U composition near the target sites and 
secondary structure accessibility. Global features are the length of the UTR, relative 
position of the target site in the UTR and conservation score. PhastCons score is a 
probability that each nucleotide belongs to a conserved element. A negative value 
indicates faster-than expected evolution a positive value imply conservation (Threshold 




Figure 27. Endogenous AKAP12 expression in stable anti-miR-186 PC-3 cells and 
metastatic PCa. Total RNA was isolated from cell lysates collected from stable anti-miR-
186 PC-3 cells and normal epithelial and PCa cells using mirVana microRNA isolation 
kit. A) AKAP12 expression was up-regulated by 1.66-fold change in stable PC-3 cells 
relative to empty vector (p-value= 0.0006). B) Relative to RWPE1 cells, AKAP12 was 
under-expressed in androgen sensitive metastatic PCas cells (i.e., LNCaP, MDA PCa 
2b). However, AKAP12 was up-regulated by 2.0 in PC-3 cells. Data was quantitated 
from at least three independent experiments. Statistical analysis was performed using an 


















Figure 28. Protein expression of AKAP12 and TRIB3 in 293T and PC-3 cell lysates. A) 
Hek-293T cells were transiently transfected with miR-186 mimic (19 nM) and scramble 
control (19 nM). Protein expression of AKAP12 was decreased (70%) to scramble 72 hrs 
post-transfection.  Next, TRIB3 protein expression was examined in HEK 293T cells, 
however no significant difference was detected between scramble and miR-186 mimic. 
B) PC-3 cells were transiently transfected with miR-186 inhibitor (33nM) and scramble 
control (33 nM).  AKAP12 protein expression was slightly up-regulated by 11% in PC-3 
cells 24 hrs post-transfection relative to scramble. However, no difference was detected 
for TRIB3 protein expression. Data was quantitated from at least two independent 






 Nearly 2,000 human miRNAs promiscuously regulate 30-60% of gene 
expression, which proposes a great dilemma for miRNA target selection and 
validation. Although multiple miRNAs may regulate the same mRNA transcript, 
the utilization of in silico tools (i.e., MetaCore, Ingenuity MirBase, TargetScan 
and MicroRNA.org), deep sequencing technologies and transient/stably 
transfected cell models aid in the identification of direct miRNA targets. In the 
current study, microarray analyses, in silico tools, specific statistical parameters, 
published reports and PCa in vitro studies in Chapter 3 were utilized to identify 
23 putative miR-186 targets using physiological stable miR-186 overexpressing 
RWPE1 and miR-186 inhibited PC-3 cell models. Although over 2,000 targets 
were either up-regulated or down-regulated in the transfected RWPE1 and PC-3 
cell lines, respectively, we only focused on 23 targets due to their biological 
function in cancer as well as time and budget constraints. To our knowledge, our 
lab is the first to demonstrate AKAP12 as a direct target of miR-186-5p in a 
metastatic PCa cell line (PC-3).  Following miR-186 inhibition, we demonstrated 
AKAP12 protein was up-regulated by 11% in the PC-3 cells. Although this up-
regulation of AKAP12 was modest, AKAP12 is known to be hypermethylated in a 
number of cancers including prostate [145-151]. It is possible this may partially 
attribute to the modest up-regulation of AKAP12 in PC-3 cells.       
 AKAP12 (A-kinase anchor protein 12) also known as the mouse 
homolog SSecKS functions as a scaffold protein in signal transduction that 
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associates with protein kinases A (PKA) and C and phosphatase [152]. 
Specifically, it binds to the regulatory subunit of protein kinase A and presumably 
alters various cancer hallmarks [143, 153-155]. Previously, several investigators 
demonstrate the down-regulation of AKAP12, a tumor suppressor, in several 
cancers, including prostate [145-151]. Overexpression of AKAP12 in vitro 
corresponds with a decrease in cell invasion, and anchorage independent growth 
of mouse PCa cell models, MLL [143, 153]. Furthermore, AKAP12 knockout in 
vivo resulted in prostatic hyperplasia [156]. However, additional studies are 
warranted to elucidate the impact of loss of AKAP12 on tumor growth and cellular 
behavior using PCa cell models.  Also, AKAP12 was identified as a direct target 
of miR-186 in only one other report other than the current study. A study by 
Goppert et al reported a down-regulation of the AKAP12 transcript due to miR-
186 overexpression in HEK 293T cells [105]. 
In the current study, we demonstrate miR-186-5p overexpression down-
regulates endogenous AKAP12 protein for the first time to our knowledge. 
Additionally, miR-186-5p inhibition in metastatic PC-3 cells resulted in an up-
regulation of the AKAP12 transcript and endogenous protein as well. We 
speculate AKAP12 may partially, but not exclusively mediate the biological 
effects of miR-186 on tumor behavior. Therefore, additional studies are needed 
to identify other miR-186-5p targets that may contribute to the effect of miR-186 
inhibition on cell proliferation, anchorage independent growth and invasion. 
Collectively, the findings of our study and other studies suggest miR-186-5p 
expression impacts the tumor aggressive phenotype.   
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Fourteen studies have identified and validated miR-186s as either an 
oncomiR or tumor suppressor in several different cancers (Table 3). It’s specific 
role in cancer appears to be tumor specific.  Seven out of 14 reports suggest 
miR-186-5p plays a tumor suppressor role and targets oncogenic-related genes 
for which cancers [106-112, 130, 131]. For instance, two independent studies 
revealed ectopic expression of miR-186-5p in NSCLC cell models has led to the 
down-regulation of oncogenic ROCK1 and motility promoting PTTG1 protein 
expression [106, 107]. However in both studies, the β-actin loading controls (i.e., 
b-actin, GAPDH) were not evenly distributed comparing the negative control and 
miR-186 over-expressing cell lines. In contrast, six studies support an oncogenic 
role for miR-186-5p and have validated tumor-suppressor-related genes as miR-
186-5p targets as well. Overexpression of miR-186-5p resulted in the repression 
of tumor suppressors, FOXO1, N5RA2, and PPM1B in endometrial, pancreatic 
and bladder cancer cell models [100, 105, 130]. Additionally, these targets have 
been shown as down-regulated at same time miR-186-5p was up-regulated in 
tumor tissue relative to normal tissue.  
 
 We have considered the limitations, strengths and future directions of this 
study. Although we hypothesized that primarily tumor suppressor genes would be 
altered by oncogenic miR-186, a mixture tumor suppressor and oncogenic-
associated genes were affected by miR-186 expression. Microarray analyses 
revealed ectopic expression of RWPE1 cells led to the down-regulation of tumor 
suppressor genes, namely (i.e., PTEN, FOXO3, AKAP12, FOXG1, SMAD4), 
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transcription factor (YY1), pro-angiogenic (VEGFA), oncogenic (c-Myc) and 
chemokine (i.e., CCL20) genes. In contrast, miR-186 inhibition led to the up-
regulation of tumor suppressor (i.e., FOXO3, p53), oncogenic (i.e., JUN, P300, c-
Myc), cell adhesion (i.e., WNT5A), cytokine (i.e., IL1R1), pro-apoptotic (i.e., 
TRIB3) and cellular death-related (CASP9) genes. We speculate that the up-
regulation and down-regulation of oncogenic genes in both PC-3 and RWPE1 
cells may represent a residual effect of normal epithelial and tumor cells 
attempting to retain their original phenotype. For instance, well known 
oncogenes, c-Myc and JUN, were slightly up-regulated in stably miR-186 
inhibited PC-3 cells. We speculate up-regulation of these oncogenes may trigger 
a survival mechanism to help this metastatic PC3 cell line retain its tumor 
phenotype. Unfortunately, in our study the up-regulation tumor suppressor genes 
involved in cell proliferation, anchorage independent growth and cellular invasion 
apparently outweighed the tumor promoting properties of up-regulated 
oncogenes.  In the case of the over-expressing miR-186 normal epithelial cell 
lines,  we evaluated whether miR-186 over-expression or inhibition would 
modulate a limited number of mRNA transcripts (n = 11,000).  However, future 
analyses of the entire human transcriptome may elucidate novel miR-185-5p 
targets using RNA-seq or next generation sequencing of transfected PCa cell 
models and micro-dissected tissue-based studies.   
 Based upon the aforementioned reports and our study findings, AKAP12 
may be a potential therapeutic target against PCa using pre-clinical studies. 
Based on the direct impact of AKAP12 on cell proliferation, invasion and 
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anchorage independent growth [143, 153-155], future studies may assess 
whether ectopic or knock-in AKAP12 expression alone and/or in combination with 
chemopreventive and/or chemotherapeutic agents may inhibit prostate tumor 
growth and metastasis. Ultimately, we speculate that ectopic expression of 
AKAP12 will reduce tumor growth and the metastatic potential of prostate tumor 
cells as well as demonstrate a synergistic interaction with PCa therapeutic 
agents.  In closing, miRNAs may serve as valuable tools to find potential 




















DISCUSSION, STRENGTHS AND LIMITATIONS AND CLINICAL RELEVANCE 
Discussion 
            Aberrant expression of miRNAs is commonly associated with various 
malignancies, including PCa. MiRNAs regulate a vast number of cancer-related 
genes that regulate cell survival, proliferation, differentiation, migration, epithelial 
mesenchymal transition, immune surveillance, angiogenesis, invasion and 
metastasis [53, 54].  Their expression is not only detectable in mammalian cells 
and tumor tissue, but also biological fluids (e.g., serum, plasma, urine) [52-54, 
117, 121].  Consequently, miR expression in biological specimens offers an 
opportunity to find and validate new clinical biomarkers as ideal cancer 
diagnostic, prognostic and ultimately clinical management tools.   
 
            The primary objectives of the current study were to identify, validate and 
characterize an oncogenic miRNA, miR-186-5p, using serum and cancer cell 
models collected from PCa patients and appropriate controls.  We assessed 
whether 377 miRNAs were differentially expressed comparing non-cancerous 
controls to PCa patients with non-metastatic and bone-specific metastatic 
disease using Taqman array and qRT-PCR data.  Out of the 
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377 miRNAs, miRNA-106b-5p and -186-5p were up-regulated in the serum of 
European American men diagnosed with PCa (tumor stage I, III, IV) relative to 
disease free individuals.  Since the literature on the role of miR-186 and PCa was 
understudied relative to miR-106b, we focused on the quantitation and 
characterization of miR-186 in immortalized PCa cell models and normal 
epithelial cells.  Relative to normal epithelial cells, miR-186 was significantly up-
regulated in a few metastatic PCa cell lines (i.e., PC-3, MDA PCa-2b and 
LNCaP), especially the PC-3 cells.  In addition, inhibition of miR-186-5p in PC-3 
and MDA-PCA-2b cells resulted in the reduction of cell proliferation, colony 
formation and cell invasion by 27-66% relative to appropriate controls for 
transient transfections.  In terms of a putative miR-186 target, we demonstrate 
inhibition of miR-186 in PC-3 cells corresponds with an upregulation of a tumor 
suppressor gene AKAP12 based on micro-array data, quantitative real time PCR 
and western blot analysis.  These findings were further confirmed upon ectopic 
expression of miR-186, which led to down-regulation of AKAP12 in HEK 293T 
cells.  Lastly, previous empirical, text mining or in silico studies suggest AKAP12 
is a likely miR-186 target based on bioinformatics analysis, 
immunohistochemistry staining, micro-array, qRT-PCR western blot and a 
luciferase reporter assay [105] (mirtarbase.mbc.nctu.edu; microrna.org). 
 
 There is a lot of controversy surrounding the role of miR-186 in relation to 
tumorigenesis.  Six published studies suggest miR-186 has tumor suppressing 
potential; where as other studies indicate an oncogenic role [106-112].  Six other 
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studies propose miR-186 has oncogenic potential.  MiR-186 expression is up-
regulated in endometrial, pancreatic, esophageal, cervical, head/neck and non-
melanoma skin cancer [99-104].  Controversy for miR-186 also exists for PCa 
[63, 113].   In 2008, Ambs et al. observed miR-186 expression was up-regulated 
in PCa relative to controls; whereas, Erdmann and co-workers (2014) indicate 
miR-186 was down-regulated in PCa patients with non-organ confined PCa and 
metastases.  Neither of these two studies characterized the role of miR-186 in 
PCa using pre-clinical models.  We addressed this gap in the literature by 
inhibiting the expression of miR-186 in metastatic PCa cell lines and monitoring 
the effects on several aggressive cancer phenotypes.  Commensurate with the 
Ambs et al. report, our results are consistent with miR-186’s role as an oncomiR.  
In short, inhibition of miR-186 leads to a reduction of cell proliferation, colony 
formation and invasion as well as re-expression of a tumor suppressor gene, 
(i.e., AKAP12), which is intimately involved in the aforementioned transformative 
tumor processes. 
 
AKAP12 as a miR-186 gene target based on empirical and in silico evidence 
from published reports and our own studies 
AKAP12 has been identified as a putative target of miR-186 in two studies 
including this study.  Additionally, we observed an increase in the transcript and 
protein expression levels of AKAP12 after miR-186-5p inhibition in metastatic 
PC-3 cells. Our findings and published reports on AKAP12 taken together 
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suggest AKAP12 may be partially responsible for the suppression of proliferation, 
invasion and anchorage independent growth in PC-3 cells [143, 153-155].   
The Role of AKAP12 in Tumorigenesis 
Based on our data, several published reports and in silico evidence, we 
speculate AKAP12, a miR-186 gene target, may contribute to the observance of 
significant reductions in cell proliferation, anchorage independent growth and cell 
invasion in MiR-186 inhibited metastatic PCa cell models.  AKAP12 (a.k.a., 
SSeCKs), a major protein kinase C substrate, is a tumor suppressor gene that is 
down-regulated in many solid tumors, including PCa [145-151].  Several 
independent studies demonstrate AKAP12’s ability to suppress cancer 
phenotypes such as cell proliferation, anchorage independent growth, and cell 
invasion [143, 153-155].  Transient co-expression of AKAP12 significantly 
reduced colony formation and focus formation in v-Src NIH3T3 cell lines 
(genetically modified to have enhanced anchorage independent growth) [154, 
155].   
Six out of seven published reports indicate AKAP12 plays a role in cell 
proliferation [145, 152, 156-160]. Early passaged AKAP12 -/- or knock out MEFs 
cells exhibited a higher cellular proliferation than wild type MEFs [158]. However 
in later passages, AKAP12 KO MEFs lost capacity to proliferate and underwent 
pre-mature senescence due to the hyperactivity of PKC α isoform, which induces 
p16Ink4a/Rb via the mitogen-activated protein kinase kinase 1 (MEK) signaling 
pathway.  In another study, overexpression of AKAP12 significantly reduced cell 
proliferation in S2-6 cells (i.e., equine fibroblasts transformed with the BPV-1 
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genome), after 6 -10 days relative to Tet-regulated S2-6 clone [157]. This 
overexpression of AKAP12 also leads to G1 cell cycle arrest via down-regulation 
of the cyclin D transcript. Moreover, AKAP12 null mice had  higher levels of 
cellular proliferation within the anterior and ventral prostatic lobes relative wild 
type mice [156].  Although higher levels of cell death within the anterior prostatic 
lobe were detected in knock out mice, the number of newly proliferated cells far 
exceeded the apoptotic cells.   
 
            Two studies suggest ectopic expression of SSeCKS (AKAP12 in humans) 
reduces tumor invasion in vitro [143, 153]. In one study, ectopic expression of 
SSeCKS in v-Src NIH3T3 cells (genetically modified to have enhanced 
aggressive cancer behavior) significantly reduced the cellular invasion of NIH3T3 
cells relative to v-Src NIH3T3 cells with basal levels of AKAP12 via RhoA- and 
Cdc42-Dependent Pathways [153]. Notably, activated RhoA and Cdc42 could 
reverse SSeCKS suppression of cytoskeletal architecture.   In another study, re-
expression of SSeCKS in MAT-LyLu (MLL) PCa cell line derived from rodents 
decreased the chemotaxis and cell invasion through a matrigel by 4-6-fold 
relative to MLL cells with endogenous levels of SSeCKS [143]. This increased 
invasive potential mediated through overexpression of AKAP12 in MLL cells is 
primarily dependent on MMP-2 expression and to a lesser extent MMP-9.  
Treatment of MML cells with MMP inhibitor, GM6001, reduces cellular invasion 
and the activity of MMP-2/9 [143]. Moreover, SSeCKS re-expression reduces 
chemotaxis, cell invasion and MMP-2 transcript levels in MML cells. Matrix 
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metalloproteinases (MMPs), including MMP2, play a role in the degradation of 
the extracellular matrix proteins, necessary for the initiation of aggressive cellular 
behaviors, including cell proliferation, migration, invasion, differentiation, 
angiogenesis and apoptosis.  The SSeCKS mediated reductions in chemotaxis 
and cell invasion appear to be influenced by SSeCKS’s inhibitory effect on MEK, 
which in turn blocks MEK/ERK signaling activation and subsequently MMP2 
transcription.  SSeCKS appears to regulate MEK/ERK signaling via inhibition of 
PKC-induced activation of Raf, presumably through direct scaffolding of PKC by 
SSeCKS [143].  The influence of SSeCKS (AKAP12) on aggressive cancer 
behavior can be reversed by co-expressing  CA-MEK1, MEK2 or ERK2 in 
constitutively SSeCKS expressing MLL cells, which increases chemotactic 
motility.  Re-expression of SSeCKS in MLL cells does not appear to alter RNA 
levels of MMP-14 and TIMP-2, which are both required for MMP-2 activation 
[143].  Collectively, these findings suggest SSeCKS potentially inhibit motility 
parameters related to metastasis, presumably by deactivating Raf/MEK/ERK 
pathways, which result in the down-regulation of MMP-2. 
 
Commensurate with the aforementioned in vitro studies, our results 
demonstrate that transient inhibition of miR-186 leads to an increase in AKAP12 
transcript expression as well as a decrease in cell proliferation (PC-3, MDA PCa 
2b), anchorage dependent growth (PC-3, MDA PCa 2b) and cell invasion (PC-3, 
MDA PCa 2b) in metastatic PCa cells.  The influence of miR-186 inhibition on 
cellular behavior was more pronounced for the PC-3 cells and MDA PCa 2b cells 
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derived from European-American and African-American men diagnosed with 
bone-specific metastatic PCa, respectively.  Interestingly, miR-186 inhibition did 
not significantly influence anchorage independent growth of the MDA PCa 2b 
cells unless cells were treated with DHT.  This suggests androgen sensitivity may 
increase susceptibility of cells to the tumor suppressing effects of miR-186-5p 
inhibition.  This androgen receptor-mediated change in anchorage independent 
growth for MDA PCa 2b cells did not reach the level of significance observed for 
miR-186-5p inhibited PC-3 cells. Although androgen-insensitivity may contribute 
toward the cancer cell lines responsivity to miR-186 inhibition, we cannot rule out 
the possibility of other genomic differences between these two cell lines.  We 
speculate the presence of a mutant P53 and null PTEN tumor suppressor genes 
within PC-3 may make this cell line more dependent on miR-186’s oncogenic 
potential to maintain a metastatic phenotype.  Future studies will test this 
hypothesis by inhibiting or re-expressing P53 and/or PTEN within PC-3 cells, 
respectively. 
 
Limitations and Strengths  
  We have considered the strengths, limitations and future directions of the 
current study.  The current study demonstrates that over expression of miR-186-
5p in serum collected from PCa patients relative to controls, even in the presence 
of a small sample size.  Our limited sample size may have compromised our 
capacity to detect other oncomiRs that were differentially expressed in serum 
from PCa patients. Future studies are needed to confirm up-regulation of miR-
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186 in serum and matched micro-dissected PCa tissue specimens collected from 
ethnically/racially diverse populations.  Such studies require appropriate sample 
sizes to have adequate statistical power to detect significant differences in miR-
186 expression comparing lethal and non-lethal PCa.  
Moreover, we may have limited our capacity to identify additional 
oncomiRs, since we did not include an acceptable internal control (i.e., C. 
elegans miR-39) within the Taqman array cards designed to analyze 377 miRs.  
We attempted to address this issue using a global normalization technique.  
Global normalization is a technique that takes the median Ct value of all miRNA 
profiles and screens for differentially expressed miRNAs that are down- or up-
regulated relative to the median Ct values.   Although global normalization led us 
to two important oncomiRs detected in our cell models transiently transfected 
with a miR-186 inhibitor, global normalization can lead to false positives and false 
negatives.   For instance, miR-186 upregulated in serum collected from PCa 
patients relative to disease-free individuals following normal globalization of the 
array data; however, this same miR was down-regulated during validation using 
qRT-PCR and normalization with an external control (i.e., C. Elegans miR-39).  
To minimize discordant findings attributed to varied normalization methods, we 
will add miR-39 as an external control prior to serum processing and analysis 
using taqman array and qRT-PCR.  However, given what we learned about 
serum-based miRNAs, miR-39 is an appropriate control.  Since there is no 
appropriate internal control for serum-based miRNAs, we used a non-human 
derived miRNA (miR-39) for our qRT-PCR validation of miR-186, prior to the 
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isolation of total RNA and conversion of RNA to cDNA [52].  C. Elegans miRNAs 
(e.g., miR-39) may serve as ideal external controls for the analysis of serum-
based human miRNAs because they help to account for any miRNA losses 
during biospecimen processing [52, 122].  The use of miR-39 was ideal for our 
serum based analysis, since C. elegans miR-39 is not detected in humans and is 
unaffected by disease states.  
Despite the aforementioned limitations, we demonstrated miR-186-5p was 
significantly up-regulated in three metastatic PCa cell lines (i.e., PC-3, MDA PCa 
2b and LNCaP cells) relative to normal epithelial cells. More importantly, we 
established a link between miR-186 and several hallmarks of cancer (i.e., 
proliferation, anchorage independent growth and invasion). Inhibition of mIR-186-
5p reduced cellular proliferation, anchorage independent growth and cell invasion 
in metastatic PCa cells. This decrease in aggressive cancer behavior may be 
partially attributed to up-regulation of AKAP12 via miR-186 inhibition. However, 
the up-regulation of other miR-186-5p gene targets may also contribute this 
decrease in aggressive behavior as well.  Our data demonstrates an over-
expression of AKAP12 following inhibition of miR-186 in vitro.  Since AKAP12 
appears to regulate cellular proliferation, anchorage independent growth, and cell 
invasion in other cancers, we speculate its loss in PCa may contribute toward 
enhanced cellular proliferation, hyperplasia and ultimately prostate 
tumorigenesis.  However, additional studies are needed to assess whether 
ectopic expression of AKAP12 leads to a decrease in cell proliferation, 
anchorage independent growth, and cell invasion using various PCa pre-clinical 
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studies.  In addition, future pre-clinical or human tissue-based will assess 
whether AKAP12 expression levels are inversely related to markers involved in 
cellular proliferation (e.g., e-Cadherin, PTK2), anchorage independent growth 
(e.g., PTK2), and cell invasion (e.g., MMP-2, MMP-9) in cell models with ectopic 
expression of AKAP12 or immunohistochemistry staining of cancerous tissue 
derived from animal models or humans.  In addition, we will assess whether over 
expression of AKAP12 will inhibit tumor growth and metastasis using a PCa 
animal model. 
   In closing, we added new insights toward a definitive role of miR-186 in 
PCa.  Commensurate with previously mentioned studies [143, 145, 152, 153, 
156-160], we provide convincing data that reveals miR-186 inhibition leads to up-
regulation of AKAP12 as well as a 27-46% reduction of cell proliferation, 
anchorage independent growth and invasion in metastatic PC-3 and/or MDA 
PCa-2b cells.  Ultimately, our study findings serve as a foundation for future 
studies focused on the identification and characterization of a new miRNA 
biomarkers needed to distinguish between lethal and non-lethal PCa.  In addition, 
we offer guidance toward potential targets (e.g., AKAP12) that can be tested as a 
therapeutic target for the effective treatment of aggressive PCa.   These efforts, if 
successful, may help to reduce the burden of PCa among all men. 
 
Clinical Relevance 
MiRNAs differentially expressed in cancer are steadily beginning to be 
accepted as potential prognostic and diagnostic tools in PCa. Due to their 
regulation of a vast number of gene targets and stable expression in biological 
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fluids and tissue, miRNAs show great promise as potential biomarkers to aid 
current screening tools. Clinical trial studies have yet to identify a procedure that 
can completely replace the PSA test and digital rectal exam. 
PCa detection has been solely dependent on procedures such as the PSA 
test, digital rectal exam (DRE) and tumor biopsies. Unfortunately, alone the PSA 
test is not a reliable tool in disease due to various biological stimulants [39, 40, 
44, 46, 161]. The DRE is an invasive technique that also is insufficient alone to 
detect PCa [40, 44, 46]. The combinatorial effort of both tools do not drastically 
improve detection and can lead to false positive test results. Consequently, there 
is a great need for biomarkers to aid in PCa detection and improve the overall 
accuracy of these tools. To definitively diagnose PCa, physicians must collect a 
biopsy from the prostate for histological evaluation. Tumor biopsies are very 
invasive for patients and associated with urological problems. The measurement 
of miRNA expression in routinely collected biological fluids may serve as an 
alternative to these extremely invasive procedures.   
The research presented in this dissertation is clinically relevant due to the 
number of phase I and II clinical trials evaluating the miRNA expression in 
various malignancies including PCa [NCT01220427, NCT02366494, 
NCT01503229, NCT02471469, NCT01444820, and NCT02391051]. Some trials 
are even investigating the use of tumor suppressor miRNA mimics as therapeutic 
agents in cancer [NCT01829971, NCT02369198]. In the current study, miR-186 
has been identified as a potential oncogenic miRNA in PCa. Furthermore, 
inhibition of this miRNA has shown to repress the cellular behavior associated 
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with the tumor phenotype. Ultimately, therapeutic agents that inhibit miR-186 




1. American Cancer S. Cancer Facts and Figures 2015. Altanta, Ga: 
American Cancer Society; 2015. 
2. American Cancer S. Cancer Treatment and Survivorship Facts and 
Figures 2014-2015. Altanta, GA: American Cancer Society; 2014. 
3. American Cancer S. Cancer Facts and Figures for African Americans. 
Altanta, GA: American Cancer Society; 2013. 
4. Abdelrahaman E, Raghavan S, Baker L, Weinrich M, Winters SJ. Racial 
difference in circulating sex hormone-binding globulin levels in prepubertal boys. 
Metabolism: clinical and experimental. 2005;54:91-6. 
5. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. 
Testosterone, sex hormone-binding globulin, and body composition in young 
adult African American and Caucasian men. Metabolism: clinical and 
experimental. 2001;50:1242-7. 
6. Sasaki R, Habuchi T, Sato K, Akao T, Kakinuma H, Zhang LQ, et al. The 
clinical utility of measuring total PSA, PSA density, gamma-seminoprotein and 
gamma-seminoprotein/total PSA in prostate cancer prediction. Jpn J Clin Oncol. 
2000;30:337-42. 
7. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical 
characteristics and biopsy specimen features in African-American and white men 
without prostate cancer. J Natl Cancer Inst. 1998;90:756-60. 
8. Guo Y, Sigman DB, Borkowski A, Kyprianou N. Racial differences in 
prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-
American patients. Prostate. 2000;42:130-6. 
9. deVere White RW, Deitch AD, Jackson AG, Gandour-Edwards R, 
Marshalleck J, Soares SE, et al. Racial differences in clinically localized prostate 
cancers of black and white men. J Urol. 1998;159:1979-82; discussion 82-3. 
10. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated 
caveolin-1 levels in African-American versus white-American prostate cancer. 
Clin Cancer Res. 2000;6:3430-3. 
11. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. 
Tumor immunobiological differences in prostate cancer between African-
American and European-American men. Cancer Res. 2008;68:927-36. 
12. Pienta KJ, Loberg R. The "emigration, migration, and immigration"of 
prostate cancer. Clin Prostate Cancer. 2005;4:24-30. 
13. American Cancer S. 2014  [cited 2015; Available from: 
http://www.cancer.org/treatment/understandingyourdiagnosis/understandingyour
pathologyreport/prostatepathology/prostate-cancer-pathology 
14. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. 
Pre-treatment risk stratification of prostate cancer patients: A critical review.  
 157 
 
Canadian Urological Association journal = Journal de l'Association des urologues 
du Canada. 2012;6:121-7. 
15. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes 
Dev. 2000;14:2410-34. 
16. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new 
prospects for old challenges. Genes Dev. 2010;24:1967-2000. 
17. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the 
evidence. Histopathology. 2012;60:199-215. 
18. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. 
Inflammation in prostate carcinogenesis. Nature reviews Cancer. 2007;7:256-69. 
19. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, 
Platz EA. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. 
Cancer Epidemiol Biomarkers Prev. 2006;15:2160-6. 
20. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. 
Inflammation and prostate cancer. Future Oncol. 2008;4:637-45. 
21. Woenckhaus J, Fenic I. Proliferative inflammatory atrophy: a background 
lesion of prostate cancer? Andrologia. 2008;40:134-7. 
22. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative 
inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 
2000;56:828-32. 
23. Servian P, Celma A, Planas J, Placer J, de Torres IM, Olivan M, et al. 
Clinical significance of proliferative inflammatory atrophy finding in prostatic 
biopsies. Prostate. 2015;75:1669-75. 
24. Montironi R, Mazzucchelli R, Algaba F, Lopez-Beltran A. Morphological 
identification of the patterns of prostatic intraepithelial neoplasia and their 
importance. Journal of clinical pathology. 2000;53:655-65. 
25. Brawer MK. Prostatic intraepithelial neoplasia: an overview. Reviews in 
urology. 2005;7 Suppl 3:S11-8. 
26. Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, van 
Dekken H. Interphase cytogenetics of prostatic adenocarcinoma and precursor 
lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic 
intraepithelial neoplasias. Genes Chromosomes Cancer. 1995;12:241-50. 
27. Colanzi P, Santinelli A, Mazzucchelli R, Pomante R, Montironi R. Prostatic 
intraepithelial neoplasia and prostate cancer: analytical evaluation. Advances in 
clinical pathology : the official journal of Adriatic Society of Pathology. 
1998;2:271-84. 
28. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast 
Cancer Res. 2008;10 Suppl 1:S2. 
29. Nowell PC. The clonal evolution of tumor cell populations. Science. 
1976;194:23-8. 
30. Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived 
chemoattractants. Cancer Res. 1985;45:3517-21. 
31. Zlotnik A, Yoshie O. Chemokines: a new classification system and their 
role in immunity. Immunity. 2000;12:121-7. 




33. Chang SS. Treatment options for hormone-refractory prostate cancer. 
Reviews in urology. 2007;9 Suppl 2:S13-8. 
34. Davis SN, Diefenbach MA, Valdimarsdottir H, Chen T, Hall SJ, Thompson 
HS. Pros and cons of prostate cancer screening: associations with screening 
knowledge and attitudes among urban African American men. Journal of the 
National Medical Association. 2010;102:174-82. 
35. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et 
al. Operating characteristics of prostate-specific antigen in men with an initial 
PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66-70. 
36. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. 
Prostate specific antigen best practice statement: 2009 update. J Urol. 
2009;182:2232-41. 
37. Ayyildiz SN, Ayyildiz A. PSA, PSA derivatives, proPSA and prostate health 
index in the diagnosis of prostate cancer. Turkish journal of urology. 2014;40:82-
8. 
38. Rausch S, Hennenlotter J, Wiesenreiter J, Hohneder A, Heinkele J, 
Schwentner C, et al. Assessment of a new point-of-care system for detection of 
prostate specific antigen. BMC urology. 2016;16:4. 
39. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-
specific antigen test: a review of current evidence. JAMA. 2014;311:1143-9. 
40. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et 
al. Screening and prostate-cancer mortality in a randomized European study. N 
Engl J Med. 2009;360:1320-8. 
41. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, 
et al. Screening and prostate cancer mortality: results of the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of 
follow-up. Lancet. 2014;384:2027-35. 
42. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate 
cancer. Cochrane Database Syst Rev. 2013;1:CD004720. 
43. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. 
Mortality results from the Goteborg randomised population-based prostate-
cancer screening trial. The Lancet Oncology. 2010;11:725-32. 
44. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, 
et al. Mortality results from a randomized prostate-cancer screening trial. N Engl 
J Med. 2009;360:1310-9. 
45. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et 
al. American Cancer Society guideline for the early detection of prostate cancer: 
update 2010. CA Cancer J Clin. 2010;60:70-98. 
46. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, 
et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, 
and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. 
J Natl Cancer Inst. 2012;104:125-32. 
47. Chang RT, Kirby R, Challacombe BJ. Is there a link between BPH and 
prostate cancer? The Practitioner. 2012;256:13-6, 2. 




49. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are 
promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 
2010;127:118-26. 
50. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical 
evaluation of microRNA expression profiling in non small cell lung cancer. Lung 
Cancer. 2013;81:388-96. 
51. Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, et al. Identification of miR-
133b and RB1CC1 as independent predictors for biochemical recurrence and 
potential therapeutic targets for prostate cancer. Clin Cancer Res. 2014;20:2312-
25. 
52. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. 
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int 
J Cancer. 2011;128:608-16. 
53. Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs 
in Prostate Cancer Pathogenesis. Clinical genitourinary cancer. 2015;13:261-70. 
54. Ayub SG, Kaul D, Ayub T. Microdissecting the role of microRNAs in the 
pathogenesis of prostate cancer. Cancer genetics. 2015;208:289-302. 
55. Miah S, Catto JW. MicroRNA in prostate cancer: an opportunity to 
individualize patient care. J Urol. 2012;187:1155-6. 
56. Saumet A, Lecellier CH. microRNAs and Personalized Medicine: 
Evaluating Their Potential as Cancer Biomarkers. Adv Exp Med Biol. 2015;888:5-
15. 
57. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nature cell 
biology. 2009;11:228-34. 
58. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, 
mechanism, function, and recent clinical trials. Biochim Biophys Acta. 
2010;1803:1231-43. 
59. Wienholds E, Plasterk RH. MicroRNA function in animal development. 
FEBS Lett. 2005;579:5911-22. 
60. Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body 
fluids of prostate cancer patients. Methods. 2013;59:132-7. 
61. Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, et al. 
MicroRNA signature helps distinguish early from late biochemical failure in 
prostate cancer. Clin Chem. 2013;59:1595-603. 
62. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero 
JA. miRNAs as biomarkers in prostate cancer. Clinical & translational oncology : 
official publication of the Federation of Spanish Oncology Societies and of the 
National Cancer Institute of Mexico. 2012;14:803-11. 
63. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. 
Genomic profiling of microRNA and messenger RNA reveals deregulated 
microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-70. 
64. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, 




65. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger 
J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. 
Urology. 2011;77:1265 e9-16. 
66. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the 
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. 
elegans. Cell. 1993;75:855-62. 
67. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-
4 encodes small RNAs with antisense complementarity to lin-14. Cell. 
1993;75:843-54. 
68. Health USNIo. ClinicalTrials.gov.  [cited 2015; Available from: 
https://clinicaltrials.gov 
69. Patron JP, Fendler A, Bild M, Jung U, Muller H, Arntzen MO, et al. MiR-
133b targets antiapoptotic genes and enhances death receptor-induced 
apoptosis. PLoS One. 2012;7:e35345. 
70. Costa-Pinheiro P, Ramalho-Carvalho J, Vieira FQ, Torres-Ferreira J, 
Oliveira J, Goncalves CS, et al. MicroRNA-375 plays a dual role in prostate 
carcinogenesis. Clinical epigenetics. 2015;7:42. 
71. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta 
biochimica et biophysica Sinica. 2010;42:363-9. 
72. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et 
al. miR-221 and miR-222 expression affects the proliferation potential of human 
prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 
2007;282:23716-24. 
73. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-
regulated miRNA suppresses Bak1 expression and induces androgen-
independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 
2007;104:19983-8. 
74. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS 
and promotes apoptosis resistance and invasion in prostate cancer cells. 
Biochem Biophys Res Commun. 2009;383:280-5. 
75. Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, et al. 
MicroRNA-106b-25 cluster expression is associated with early disease 
recurrence and targets caspase-7 and focal adhesion in human prostate cancer. 
Oncogene. 2013;32:4139-47. 
76. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. 
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-
targeting intron that cooperates with its host gene MCM7 in transformation. 
Science signaling. 2010;3:ra29. 
77. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM. Down-regulation of 
RE-1 silencing transcription factor (REST) in advanced prostate cancer by 
hypoxia-induced miR-106b~25. Exp Cell Res. 2014;320:188-99. 
78. Yu JJ, Wu YX, Zhao FJ, Xia SJ. miR-96 promotes cell proliferation and 




79. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA, et 
al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-
resistant prostate cancer. Oncogene. 2012;31:4460-71. 
80. Hsu TI, Hsu CH, Lee KH, Lin JT, Chen CS, Chang KC, et al. MicroRNA-
18a is elevated in prostate cancer and promotes tumorigenesis through 
suppressing STK4 in vitro and in vivo. Oncogenesis. 2014;3:e99. 
81. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b 
suppresses prostate cancer metastasis by regulating epithelial-mesenchymal 
transition signaling. Mol Cancer Ther. 2012;11:1166-73. 
82. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. 
MicroRNA-34a modulates c-Myc transcriptional complexes to suppress 
malignancy in human prostate cancer cells. PLoS One. 2012;7:e29722. 
83. Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, et al. miR-146a 
functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate. 
2014;74:1613-21. 
84. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in 
hormone-refractory prostate cancer. Rna. 2008;14:417-24. 
85. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, et al. The 
functional significance of microRNA-145 in prostate cancer. Br J Cancer. 
2010;103:256-64. 
86. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits 
prostate cancer EMT, growth and metastasis. PLoS One. 2013;8:e83991. 
87. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. 
Role for DNA methylation in the regulation of miR-200c and miR-141 expression 
in normal and cancer cells. PLoS One. 2010;5:e8697. 
88. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. 
Genomic loss of microRNA-101 leads to overexpression of histone 
methyltransferase EZH2 in cancer. Science. 2008;322:1695-9. 
89. Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, et al. lncRNA H19/miR-
675 axis represses prostate cancer metastasis by targeting TGFBI. The FEBS 
journal. 2014;281:3766-75. 
90. Yi B, Piazza GA, Su X, Xi Y. MicroRNA and cancer chemoprevention. 
Cancer Prev Res (Phila). 2013;6:401-9. 
91. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 
1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA 
expression in LNCaP cells. Mol Cancer. 2011;10:58. 
92. Ting HJ, Messing J, Yasmin-Karim S, Lee YF. Identification of microRNA-
98 as a therapeutic target inhibiting prostate cancer growth and a biomarker 
induced by vitamin D. J Biol Chem. 2013;288:1-9. 
93. Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: 
promising role for microRNAs. Molecular nutrition & food research. 
2011;55:1219-29. 
94. Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. MicroRNAs 
221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in 
prostate cancer. Cancer Prev Res (Phila). 2011;4:76-86. 
 162 
 
95. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. 
Green tea polyphenol EGCG blunts androgen receptor function in prostate 
cancer. FASEB J. 2011;25:1198-207. 
96. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, et al. Down-
regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in 
response to radiation in prostate cancer cells. Prostate. 2011;71:567-74. 
97. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen 
MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate 
cancer. Cancer biology & therapy. 2008;7:1288-96. 
98. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. 
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 
cells. Biochem Biophys Res Commun. 2008;377:114-9. 
99. Jia W, Wu Y, Zhang Q, Gao G, Zhang C, Xiang Y. Identification of four 
serum microRNAs from a genome-wide serum microRNA expression profile as 
potential non-invasive biomarkers for endometrioid endometrial cancer. Oncology 
letters. 2013;6:261-7. 
100. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al. 
Definition of microRNAs that repress expression of the tumor suppressor gene 
FOXO1 in endometrial cancer. Cancer Res. 2010;70:367-77. 
101. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski GI. MicroRNAs 
miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic 
P2X7 receptor by activation of instability sites at the 3'-untranslated region of the 
gene that decrease steady-state levels of the transcript. J Biol Chem. 
2008;283:28274-86. 
102. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 
microRNAs in pancreatic cancer cell lines and surgical specimens by real-time 
PCR analysis. World J Surg. 2009;33:698-709. 
103. Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F, Pei HH. miR-186 and 326 
predict the prognosis of pancreatic ductal adenocarcinoma and affect the 
proliferation and migration of cancer cells. PLoS One. 2015;10:e0118814. 
104. Zhao BS, Liu SG, Wang TY, Ji YH, Qi B, Tao YP, et al. Screening of 
MicroRNA in Patients with Esophageal Cancer at Same Tumor Node Metastasis 
Stage with Different Prognoses. Asian Pac J Cancer Prev. 2013;14:139-43. 
105. Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, Breinig M, et al. 
Down-regulation of tumor suppressor A kinase anchor protein 12 in human 
hepatocarcinogenesis by epigenetic mechanisms. Hepatology. 2010;52:2023-33. 
106. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes 
migration and invasion of human non-small cell lung cancer cells and is 
modulated by miR-186. Carcinogenesis. 2013;34:2145-55. 
107. Cui G, Cui M, Li Y, Liang Y, Li W, Guo H, et al. MiR-186 targets ROCK1 to 
suppress the growth and metastasis of NSCLC cells. Tumour Biol. 2014. 
108. Sun P, Hu JW, Xiong WJ, Mi J. miR-186 regulates glycolysis through 




109. Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW, et al. 
miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell 
carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429-36. 
110. Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y, et al. miR-186 
downregulation correlates with poor survival in lung adenocarcinoma, where it 
interferes with cell-cycle regulation. Cancer Res. 2013;73:756-66. 
111. Kim SY, Lee YH, Bae YS. MiR-186, miR-216b, miR-337-3p, and miR-760 
cooperatively induce cellular senescence by targeting alpha subunit of protein 
kinase CKII in human colorectal cancer cells. Biochem Biophys Res Commun. 
2012;429:173-9. 
112. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, et al. miR-186 regulation of 
Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016;35:323-32. 
113. Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M, et 
al. Elevated expression of prostate cancer-associated genes is linked to down-
regulation of microRNAs. BMC Cancer. 2014;14:82. 
114. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation 
of microRNA expression in human prostate cancer. Oncogene. 2008;27:1788-93. 
115. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et 
al. Diagnostic and prognostic implications of microRNA profiling in prostate 
carcinoma. Int J Cancer. 2010;126:1166-76. 
116. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, 
et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur 
Urol. 2011;59:671-81. 
117. Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum 
microRNA levels associate with absence of high-grade prostate cancer in a 
retrospective cohort. PLoS One. 2015;10:e0124245. 
118. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-
invasive biomarkers for cancer. Mol Cancer. 2010;9:306. 
119. Ruegger S, Grosshans H. MicroRNA turnover: when, how, and why. 
Trends in biochemical sciences. 2012;37:436-46. 
120. Fujita Y, Kuwano K, Ochiya T, Takeshita F. The impact of extracellular 
vesicle-encapsulated circulating microRNAs in lung cancer research. BioMed 
research international. 2014;2014:486413. 
121. Balci S, Ayaz L, Gorur A, Yildirim Yaroglu H, Akbayir S, Dogruer Unal N, 
et al. microRNA profiling for early detection of nonmelanoma skin cancer. Clinical 
and experimental dermatology. 2015. 
122. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-
Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for 
cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-8. 
123. Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, et al. An elevated 
serum miR-141 level in patients with bone-metastatic prostate cancer is 
correlated with more bone lesions. Asian journal of andrology. 2013;15:231-5. 
124. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, et 
al. Plasma miRNAs as biomarkers to identify patients with castration-resistant 




125. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for 
assessing differential expression in microarray experiments. Bioinformatics. 
2005;21:2067-75. 
126. Smyth GK. Bioinformatics and Computational Biology Solutions using R 
and Bioconductor. New York: Springer; 2005. 
127. GK S. Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Stat Appl Genet Mol Biol 
2004;3:1-25. 
128. Choi N, Park J, Lee JS, Yoe J, Park GY, Kim E, et al. miR-93/miR-
106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer 
progression. Oncotarget. 2015;6:23533-47. 
129. Kim K, Chadalapaka G, Pathi SS, Jin UH, Lee JS, Park YY, et al. 
Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-
induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther. 
2012;11:1852-62. 
130. Yang J, Yuan D, Li J, Zheng S, Wang B. miR-186 downregulates protein 
phosphatase PPM1B in bladder cancer and mediates G1-S phase transition. 
Tumour Biol. 2015. 
131. Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. MiR-186 suppresses the 
growth and metastasis of bladder cancer by targeting NSBP1. Diagnostic 
pathology. 2015;10:146. 
132. Summerer I, Unger K, Braselmann H, Schuettrumpf L, Maihoefer C, 
Baumeister P, et al. Circulating microRNAs as prognostic therapy biomarkers in 
head and neck cancer patients. Br J Cancer. 2015;113:76-82. 
133. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. 
134. Koochekpour S, Willard SS, Shourideh M, Ali S, Liu C, Azabdaftari G, et 
al. Establishment and characterization of a highly tumorigenic African American 
prostate cancer cell line, E006AA-hT. International journal of biological sciences. 
2014;10:834-45. 
135. Wistuba, II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, et 
al. Comparison of features of human lung cancer cell lines and their 
corresponding tumors. Clin Cancer Res. 1999;5:991-1000. 
136. Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in 
cancer. Critical reviews in biochemistry and molecular biology. 2015:1-14. 
137. Vaksman O, Hetland TE, Trope CG, Reich R, Davidson B. Argonaute, 
Dicer, and Drosha are up-regulated along tumor progression in serous ovarian 
carcinoma. Hum Pathol. 2012;43:2062-9. 
138. Han Y, Liu Y, Gui Y, Cai Z. Inducing cell proliferation inhibition and 
apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of 
the bladder. J Surg Oncol. 2013;107:201-5. 
139. Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT, et al. A 
dosage-dependent pleiotropic role of Dicer in prostate cancer growth and 
metastasis. Oncogene. 2014;33:3099-108. 
140. Tang N, Zhang J, Du Y. [Curcumin promoted the apoptosis of cisplain-
resistant human lung carcinoma cells A549/DDP through down-regulating miR-
186*]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13:301-6. 
 165 
 
141. Chen F, Zhou C, Lu Y, Yuan L, Peng F, Zheng L, et al. [Expression of 
hsa-miR-186 and its role in human colon carcinoma cells]. Nan fang yi ke da xue 
xue bao = Journal of Southern Medical University. 2013;33:654-60. 
142. Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, et al. 
AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric 
carcinoma and shows growth suppressor activity. Oncogene. 2004;23:7095-103. 
143. Su B, Bu Y, Engelberg D, Gelman IH. SSeCKS/Gravin/AKAP12 inhibits 
cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- 
Raf/MEK/ERK pathway. J Biol Chem. 2010;285:4578-86. 
144. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling 
of microRNA targets predicts functional non-conserved and non-canonical sites. 
Genome Biol. 2010;11:R90. 
145. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C 
kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. 
Cancer Res. 2001;61:5644-51. 
146. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, 
et al. Identification of differentially expressed genes in pulmonary 
adenocarcinoma by using cDNA array. Oncogene. 2002;21:5804-13. 
147. Lim EH, Aggarwal A, Agasthian T, Wong PS, Tan C, Sim E, et al. 
Feasibility of using low-volume tissue samples for gene expression profiling of 
advanced non-small cell lung cancers. Clin Cancer Res. 2003;9:5980-7. 
148. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu 
H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue 
inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary 
thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 
2003;9:68-75. 
149. Feng XD, Huang SG, Shou JY, Liao BR, Yingling JM, Ye X, et al. Analysis 
of pathway activity in primary tumors and NCI60 cell lines using gene expression 
profiling data. Genomics, proteomics & bioinformatics. 2007;5:15-24. 
150. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, et al. 
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin 
a in multiple myeloma cells. Cancer Res. 2008;68:44-54. 
151. Daino K, Ugolin N, Altmeyer-Morel S, Guilly MN, Chevillard S. Gene 
expression profiling of alpha-radiation-induced rat osteosarcomas: identification 
of dysregulated genes involved in radiation-induced tumorigenesis of bone. Int J 
Cancer. 2009;125:612-20. 
152. Gelman IH. Suppression of tumor and metastasis progression through the 
scaffolding functions of SSeCKS/Gravin/AKAP12. Cancer metastasis reviews. 
2012;31:493-500. 
153. Gelman IH, Gao L. SSeCKS/Gravin/AKAP12 metastasis suppressor 
inhibits podosome formation via RhoA- and Cdc42-dependent pathways. Mol 
Cancer Res. 2006;4:151-8. 
154. Johnson PJ, Coussens PM, Danko AV, Shalloway D. Overexpressed 
pp60c-src can induce focus formation without complete transformation of NIH 
3T3 cells. Mol Cell Biol. 1985;5:1073-83. 
 166 
 
155. Lin X, Gelman IH. Reexpression of the major protein kinase C substrate, 
SSeCKS, suppresses v-src-induced morphological transformation and 
tumorigenesis. Cancer Res. 1997;57:2304-12. 
156. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH. Loss of the 
SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res. 
2008;68:5096-103. 
157. Lin X, Nelson P, Gelman IH. SSeCKS, a major protein kinase C substrate 
with tumor suppressor activity, regulates G(1)-->S progression by controlling the 
expression and cellular compartmentalization of cyclin D. Mol Cell Biol. 
2000;20:7259-72. 
158. Akakura S, Nochajski P, Gao L, Sotomayor P, Matsui S, Gelman IH. Rb-
dependent cellular senescence, multinucleation and susceptibility to oncogenic 
transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle. 
2010;9:4656-65. 
159. Gelman IH. Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of 
Cell Proliferation, Cancer Malignancy, and Barriergenesis. Genes & cancer. 
2010;1:1147-56. 
160. Gelman IH. The role of SSeCKS/gravin/AKAP12 scaffolding proteins in 
the spaciotemporal control of signaling pathways in oncogenesis and 
development. Frontiers in bioscience : a journal and virtual library. 2002;7:d1782-
97. 
161. Society AC. What tests can detect prostate cancer early? Prostate Cancer 











• Research scientist with experience in developing, leading, and conducting 
multi-disciplinary scientific studies in the areas of cancer and genetic 
epidemiology. 
• Proficient communicator with the ability to provide results by preparing 
comprehensive written and oral summaries of research development and 
research findings.  
• Adept at evaluating research studies through collaborations with basic 
scientists and community partners.    
• Skilled at training and providing guidance to colleagues and students in 
research-related tasks.   
 
EDUCATION 
     University of Louisville, Louisville, KY 
     Ph.D., Pharmacology and Toxicology                                      May 2016  
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     M.S., Pharmacology and Toxicology                                        December 2014 
     Smith College, Northampton, MA             May 2010 
     B.A., Biochemistry                                                              
RESEARCH AND PROFESSIONAL EXPERIENCE 
Doctoral Candidate, Pharmacology and Toxicology Department                                                   
08/2011-05/2016 
University of Louisville, Louisville, KY 
P.I.: Dr. LaCreis Kidd 
• Received training in statistical analysis software (SAS), Linux operating 
system programming, Collaborative Institutional Training Initiative (CITI) in 
Human Subject Research, Health Insurance Portability and Accountability Act 
(HIPPA) Privacy, Bloodborne Pathogens, and Laboratory Safety and Hazardous 
Waste 
• Developed written evaluations and peer-reviewed manuscripts to 
disseminate research findings and study progress 
• Developed laboratory protocols and facilitated the training of 
undergraduates and medical students 
• Mentored and aided in the development of research projects for summer 
research students 
• Investigating inflammatory and immune response related genetic variants 
linked to PCa risk through data mining techniques (e.g., logistic regression and 
multi-factor dimensionality reduction (MDR) modeling) 
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• Evaluating miRNA expression profiles in PCa serum and cell lines as 
potential prognostic tools for PCa through the utilization of molecular and cellular 
biology techniques to examine the impact of microRNA expression on cellular 
behavior in normal prostate and PCa cells 
• Presenting research findings at local/national scientific meetings 
• Managing and maintaining human cell culture lines for experiments, 
laboratory inventory, and administrative documents  
 
Summer Research Intern, James Graham Brown Cancer Center                                  
06/2011—08/2011 
University of Louisville, Louisville, KY 
P.I.: Dr. LaCreis Kidd 
• Evaluated chemokine-associated genetic variants as predictors of PCa 
risk among men of African Descent though SAS programming and MDR 
modeling  
• Routinely met with research team members and principal investigator to 
discuss study progress and propose solutions to methodological problems in 
order to achieve research goals in a timely manner 
• Presented research findings at the regional Research Louisville 
symposium  
 




North Carolina Central University, Durham, NC                                           
PIs: Dr. Maxwell Gyamfi and Dr. Sean Kimbro 
• Received American Association for Laboratory Animal Science (AALAS) 
certification training in animal care for research and education through the 
AALAS Learning Library 
• Evaluated the role of mouse and human xenobiotic nuclear receptor 
pregnane X receptor (PXR) in obesity in vivo through protein analysis of targets 
involved in S-Adenosyl methionine (SAM) synthesis and metabolism, 
measurement of triglyceride, cholesterol and non-esterified free fatty acid in 
hepatic tissue as well as glucose tolerance, lipid profiling (triglycerides, HDL, 
LDL, and VDL) and liver toxicity (ALT/AST levels) in the serum  
 
AWARDS AND HONORS 
• Dean’s Citation, University of Louisville        2016                                                                                              
• AACR MICR Scholar in Cancer Research Travel Award                      2016 
•          ASPET Dolores C. Shockley Best Abstract Award 2nd Place              2016 
• ASPET Underrepresented Graduate Student Travel Award    2016  
• ASPET Dolores C. Shockley Best Abstract Award 1st Place              2015  
• ASPET Underrepresented Graduate Student Travel Award               2015  
• Alice Eaves Barns Award, University of Louisville       2014   
• Dean’s Citation, University of Louisville        2014                                                                                              
• Fall Graduate Research Symposium Poster Winner,  
           University of Louisville          2014  
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• Southern Regional Education Board Doctoral Scholar Fellowship,            
           University of Louisville              2012-2015 
• Integrated Programs in Biomedical Sciences Fellowship (IPIBS),  
           University of Louisville                2011-2012 
• Dean’s List, Smith College   2009-2010                                                                                          
• Jackie Robinson Foundation Scholar, Smith College                  2006-2010                                                                 
• American Chemical Society Scholar, Smith College                   2006-2010                                                                  
 
PROFESSIONAL MEMBERSHIP 
• Sigma Xi, The Scientific Research Society, Member, 2010                                                                         
• American Association of Cancer Research (AACR), Member, 2012-2016                                           
• Black Biomedical Graduate Student Organization (BBGSO), President,    
           2012-2016    
• Golden Key International Honour Society, Member, 2012-2016   
• Minority Association of Graduate Students (MAGS), Vice President,      
           2015-2016                                 
• Society of Toxicology, Member, 2014-2016                                                                                       
• American Society for Pharmacology and Experimental Therapeutics    
          (ASPET), Member, 2014-2016 
 
INVITED ORAL PRESENTATIONS 
• American Society of Investigative Pathology (ASIP)/ American Association 
of Anatomists (AAA) Career Development & Mentoring Program and Lunch: 
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Fundamentals of Success: How to Give an Award Winning Presentation, March 
29, 2015. 
• American Society of Investigative Pathology (ASIP), Breast and 
PCa Mini-Symposium, March 30, 2015. 
•      Translating MicroRNA Cancer Biology to Therapy Symposium, April 
6, 2016. 
 
PEER REVIEWED MANUSCRIPTS 
• Kidd L.R., Jones D.Z., Beache S., Rogers E.N., Ragin C., Jackson M., 
McFarlane-Anderson N., Tulloch-Reid M, Flores-Obando R., Barve S.S., Rudd 
J.E., and Kimbro K.S.. Chemokine Ligand 5 (CCL5) and Chemokine Receptor 
(CCR5) Genetic Variants and PCa Risk among men of African Descent. 
Hereditary Cancer in Clinical Practice, 10(1):16, 2012. 
• Rogers E.N., Jones D.Z., Yeyeodu, S.T, Ragin C., Jackson M., 
McFarlane-Anderson N., Tulloch-Reid M, Kimbro K.S., and Kidd L.R. Toll-like 
Receptor (TLR)-Associated Sequence Variants as Predictors of PCa Risk Among 
Men of African Descent. Genes and Immunity, 10.1038/gene.2013.22, 2013. 
• Kidd, L.R., Rogers, E.N., Yeyeodu, S.T., Jones, D.Z., Kimbro, K.S.  
Contribution of Toll-like Receptor Signaling Pathways to Breast Tumorigenesis 
and Treatment. Breast Cancer: Targets and Therapy, 10.2147/BCTT.S29172, 
2013. 
• Jones D.Z., Ragin C., Jackson M.,Kidd N.C., Flores-Obando 
R.E.McFarlane-Anderson N., Tulloch-Reid M, Kimbro K.S., and Kidd L.R. The 
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Impact of Genetic Variants in Inflammatory-related Genes on PCa Risk among 
men of African Descent. Hereditary Cancer in Clinical Practice,11(1):19, 2013. 
• Spruiell K., Jones D.Z., Cullen J.M., Awumey E.M., Gonzalez F. J., and 
Gyamfi, M.A. Role of human pregnane X receptor in high fat diet-induced obesity 
in pre-menopausal female mice. Biochemical Pharmcology, 2014 Apr 7. pii: 
S0006-2952(14)00207-X. doi: 10.1016/j.bcp.2014.03.019. 
 
ABSTRACTS AND PRESENTATIONS: NATIONAL/LOCAL MEETINGS 
• Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N., Morrison S., 
Flores-Obando F., Kimbro K.S., and Kidd, L.R. Chemokine-associated genetic 
variants as predictors of PCa risk among men of African Descent. Research 
Louisville!, Louisville, Kentucky, September 28, 2011. 
• Kidd L.R., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N., 
Morrison S., Flores-Obando F., Kimbro K.S. Chemokine-associated genetic 
variants as predictors of PCa risk among men of African Descent. American 
Association for Cancer Research (AACR) Cancer Health Disparities, 
Washington, D.C. July 19, 2011. 
• Ragin C., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N., 
Morrison S., Flores-Obando F., Kimbro K.S., Kidd L.R. Inflammatory Cytokine 
SNPs and PCa in Black men. Caribbean Exploratory Research Center (CERC) 




• Kidd L.R., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N., 
Morrison S., Flores-Obando F., Kimbro K.S. Chemokine-associated Loci and 
PCa Among Men of African Descent. American Association for Cancer Research 
(AACR), Chicago, IL, November 15, 2011. 
• Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L., 
Barve S.S., McNally L.R., and Kidd L.R. Potential micro-RNA Biomarkers 
Associated with Cell Migration and Metastasis. Research Louisville!, Louisville, 
Kentucky, August 24, 2012. 
• Anene D., Jones D.Z., Aloway A., Anene P., Avila D.V., Gobejishvili L., 
Barve S.S., McNally L.R., and Kidd L.R. Are Cell Adhesion Associated Micro-
RNAs Linked With Metastatic PCa? Research Louisville!, Louisville, Kentucky, 
August 24, 2012. 
• Aloway A., Jones D.Z., Anene D., Anene P., Avila D.V., Gobejishvili L., 
Barve S.S., McNally L.R., and Kidd L.R.  Cell Survival miRNAs (29a, 29c, and 
221) and Pre-metastatic PCa? Research Louisville!, Louisville, Kentucky, August 
24, 2012. 
• Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L., 
Barve S.S., McNally L.R., and Kidd L.R. Potential micro-RNA Biomarkers 
Associated with Cell Migration and Metastasis. James Graham Brown Cancer 
Center Retreat, Louisville, Kentucky, October 3, 2012. 
• Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L., 
Barve S.S., McNally L.R., and Kidd L.R. Reduced Expression of miR-342-3p in 
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stage I, III, and IV PCa. American Association for Cancer Research (AACR), 
Washington, D.C., November 15, 2012. 
• Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L., 
Hobbing K., Clark G., and Kidd L.R. TGF-beta Signaling in PCa cell lines derived 
from European- and African-American men. Research Louisville!, Louisville, 
Kentucky, September 24, 2013. 
• Linder J., Jones D.Z., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L., 
Hobbing K., Clark G., and Kidd L.R. microRNA-885-5p and its role in the TGF-
beta pathway using PCa cell lines derived from European- and African-American 
men. Research Louisville!, Louisville, Kentucky, September 24, 2013. 
• Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L., 
Hobbing K., Clark G., and Kidd L.R. TGF-beta Signaling in PCa cell lines derived 
from European- and African-American men. James Graham Brown Cancer 
Center Retreat, Louisville, Kentucky, October 25, 2013. 
• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect 
of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. Research 
Louisville!, Louisville, Kentucky, September 16, 2014. 
• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect 
of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. James 
Graham Brown Cancer Center Retreat, Louisville, Kentucky, October 17, 2014.         
• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect 
of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. Fall 2014 
Graduate Research Symposium, Louisville, Kentucky, November 14, 2014.  
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• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-
186 inhibition alters cell proliferation and colony formation in PCa. Experimental 
Biology Meeting, Boston, MA, March 29, 2015. 
• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-
186 inhibition alters cell proliferation and colony formation in PCa. American 
Association for Cancer Research (AACR), Philadelphia, PA, April 21, 2015. 
• Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-
186 inhibition alters cell proliferation and colony formation in PCa. Ohio Valley 
Society of Toxicology (OVSOT), Cincinnati, OH, June 29, 2015. 
• Packer T.A., Jones D.Z., and Kidd, L.R. Impact of Quercetin on miR-21, 
Cell Proliferation and Migration of Metastatic and Non-Metastatic PCa Cell lines. 
Undergraduate R25 Poster Session, Louisville, Kentucky, July 30, 2015. 
• Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R. miR-
186 suppresses cell proliferation and anchorage-independence in a metastatic 
PCa cell line. Research Louisville!, Louisville, Kentucky, October 27, 2015. 
• Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R. miR-
186 inhibition suppresses cell proliferation and anchorage-independence in a 
metastatic prostate cancer cell line. Experimental Biology Meeting, San Diego, 
CA, April 4, 2016. 
• Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R. 
Inhibition of miR-186 and repression of aggressive prostate cancer phenotype 
using a metastatic cell model. American Association for Cancer Research 
(AACR) Meeting, New Orleans, LA, April 18, 2016. 
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SERVICE TO UNIVERSITY 
• University of Louisville School of Medicine Diversity Committee,  
            Graduate Student Representative                     2014-2016 
SERVICE TO PROFESSION 
• American Society for Pharmacology and Experimental Therapeutics 
(ASPET) Mentoring and Career Development Committee, Graduate Student 
Representative                                                                                 2015-2016 
